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Abstract 
Relapsed acute lymphoblastic leukaemia (ALL), diffuse large B-cell lymphoma (DLBCL) and 
follicular lymphoma (FL) comprise a group of malignancies with poor prognosis and 
therapeutic strategies are needed to improve outcomes. Recent studies have shown that 
heterozygous inactivating mutations in the histone acetyl transferase, CREBBP, are 
frequent in these malignancies, and are thought to lead to impaired transcription of 
glucocorticoid (GC) response genes. Given the pivotal role of GC in the treatment of 
lymphoid malignancies and the finding that CREBBP mutations often arise at relapse, it 
has been postulated that CREBBP mutations confer chemoresistance to GC therapy. To 
study the role of CREBBP haploinsufficiency in ALL, DLBCL and FL, small hairpin RNA and 
small interfering RNA methods were used to knock down CREBBP in a number of cell lines 
and primary derived samples. Models were functionally relevant, with reduced 
acetylation of CREBBP target residue, histone 3 lysine 18 and/or histone 3 lysine 27, but 
knockdown had no significant impact on activation of cAMP-dependent target genes. 
Impaired induction of glucocorticoid receptor targets was only seen in 1 of 4 CREBBP 
knockdown models of ALL, and there was no significant difference in GC-induced 
apoptosis or chemosensitivity to other therapeutic agents frequently used in lymphoid 
malignancies, including histone deacetylase inhibitors. However, CREBBP knockdown was 
associated with enhanced signalling of the RAS/RAF/MEK/ERK pathway in RAS pathway 
mutant ALL cells, and MEK inhibitor sensitivity was retained. This suggests that CREBBP 
mutation may act to enhance the activity of oncogenes and that CREBBP/RAS pathway 
mutated relapsed ALL are candidates for MEK inhibitor clinical trials. 
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Introduction 
1.1 Blood Cell Development 
Mature blood cells are produced in the bone marrow through a hierarchical process 
known as haematopoiesis (Figure 1.1). Through this process a large number of specialised 
cell types are generated from a small number of haematopoietic stem cells (HSC) which 
reside in the bone marrow. Long term (LT) HSCs and short term (ST) HSCs are cells which 
are capable of self-renewal to maintain a pool of undifferentiated cells or differentiation 
over long and short term respectively. Differentiation is influenced by growth factors, 
cytokines and transcription factor expression, gradually changing the gene expression of 
cells, moving them towards a specialised phenotype. Disruption of this process can lead 
to uncontrolled proliferation, abnormal differentiation and apoptosis, typical features of 
haematological disorders such as leukaemia and lymphoma.  
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Figure 1.1 Haematopoiesis, the development of mature blood cells from stem cells. 
Abbreviations: LT, long term; ST, short term; MPP, multipotent progenitor; HSC, 
haematopoietic stem cell; CMP, common myeloid progenitor; CLP, common lymphoid 
progenitor; MEP, megakaryocyte erythroid progenitor; GMP, granulocyte macrophage 
progenitor. Adapted from (Ackermann et al., 2015). 
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1.2 Childhood Acute Lymphoblastic Leukaemia 
Acute lymphoblastic leukaemia (ALL) is a disorder of immature B and T-cells which have 
acquired mutations that grant them the ability to self-renew indefinitely, leading to stage-
specific developmental arrest. It is the most common childhood malignancy and cause of 
cancer related mortality (Inaba et al., 2013). The majority of leukaemias are ‘pre-B’, 
expressing the normal cell surface markers of pre-B cells.  
1.2.1 Development/Aetiology 
The events leading to ALL development are not well understood and only a small number 
can be attributed to inherited genetic defects, such as Down’s syndrome (<0.5%) or the 
rare constitutional Robertsonion translocation between chromosomes 15 and 21 
(rob(15;21)(q10;q10)c) (Pui et al., 2004; Pui et al., 2008; Li et al., 2014). Two-infection 
based hypotheses exist for leukaemia development; Kinlen’s ‘population mixing’ and 
Greaves’ ‘delayed infection’, with the unifying notion that lack of exposure to common 
pathogens early in life, leads to a pathological development of the immune system, which 
may predispose the individual to haematological malignancy (Kinlen, 2004; Greaves, 
2006). A proportion of ALLs have a clear prenatal origin, based on monozygotic twin 
studies and retrospective studies of neonatal blood spots (Guthrie Cards) in children who 
have gone on to develop ALL. Monozygotic twins have a high rate of concordance for ALL, 
this is due to the sharing of clonal progeny between twins via vascular anastomoses which 
develop in the monochorionic placenta (Greaves et al., 2003). The ETV6-RUNX1 
(t(12;21)(p13;q22)) chromosomal translocation is found in neonates at a frequency ~100 
times greater than the rate of ETV6-RUNX1 positive childhood ALL in the population (Mori 
et al., 2002; Greaves et al., 2003). This shows that chromosomal translocations which form 
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pre-leukaemic clones occur in utero, but further genetic aberrations are needed for the 
development of leukaemia, such as the deletion of wild type ETV6 (Mori et al., 2002; 
Greaves et al., 2003). Similarly, a recent study has shown that individuals who are born 
with a rare constitutional Robertsonion translocation between chromosomes 15 and 21 
(rob(15;21)(q10;q10)c) have a vastly increased chance (~2700 fold) of developing ALL with 
intrachromosomal amplification of chromosome 21 (iAMP21) (Li et al., 2014). 
1.2.2 Clinical Features 
ALL can cause a range of different symptoms, these differ depending on subtype. Many 
symptoms of ALL occur due to the shortage of healthy leukocytes. These include; fatigue, 
lethargy, fever, shortness of breath, recurrent and persistent infection, bleeding and 
petechiae (pinpoint-sized haemorrhages beneath the skin). Over one third of young 
patients present with bone pain due to expansion of the marrow by leukaemia cells 
1.2.3 Disease Classification 
ALL represents a diverse class of diseases which can be classified according to 
immunophenotyping, cytogenetics and genetic features.  
1.2.3.1 Immunophenotype 
This method is based on identifying cell surface expression of antigens on leukaemia cells, 
which reflect the stage of differentiation at which the cells became malignant. Childhood 
ALL can be broadly classified as precursor B-cell (85%) or T-cell (15%) (Onciu, 2009). The 
most important markers for sub-classifying  B-lineage ALL are; CD19, CD20, CD22, CD24, 
and CD79a (Chiaretti et al., 2014). B-cell leukaemia can be further classified into four 
subtypes; early pre-B cell, pre-B cell, transitional pre-B cell and mature B-cell. T-cell 
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markers include; CD1a, CD2, CD3 (membrane and cytoplasm), CD4, CD5, CD7 and CD8 
(Chiaretti et al., 2014). T-cell leukaemias are rarer than B-cell, and historically are 
associated with poor prognosis, however the use of more intensive chemotherapy has 
improved outcome substantially (Hunger et al., 2012). 
1.2.3.2 Cytogenetics 
Chromosomal abnormalities within leukaemic blasts are important prognostic indicators 
and are used to classify ALL. These abnormalities include differences in number (ploidy) 
or structure of chromosomes. Figure 1.2 outlines the different cytogenetic subgroups 
seen in childhood ALL and their relative frequencies. High Hyperdiploid (>50 
chromosomes), represents the most common cyotogenetic subgroup in B-cell precursor 
ALL (BCP-ALL), with hypodiploid (<44 chromosomes) only seen in around 1% of cases 
(Mullighan, 2012).  
Structural abnormalities are a defining feature of ALL and can arise from chromosomal 
translocations, leading to the production of fusion proteins. The most common structural 
rearrangement in childhood ALL is ETV6-RUNX1, identified in around 25% of cases 
(Mullighan, 2012). ETV6 is a gene involved in haematopoietic cell development, and 
RUNX1 is involved in embryonic haematopoiesis. Expression of this fusion protein leads 
to expansion of B-cell precursors, enhanced self-renewal capacity and impaired 
differentiation (Morrow et al., 2004; Tsuzuki et al., 2004; Fischer et al., 2005).  
Rearrangements of the MLL gene occur in around 6% of childhood ALL cases (Mullighan, 
2012). MLL fusions occur with a number of different partner genes, leading to the 
formation of a wide range of novel chimeric proteins. These fusion proteins have been 
shown to interfere with transcriptional elongation, which in turn causes deregulation of 
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target gene expression (Mueller et al., 2007; Mueller et al., 2009; Lin et al., 2010; 
Yokoyama et al., 2010).  
TCF3-PBX1 (t(1; 19)(q23;p13)) is the next most common chromosomal rearrangement in 
childhood ALL (Mullighan, 2012). TCF3 encodes two proteins; E12 and E47, both of which 
are involved in the maturation of B-cells and PBX1 is a homeobox gene expressed in most 
tissues except lymphocytes (Hunger, 1996). When the two are fused, a novel fusion 
protein is created which leads to non-physiological activation of PBX1 in lymphocytes, 
which in turn leads to transactivation of a number of genes and finally transformation of 
the cell to a malignant phenotype (Hunger, 1996; Kamps, 1997). 
 BCR-ABL1 (t(9;22)), or the Philadelphia chromosome, most commonly associated with 
chronic myeloid leukaemia (CML), is seen in a small number of cases of childhood ALL 
(Mullighan, 2012). When the non-receptor tyrosine kinase ABL1, is fused to the BCR 
signalling protein, it becomes constitutively active, causing subsequent constitutive 
activation of downstream pathways such as the RAS/RAF/MEK/ERK pathway, involved in 
cell differentiation, survival and proliferation (Ren, 2005). More recently, another 
subgroup has been identified in childhood and adolescent ALL, the BCR-ABL1-like (or Ph-
like) subgroup, seen in 15-20% of cases (Den Boer et al., 2009; Mullighan et al., 2009). 
BCR-ABL1-like cells have a genetic profile that is very similar to that of the BCR-ABL1 
subgroup, without the BCR-ABL1 translocation (Den Boer et al., 2009; Mullighan et al., 
2009). BCR-ABL1-like cases of ALL have recently been shown to have a high frequency of 
kinase-activating alterations, with a novel ATF7IP-PDGFRB fusion shown to be sensitive to 
tyrosine kinase inhibitors, suggesting that a number of BCR-ALB1-like cases could be 
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sensitive to treatment with tyrosine kinase inhibitors (Roberts et al., 2014; Ishibashi et al., 
2016). 
The intrachromosomal amplification of chromosome 21 (iAMP21) abnormality is defined 
by a gain of at least 3 copies of the region of chromosome 21 containing RUNX1, the 
molecular mechanisms of which are not understood (Mullighan, 2012). iAMP21 occurs in 
around 2% of cases of childhood B-cell ALL and is associated with a poor outcome 
(Moorman et al., 2007). New data suggest that outcome for these iAMP21 positive 
patients could be improved by using more intensive treatment (Moorman et al., 2013).  
1.2.3.3 Genetic Features 
Mutations and deletions are also important events commonly seen in childhood ALL. RAS 
pathway mutations frequently occur at a rate of around 35% in diagnostic, and 25% in 
relapse cases (Case et al., 2008; Irving et al., 2014; Irving et al., 2016). Furthermore, 50% 
of high risk (based on age at diagnosis and white blood cell count) and 70% of hypodiploid 
cases are RAS mutant (Zhang et al., 2011; Holmfeldt et al., 2013). A number of 
lymphoid/B-cell development related genes are also targets of somatic mutation in 
childhood ALL, these include; PAX5, IKZF1 (IKAROS), TCF3, EBF1 and IKZF2 (AIOLOS) 
(Mullighan et al., 2007; Mullighan et al., 2008; Mullighan et al., 2009; Kuiper et al., 2010; 
Zhang et al., 2011). Alterations in CRLF2 and the tumour suppressor gene TP53 are also 
thought to be important (Russell et al., 2009; Hof et al., 2011; Mullighan, 2012).  
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Figure 1.2 Cytogenetic subtypes seen in childhood acute lymphoblastic leukaemia (ALL) 
and their estimated frequencies. Adapted from (Mullighan, 2012). 
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1.2.4 Prognostic Factors 
Clinical and disease specific features of ALL can be used as prognostic markers and allow 
patients to be stratified for treatment. Using this method, treatment can be tailored to 
the needs of the patient, those with high risk disease receiving intensified therapy, and 
those with lower risk disease being spared the toxicity of intensive therapy. Table 1.1 
summaries the current important prognostic factors in childhood ALL. 
With regards to clinical features, both age and initial white blood cell (WBC) count are 
predictive of outcome, with older age and/or higher WBC count representing a worse 
prognosis. Standard risk is defined by an age of 1 to 9.99 years and initial WBCs count of 
<50 000 per cubic millimetre and high risk is defined as anything greater than that stated 
for standard risk (Smith et al., 1996). Black and Hispanic ethnic groups have a worse 
prognosis than White and Asian groups, likely due to the higher prevalence of TCF3-PBX1 
and CRLF2 rearrangements respectively within these groups, but this is not used to inform 
treatment (Pui et al., 2003; Harvey et al., 2010; Hunger and Mullighan, 2015).  
High hyperdiploidy, and ETV6-RUNX1 are associated with favourable outcomes, while 
hypodiploid with <44 chromosomes, MLL rearrangement, BCR-ABL1, Philadelphia-like 
ALL, CRLF2 rearrangement, iAMP21 and early T-cell precursor ALL are all associated with 
poor outcome (Nachman et al., 2007; Coustan-Smith et al., 2009; Arico et al., 2010; Harvey 
et al., 2010; Moorman et al., 2010; Harrison et al., 2014; Roberts et al., 2014).  
Response to treatment is an important prognostic marker, particularly with regards to 
glucocorticoid (GC) response. As determined by 3 individual Berlin-Frankfurt-Münster 
trials, one week of prednisolone monotherapy is a predictive marker of success in children 
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(Dordelmann et al., 1999). It has been shown that leukaemic cells from high risk groups 
grown in vitro are relatively resistant to prednisolone and the largest study to date 
comparing diagnosis and relapse samples found that relapse cells were on average 357 
fold more resistant to prednisolone than diagnosis cells (Klumper et al., 1995; Pieters et 
al., 1998). A more recent study confirms the range of GC sensitivities that are seen in ALL 
cells (Fischer et al., 2015). Minimal residual disease (MRD), the lowest level of disease 
detectable in patients with complete remission, is the single most powerful prognostic 
factor in childhood ALL (Coustan-Smith et al., 2000; Borowitz et al., 2008). High sensitivity 
methods such as PCR of clonotypic IGH or TCR gene rearrangements that are unique to an 
individual patient’s leukaemia, QRT-PCR identifying leukaemia-associated fusion genes 
such as BCR-ABL, or flow cytometry to identify aberrant immunophenotypic 
combinations, can identify as few as 1 malignant cell in 10 000 (Szczepanski, 2007; 
Campana, 2012; Pui et al., 2015). The risk of treatment failure or death is 3-5 times higher 
in children with MRD ≥0.01% (MRD positive) at the end of, and at time points after, 
induction therapy, than in those with MRD <0.01% (MRD negative), and intensification of 
therapy for these patients improves their outcome (Coustan-Smith et al., 2000; Borowitz 
et al., 2008; Conter et al., 2010; Schrappe et al., 2011; Vora et al., 2014; Pui et al., 2015).  
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Variable Favourable Feature Adverse Factor Use in Risk 
Stratification 
Demographic and clinical features 
Age 1 to <10 years <1 year or ≥10 years Part of NCI risk group 
stratification 
Sex Female Male No 
Race or ethnic 
group 
White, Asian Black, Native 
American, Hispanic 
No 
Initial WBC count Lower (<50 
000/mm3) 
Higher (≥50 
000/mm3) 
Part of NCI risk group 
stratification 
Biological or genetic features of leukaemia cells 
Immunophenotype B-cell ALL T-cell ALL Often used to select 
therapy backbone 
Cytogenetics ETV6-RUNX1, 
hyperdiploidy, 
favourable 
chromosome 
trisomies 
BCR-ABL1, MLL 
rearrangements, 
hypodiploidy  
Often used to select 
treatment intensity, 
assign patient to HSCT, 
or both. Some features 
(e.g. BCR-ABL1) can be 
used to select targeted 
therapy 
Genomic features ERG deletions IKZF1 deletions or 
mutations; 
Philadelphia 
chromosome-like 
ALL with kinase gene 
alterations 
Some research groups 
use IKZF1 deletions to 
assign patients to more 
intensive therapy; 
kinase gene mutations 
may be used to assign 
patients to targeted 
therapy, but this is not 
yet part of routine care 
Early response to treatment 
Response to 1 
week of GC 
therapy 
Good response to 
prednisolone (<1000 
blasts/mm3) 
Poor response to 
prednisolone (≥1000 
blasts/mm3) 
Easy measure and used 
by many groups; may 
be supplanted by MRD 
Marrow blasts 
after 1-2 weeks of 
multi-agent 
therapy 
M1 marrow (<5% 
blasts) by day 8 or 
15 
No M1 marrow (≥5% 
blasts) by day 8 or 
15 
Easy measure and used 
by many groups; now 
being supplanted by 
MRD 
MRD quantification 
during or at end of 
induction 
Reaching low 
(<0.01%) or 
undetectable MRD 
by specific time 
points 
Persistence of MRD 
≥0.01% at specific 
time points; the 
higher it is the worse 
prognosis 
Most important single 
prognostic factor for 
contemporary therapy; 
critical for modern risk 
stratification 
 
MRD at 3-4 months Low (<0.01%), 
preferably 
undetectable 
Persistence of MRD 
≥0.01% 
May select patients for 
HSCT or new therapies 
in first remission 
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Table 1.1. Important prognostic factors in childhood ALL. HSCT; haematopoietic stem cell 
transplant, MRD; minimal residual disease, NCI; national cancer institute. Adapted from 
(Hunger and Mullighan, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 1 Introduction 
 
 
14 
 
1.2.5 Treatment 
ALL therapy is complex and comprises the use of multiple drugs over many different 
stages of treatment protocols. Remission induction was achieved in 80-90% of children 
with ALL almost 50 years ago, though almost all relapsed with central nervous system 
(CNS) disease, thus survival rates were only 10-20% (George et al., 1968). Addition of 
craniospinal or cranial irradiation and intrathecal chemotherapy led to increased survival 
(Aur et al., 1971). This was followed by the development of an intensive 8 week induction 
and consolidation regimen, which is now the core of most modern ALL therapies (Riehm 
et al., 1980). Current treatment in the UK is divided into chemotherapeutic blocks; a short 
remission induction phase, followed by consolidation and re-intensification phases with a 
prolonged period of continuation therapy. A general treatment regime for childhood ALL 
is described in Table 1.2. Corticosteroids are of particular importance in treating ALL. 
Thanks to many multinational clinical trials allowing careful stratification of therapy, 
overall survival rates of around 90% are now being achieved (Table 1.3) (Hunger et al., 
2012; Vora et al., 2013; Vora et al., 2014). Whilst the dramatic improvements in survival 
achieved over the last 50 years are almost exclusively due to the successful dose 
stratification and scheduling, more specific, targeted therapies are beginning to be used 
in certain subtypes of childhood ALL. The BCR-ABL1 fusion occurs in 3-5% of children with 
ALL (Ph-positive ALL) and is associated with secondary alterations such as IKZF1 
alterations (Mullighan et al., 2008). Combination of the BCR-ABL1 inhibitor imatinib, with 
cytotoxic chemotherapy has proved to be highly effective in Ph-positive childhood ALL, 
and has reduced the need for haematopoietic stem cell transplant (HSCT) in the first 
remission (Schultz et al., 2009; Biondi et al., 2012; Schultz et al., 2014). Before the use of 
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tyrosine kinase inhibitors less than half of children with Ph-positive ALL survived (Arico et 
al., 2010).  
 
Table 1.2 Outline of the general regime for treatment of childhood ALL. Adapted from 
(Pui et al., 2004) 
 
 
 
 
 
 
 
 
 
Phase Aim Chemotherapeutic Agents Typically 
Used 
Remission 
Induction 
Elimination of >99% blasts and 
restoration of normal 
haematopoiesis  
 Corticosteroid (E.g. 
dexamethasone) 
 Vincristine 
 L-asparaginase 
 +/- anthracycline (high risk cases) 
Consolidation/ 
Intensification 
Reduce risk of relapse by 
eliminating any residual drug-
resistant blasts  
 Methotrexate 
 Mercaptopurine 
 Cyclophosphamide 
 Cytarabine (Ara-C) 
 Vincristine 
Maintenance Relapse prevention and 
elimination of residual disease 
 Mercaptopurine daily 
 Methotrexate weekly 
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Table 1.3 Outcomes of modern childhood ALL trials in North America and Western 
Europe. Survival rates shown are at 5 years except for the AIEOP-BFM which were 
reported at 7 years. COG; Children’s Oncology Group, SJCRH; St Jude Children’s Research 
Hospital, DFCI; Dana-Faber Cancer Institute, AIEOP-BFM; Italian Association of Pediatric 
Hematology and Oncology and Berlin-Frankfurt-Münster, MRC-NCRI; Medical Research 
Council and National Cancer Research Institute, DCOG; Dutch Childhood Oncology Group, 
EORTC CLG; European Organisation for Research and Treatment of Cancer – Children’s 
Leukemia Group, NOPHO; Nordic Society of Paediatric Oncology Haematology and 
Oncology. Adapted from (Hunger and Mullighan, 2015). 
Research 
Group 
Trial Reference Region Years Subgroup No. of 
Patients 
EFS OS 
COG Many trials (Hunger et 
al., 2012) 
US, CA, 
AU, NZ 
2000-
2005 
Overall 6994 N/A 91.3 
B-ALL 5845 N/A 92.0 
T-ALL 475 N/A 81.5 
SJCRH Total 
Therapy 
Study XV 
(Pui et al., 
2009) 
US 2000-
2007 
Overall 498 85.6 93.5 
B-ALL 422 86.9 94.6 
T-ALL 76 78.4 87.6 
DFCI DFCI ALL 
Consortium 
Protocol 00-
01 
(Vrooman 
et al., 2013) 
US, CA 2000-
2004 
Overall 492 80.0 91.0 
B-ALL 443 82.0 N/A 
T-ALL 49 69.0 N/A 
AIEOP-
BFM 
AIEOP-BFM 
ALL 2000 
(Conter et 
al., 2010; 
Schrappe et 
al., 2011) 
Wester
n 
Europe 
2000-
2006 
Overall 4480 80.3 91.1 
B-ALL 4016 80.4 91.8 
T-ALL 464 75.9 80.7 
MRC-NCRI UKALL 2003 (Vora et al., 
2013) 
UK 2003-
2011 
Overall 3126 87.2 91.5 
B-ALL 2731 N/A N/A 
T-ALL 388 N/A N/A 
DCOG DCOG 
Protocol 
ALL-9 
(Veerman 
et al., 2009) 
NL 1997-
2004 
Overall 859 81 86 
B-ALL 701 82 N/A 
T-ALL 90 72 N/A 
EORTC 
CLG 
EORTC CLG 
58591 
(Domenech 
et al., 2014) 
BE, FR 1998-
2008 
Overall 1940 82.6 89.7 
NOPHO ALL-2000 (Schmiegelo
w et al., 
2010) 
DK, FI, 
IS, NO, 
SE 
2000-
2007 
Overall 1023 79 89 
B-ALL 906 81 91 
T-ALL 115 64 72 
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1.2.6 Relapse 
Despite highly successful treatment, relapse occurs in 15-20% of childhood ALL cases, with 
5 year survival rates between 70-25% depending on the relapse risk classification (Table 
1.4) (Nguyen et al., 2008; Bhojwani and Pui, 2013). This makes relapsed childhood ALL the 
5th most common childhood malignancy and it is associated with a large number of 
childhood cancer deaths each year (Bhojwani and Pui, 2013). There are a number of 
relapse associated mutations, which in some cases lead to treatment resistance or an 
increased rate of mutation (Meyer et al., 2013; Ma et al., 2015). A repeated course of 
therapy can be used to treat relapse or allogeneic HSC transplant. In the majority of cases, 
relapse is established by a minor subclone which was present at diagnosis and has been 
selected by front-line chemotherapy (Ma et al., 2015). Next generation sequencing 
technologies with high sequencing depth allow the identification of mutations which are 
present in only a small number of the cell population, i.e. subclones. To accurately identify 
a subclone, the presence or absence of variants must be identified and allele frequencies 
must be accurately assigned. The ability of this method to determine variant frequency is 
dependent on the depth of sequencing. A sequencing depth of 500x is required to identify 
variants that are present at a frequency of 5%, 1000x to determine 1% and so on (Stead 
et al., 2013). A minimum sequencing depth of 250x is required to accurately identify and 
assign allelic frequencies (Stead et al., 2013). Modern, ultra-deep sequencing can reach 
multiple thousands depth of coverage, identifying variants that occur at very low level. 
Allele specific PCR represents another method which can be used to identify these 
variants and has been used previously by our group to identify low level KRAS mutations 
(Irving et al., 2014). This method is a modified application of PCR which involves the design 
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of primers which preferentially amplify the mutant allele over the wild type allele by 
exploiting the amplification efficiency of DNA polymerase in the presence of mismatched 
base pairs. Understanding clonal evolution and identifying minor clones which commonly 
establish relapse may allow better relapse prediction and targeting of low level alterations 
alongside standard chemotherapy at diagnosis for relapse prevention. CREBBP mutations 
are frequently found at relapse in childhood ALL and are the key focus of this thesis 
(Section 1.4.3) (Mullighan et al., 2011; Pasqualucci et al., 2011a; Inthal et al., 2012; 
Holmfeldt et al., 2013). 
Risk Group Description 5 Year Survival (%) 
S1 Late extramedullary 60-70 
S2 Early and very early extramedullary 60 
B-lineage late marrow 
B-lineage combined (early or late) 
S3 B-lineage early marrow 30 
S4 Very early marrow 25 
Very early combined 
T-lineage marrow 
 
Table 1.4 Berlin-Frankfurt-Münster (BFM) Classification for Relapse. Adapted from 
(Bhojwani and Pui, 2013). 
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1.3 Non-Hodgkin’s Lymphoma 
Non-Hodgkin’s lymphomas (NHLs) are cancers of the lymphatic system that are more 
common in old age (>65 years) and represent a heterogeneous group of lymphoid 
malignancies. Recurrent translocations which occur during different steps of B-cell 
differentiation are often the initial step in the transformation of these malignancies, but 
secondary genetic alterations are usually required for full malignant transformation 
(Nogai et al., 2011).  
1.3.1 Diffuse Large B-cell Lymphoma 
Diffuse large B-cell lymphoma (DLBCL) is the most common form of B-cell Non-Hodgkin’s 
lymphoma (B-NHL), accounting for 30-40% of newly diagnosed cases of B-NHL in the UK, 
making it the sixth most common cancer (Cancer Research UK, 2010; Campo et al., 2011). 
It is predominantly seen later in life, with average age of onset around 70 years (Cancer 
Research UK, 2010). 
1.3.1.1 Aetiology/Development 
DLBCL is a disease of mature B-cells and the events leading to its onset are not well 
understood. There are however, some links between DLBCL and infection. Firstly, 
infection with Epstein Barr virus (EBV) has been associated with onset of DLBCL, most 
frequently in elderly patients (>50 years), but also in some younger patients, without 
evidence of immunodeficiency (Kuze et al., 2000; Oyama et al., 2007; Morales et al., 
2010). EBV is maintained as an asymptomatic, persistent infection, in around 95% of the 
population and is recognised as an oncogenic agent in a range of different cancers such 
as Burkitt’s lymphoma, Hodgkin lymphoma and DLBCL as well as immunodeficiency 
related lymphoproliferative disorders (LPDs) (Swinnen, 1999; Kuze et al., 2000; Kelly et al., 
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2002; Thorley-Lawson and Gross, 2004; Shah and Young, 2009). EBV positive DLBCL of the 
elderly has been shown to have a poorer prognosis than the EBV negative disease 
(Nakamura et al., 2008; Beltran et al., 2012). Infection with human T-lymphotropic virus 
type-1 (HTLV-1) and human immunodeficiency virus (HIV) have also been identified as risk 
factors leading to the onset of DLBCL (Nakamura et al., 2008; Beltran et al., 2012).  
1.3.1.2 Clinical Features 
The first symptom of DLBCL is often swollen lymph nodes, commonly in the neck, armpit 
or groin and further symptoms often develop based on which parts of the body the 
lymphoma is developing in. For example DLBCL in the stomach can cause abdominal 
discomfort or pain. Other symptoms include fever, night sweats, unexplained weight loss, 
fatigue and loss of appetite.  
1.3.1.3 Disease Classification/Genetic Features 
DLBCL is a highly heterogeneous disease and shows significantly higher genomic 
complexity than other B-cell malignancies, with between 50 and 100 genetic lesions per 
case (Pasqualucci and Dalla-Favera, 2014). Despite this complexity, DLBCL can be 
separated into two major categories based on genetic profiling; germinal centre B-cell 
(GCB) and activated B-cell (ABC) (Table 1.5) (Figure 1.3) (Rosenwald et al., 2002; 
Rosenwald et al., 2003; Shaffer et al., 2012). A third minor subtype has also been 
identified, primary mediastinal B-cell lymphoma (PMBL), which has a genetic profile that 
closely matches that of Hodgkin’s lymphoma (Table 1.5) (Rosenwald et al., 2003; Shaffer 
et al., 2012).  
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DLBCL 
Subtype 
Immunophenotype Diagnostic 
Molecular 
Features 
Frequency Clinical Features 
GCB CD20, CD10, BCL6, 
GCET, LMO2, IRF4-, 
FOXP1- 
Gene 
expression 
profiling 
17% Median age 61 
Nodal and extranodal 
Survival ~60% at 5 
years 
Curable >50% 
ABC CD20, IRF4, FOXP1, 
CD10–, BCL6– 
GCET1–, LMO2– 
Gene 
expression 
profiling 
15% Median age 66 
Nodal and extranodal 
Survival ~40% at 5 
years 
Curable >30% 
Primary 
mediastinal B-
cell lymphoma 
CD30, CD20, 
CD10– 
Gene 
expression 
profiling 
6% Median age 33 
Mediastinal, thoracic 
> nodal 
Survival >60% at 5 
years 
Curable >60% 
 
Table 1.5. Classification of DLBCL. Adapted from (Shaffer et al., 2012). 
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Figure 1.3. Cellular origins of diffuse large B-cell lymphoma (DLBCL). Ag; antigen, FDC; 
follicular dendritic cell. Adapted from (Pasqualucci and Dalla-Favera, 2014). 
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The gene expression profile in GCB-DLBCL resembles that of a GCB cell, with evidence of 
ongoing somatic hypermutation (SHM) as well as the presence of hypermutated 
immunoglobulin (Ig) genes (Lossos et al., 2000; Shaffer et al., 2012). GCB-DLBCL is 
categorised by the overexpression of genes involved in proliferation/apoptosis such as 
BCL2, MYC and the mir-17-92 cluster and other genes such as EZH2 by either chromosomal 
translocation, copy number gain, or somatic mutation (Rao et al., 1998; Willis and Dyer, 
2000; Iqbal et al., 2004; Ota et al., 2004; He et al., 2005; Morin et al., 2010; Morin et al., 
2011; Schuetz et al., 2012; Shaffer et al., 2012; Horn et al., 2013). Mutations in GNA13 
and SGK1 are also frequently seen in this subtype along with loss of function in other 
genes, for instance TNFRSF14 and PTEN (Morin et al., 2011; Lohr et al., 2012; Zhang et al., 
2013). 
 ABC-DLBCL on the other hand, resembles the transcriptional profile of an ABC, with 
downregulated germinal centre-specific genes, activation of BCR and NFκB pathways and 
no evidence of ongoing SHM (Lossos et al., 2000; Davis et al., 2001; Lenz et al., 2007; 
Shaffer et al., 2012). ABC-DLCB is categorised by genetic aberrations which cause the 
overexpression of factors leading to constitutive NFκB and B-cell receptor (BCR) activity 
such as; MYD88, CD79A/B and CARD11 as well as another gene known as SPIB, which is 
involved in normal germinal centre reactions (Su et al., 1997; Lenz et al., 2008a; Lenz et 
al., 2008b; Davis et al., 2010; Morin et al., 2011; Ngo et al., 2011). Genes with frequent 
loss of function in ABC-DLBCL include the NFκB inhibitor TNFAIP3, terminal differentiation 
block associated PRDM1/BLIMP1 and cell cycle checkpoint factor CDKN2A/B (Pasqualucci 
et al., 2006; Lenz et al., 2008b; Compagno et al., 2009; Morin et al., 2011).  
  Chapter 1 Introduction 
 
 
24 
 
A number of unifying genetic abnormalities are seen between both of the major subtypes 
of DLBCL. These include; loss of function in genes involved in histone/chromatin 
modifications, such as CREBBP/EP300 and MLL2/MLL3, and genes involved in immune 
escape, for example B2M and CD58, as well as other genes, for instance FOXO1 and TP53 
(Morin et al., 2011; Pasqualucci et al., 2011a; Pasqualucci et al., 2011b). Gains of function 
in BCL6 and MEF2B are also frequently seen in both subtypes (Pasqualucci et al., 2003; 
Morin et al., 2011). These alterations lead to increased activity of the BCL6 oncogene, or 
acquisition of the ability to evade the immune response (Shaffer et al., 2012). 
1.3.1.4 Prognostic Factors 
Table 1.6 shows a list of prognostic factors which are used in DLBCL (Vaidya and Witzig, 
2014). The international prognostic index (IPI), established in 1993 is the most robust 
prognostic tool for DLBCL and is used in clinical trials (Shipp, 1993). This model uses 5 
factors to predict survival, age >60, elevated serum lactate dehydrogenase (LHD), ECOG 
performance status ≥2, Ann Arbor state II or IV and number of involved extranodal sites 
≥2 (Shipp, 1993; Vaidya and Witzig, 2014). Table 1.7 shows overall survival with and 
without rituximab therapy based on IPI risk group.  Despite  ABC-DLBCL having a much 
lower 5 year survival rate than the less aggressive GCB-DLBCL form of DLBCL, gene 
expression profiling has limited clinical utility in making treatment decisions for newly 
diagnosed DLBCL (Alizadeh et al., 2000; Rosenwald et al., 2002; Rosenwald et al., 2003; 
Vaidya and Witzig, 2014).  
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Standard Prognostic 
Factors 
1. The International Prognostic Index (IPI) 
2. Immunohistochemistry for cell of origin (e.g. Hans 
algorithm) 
3. Imaging with positron emission tomography (PET)/CT 
scan 
4. Fluorescent in situ hybridization (FISH) for MYC and 
BCL2 rearrangements 
5. Absolute lymphocyte and absolute monocyte count 
Provisional Prognostic 
Factors 
1. Gene expression profiling for cell of origin 
2. Serum immunoglobulin free light chains 
3. Serum 25-hydroxy vitamin D levels 
4. Serum cytokine/chemokines 
 
Table 1.6. List of prognostic factors in DLBCL. Adapted from (Vaidya and Witzig, 2014). 
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Number of 
Risk Factors 
Risk Group 5-year OS% 
(without rituximab) 
3-year OS% 
(with rituximab) 
0-1 Low 73 91 
2 Low-intermediate 51 81 
3 High-intermediate 43 65 
4-5 High 26 59 
 
Table 1.7. Treatment outcomes in diffuse large B-cell lymphoma based on IPI risk group. 
Risk factors: age >60 years; number of extranodal disease sites >1; serum lactate 
dehydrogenase (LDH) above normal ECOG performance status ≥2; Ann Arbor stage III or 
IV. OS; overall survival. Adapted from (Vaidya and Witzig, 2014). 
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Translocations involving MYC are present in 5-10% of DLBCL cases and are associated with 
one study reporting an inferior 5-year progression free survival (31% compared to 66% in 
cases without MYC translocation), however this was not confirmed in similar retrospective 
studies  (Kramer et al., 1998; Klapper et al., 2008; Savage et al., 2009; Barrans et al., 2010). 
Overexpression of the anti-apoptotic protein, BCL2, occurs in 47-58% of DLBCL cases and 
was associated with a higher relapse rate and worse overall survival before the 
introduction of rituximab therapy (Hermine et al., 1996; Hill et al., 1996; Gascoyne et al., 
1997; Mounier et al., 2003). Some cases of DLBCL harbour MYC translocation along with 
additional translocations involving the BCL2 or the BCL6 loci. These are termed double-hit 
lymphomas (DHL), and have a poorer prognosis than MYC translocation alone (Aukema et 
al., 2011). 
Absolute lymphocyte count (ALC) is a surrogate marker for host immunity. High ALC levels 
are associated with a good prognosis and are a prognostic marker independent of cell of 
origin (GCB or non-GCB) (Kim et al., 2007; Oki et al., 2008; Song et al., 2010; Wilcox et al., 
2011; Porrata et al., 2012). Conversely, high absolute monocyte count (AMC) is associated 
with a poor prognosis and a ratio of ALC/AMC has been shown to be an independent 
prognostic factor after adjusting for IPI (Vaidya and Witzig, 2014). Around 32% of DLBCL 
cases have increased immunoglobulin free light chain (FLC) (Maurer et al., 2011). 
Immunoglobulin FLC, both polyclonal and monoclonal (polyclonal; elevations in κ and λ, 
monoclonal; elevations in just one of the light chains), is associated with inferior event 
free survival and overall survival in DLBCL (Maurer et al., 2011). Low levels of circulating 
vitamin D and elevated pre-treatment cytokine levels have also been associated with an 
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inferior prognosis in DLBCL (Ennishi et al., 2009; Ansell et al., 2012; Bittenbring et al., 
2014).  
18-fluorodeoxyglucose positron emission tomography (18FDG-PET) with computed 
tomography (PET/CT) is a highly sensitive method for determining the sites of disease in 
DLBCL. Obtaining a FDG-PCT/CT scan at diagnosis has become the standard of care as it 
leads to a change in the stage of disease in between 20 and 40% of cases. Scanning in this 
way is also effective for the assessment of residual disease, with a positive FDG-PET/CT at 
the end of treatment being associated with inferior progression free survival and overall 
survival (Jerusalem et al., 1999; Mikhaeel et al., 2000; Buchmann et al., 2001; Schoder et 
al., 2001; Spaepen et al., 2001; Sasaki et al., 2002; Kostakoglu et al., 2004; Seam et al., 
2007; Dupuis et al., 2009).  
1.3.1.5 Treatment 
Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was identified as the 
best treatment for NHL in 1993, and remains the backbone of NHL today (Fisher et al., 
1993). The addition of the anti-CD20 monoclonal antibody rituximab (R-CHOP), led to a 
15% increase in overall survival across all DLBCL cases (Coiffier et al., 2002; Habermann et 
al., 2006; Pfreundschuh et al., 2006; Pfreundschuh et al., 2008). Recently, a number of 
new agents have been trialled for use in addition to R-CHOP, such as the anti-CD22 
monoclonal antibody, epratuzumab, the proteasome inhibitor, bortezomib and the 
immunomodulatory agent, lenalidomide (Micallef et al., 2011; Nowakowski et al., 2011; 
Ruan et al., 2011; Chiappella et al., 2013). 
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1.3.2 Follicular Lymphoma 
Follicular lymphoma (FL) is the second most common form of B-NHL, making up around 
20% of all new diagnoses in the UK (Cancer Research UK, 2010). FL is an initially indolent 
disease associated with old age, with an average age of onset around 60 years (Blood, 
1997; Armitage and Weisenburger, 1998; Harris et al., 1999). 
1.3.2.1 Aetiology/Development 
The aetiology of FL is poorly understood, but like DLBCL, risk of FL has been linked to EBV 
and HTLV-1 infection and also infection with human herpes virus 8 (HHV-8) (Hartage et 
al., 2006; Ma, 2012). FL is a disease of mature B-cells, all of which share identical Ig gene 
rearrangements, suggesting that founding mutations occur post-VDJ recombination 
(Green et al., 2013). FL cells express B-cell markers such as; LMO2, CD10 and BCL6 along 
with mature B-lineage markers, including surface Ig and CD19 (Bilalovic et al., 2004). 
1.3.2.2 Clinical Features 
The symptoms of FL are similar to those seen in other lymphoid malignancies and include; 
loss of appetite and weight, fever, tiredness or fatigue and frequent infections. If FL occurs 
in the bone marrow it can cause low blood cell counts which can result in anaemia and 
low platelet counts. 
1.3.2.3 Disease Classification/Genetic Features 
Diagnosis of FL is based on histology, with increasing number of centroblasts indicative of 
increasing clinical aggressiveness. The World Health Organisation (WHO) classification 
adopts grading of 1-3 based on this number. FL cells express CD19, CD20, CD10, BCL6 and 
monoclonal Ig light chain and are negative for CD5 and CD23 (Freedman, 2014). The 
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genetic hallmark of FL, occurring in >90% of cases, is a t(14;18)(q32;q21) translocation, in 
which the oncogene BCL2 is placed under the control of the Ig heavy-chain locus (Weiss 
et al., 1987; Zelenetz et al., 1991). There are a number of genes which have been identified 
as recurrently mutated in FL, these include; CREBBP, MLL2, TNFRSF14, BCL2, HER2, IKZF2 
and CD40 (Pasqualucci et al., 2011a; Pasqualucci et al., 2011b; Lohr et al., 2012; Weigert 
et al., 2012; Green et al., 2013).  A recent study by Green et al. shed light onto the 
hierarchy of genetic events in FL (Figure 1.4) (Green et al., 2013). BCL2 translocation 
appears to be an initiating mutation, given that it is present at diagnosis and relapse but 
is not sufficient to cause malignant transformation alone (Ladetto et al., 2003; Green et 
al., 2013). CREBBP mutations on the other hand, are also seen frequently and are 
uniformly expressed between subpopulations (Green et al., 2013). Although they are not 
always seen at diagnosis, they are always kept between diagnosis and relapse, suggesting 
they constitute driver mutations (Green et al., 2013). MLL2 and TNFRSF14 mutations 
however, are variably expressed between subpopulations and can be lost between 
diagnosis and relapse, suggesting they are tertiary events or accelerator mutations (Green 
et al., 2013).  
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Figure 1.4. Hierarchy of somatic mutations arising in follicular lymphoma. Adapted from 
(Green et al., 2013). 
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FL has a tendency to transform into the more aggressive DLBCL (Montoto and Fitzgibbon, 
2011) (Section 1.3.1). Evidence suggests that between 16 and 70% of patients may 
undergo this transformation (Montoto and Fitzgibbon, 2011). This transformation may 
occur due to mutations in a common precursor clone (CPC), with mutations in genes 
involved in epigenetic modification and resistance to apoptosis frequently seen 
(Pasqualucci et al., 2014). Other genetic events which are frequently observed in 
transformed FL (tFL) include; mutations in TP53, KMT2D, CREBBP, EZH2 and BCL2, 
mutation or epigenetic silencing of CDKN2A/p16, BCL6 translocations, alterations of 
chromosome 1p36, and altered MYC expression (Lo Coco et al., 1993; Sander et al., 1993; 
Pinyol et al., 1998; Lossos et al., 2002; Akasaka et al., 2003; Martinez-Climent et al., 2003; 
Pasqualucci et al., 2014; Bouska et al., 2016). Despite the frequency of these mutations, 
no single lesion appears to be selected for during transformation to DLBCL (Pasqualucci 
et al., 2014). 
1.3.2.4 Prognostic Factors 
FL is considered an indolent disease which is usually incurable in advanced stages. Table 
1.8 shows a list of prognostic models used for risk stratification in FL. The two best 
measures of outcome are the FL international prognostic index (FLIPI) and histological 
tumour grade (Relander et al., 2010). FLIPI determines prognosis based on five prognostic 
factors; age, serum lactate dehydrogenase, haemoglobin level, tumour stage and number 
of nodal areas involved (Solal-Celigny et al., 2004). A modified version of this named FLIPI2 
has also been developed (Table 1.8) (Federico et al., 2009). Loss of chromosomal material 
at 6q25-27 and deletions in 9p21, 6q25 and 6q26 have all been reported to be associated 
with inferior survival in FL (Cheung et al., 2009; Schwaenen et al., 2009). Transformation 
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to DLBCL is clinically important in FL, with an average survival of around 2 years post-
transformation (Montoto and Fitzgibbon, 2011). Deletions in 1p36.22-p36-33 and 6p21-
q24.3 as well as uniparental disomy of chromosome 16 are highly associated with 
transformation and inferior survival in FL (Viardot et al., 2002; O'Shea et al., 2009). Table 
1.9 describes overall survival and progression free survival associated with different FLIPI 
classifications of FL.  
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Prognostic Model Risk Factor 
Follicular lymphoma international 
prognostic index (FLIPI) 
Age >60 
Serum LDH>ULN 
Haemoglobin level <12.0g/dl 
Stage III or IV 
Number of nodal sites >4 
FLIPI2 Age >60 
Bone marrow involvement 
Haemoglobin level <12.0g/dl 
Greatest diameter of the largest involved node 
>6cm 
Serum beta-2 microglobulin level greater than 
the upper limit of normal 
Groupe d’Etude des Lymphomes 
Folliculaires (GELF) criteria for high 
tumour burden 
Any site >7cm 
≥3 sites >3cm 
Spleen below unbilican line 
Compressive symptoms 
Pleural or peritoneal effusions – 5 000 tumour 
cells/mm3 
Absolute neutrophil count <1000/mm3 
Platelet count <100 000/mm3 
 
Table 1.8. Prognostic models for follicular lymphoma. LDH; lactate dehydrogenase, ULN; 
upper limit of normal. Adapted from (Freedman, 2014). 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 1 Introduction 
 
 
35 
 
Risk Group Number of Risk Factors 2 year OS% 2 year PFS% 
Low risk 0-1 98 84 
Intermediate risk 2 94 70 
High Risk ≥3 87 42 
 
Table 1.9. Treatment outcomes of FL based on FLIPI. OS; overall survival, PFS; progression 
free survival. Adapted from (Freedman, 2014). 
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1.3.2.5 Treatment 
FL is considered ‘incurable’ by standard chemotherapy, though advances in understanding 
and treatment have improved clinical outcomes and management of the disease. Less 
than 10% of patients are diagnosed with early stage disease (I/II) (Friedberg et al., 2012). 
Early stage FL is often treated with external beam radiation therapy (XRT), though recent 
reports showed that >50% of stage I/II patients did not require radiotherapy at a median 
of 6 years and 85% of patients were alive at 10 years  (Wilder et al., 2001; Advani et al., 
2004). FL is a disease predominant in older age so for those with a life expectancy of 15 
years or less diagnosed with early stage FL, a wait-and-watch, or palliative approach is 
often the best option (Kahl and Yang, 2016). 
Advanced stage FL is separated into 4 categories for treatment purposes; 1) 
asymptomatic, low tumour burden, 2) asymptomatic, high tumour burden, 3) 
symptomatic, low tumour burden and 4) symptomatic, high tumour burden. 
Asymptomatic, low tumour burden and symptomatic high tumour burden represent the 
most common groups (Kahl and Yang, 2016). Asymptomatic, low tumour burden patients 
are candidates for a watch and wait strategy. Treatment of symptomatic, high tumour 
burden FL is with R-CHOP therapy as described in section 1.3.1.5, with investigations 
taking place into the use of novel agents such as lenalidomide, ibrutinib, venetoclax and 
duvelisib (Kahl and Yang, 2016). The alkylating agent bendamustine can be used for the 
treatment of relapsed or refractory FL, with an overall response rate of 75% and a 
progression free survival of 9.3 months achieved in clinical trials (Kahl et al., 2010). 
Fludarabine regimens, as well as radiotherapy, are also options for the treatment of 
relapsed or refractory FL (Kahl and Yang, 2016). A novel treatment option for relapsed FL 
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is the phosphatidylinositol 3-kinase (PI3K) δ inhibitor idelalisib, which showed a response 
rate of 27% in clinical trials (Gopal et al., 2014). 
 
1.4 CREBBP 
Cyclic adenosine monophosphate (cAMP) response element binding protein (CREB), 
binding protein (CREBBP/CBP) is a member of the KAT3 family of histone 
acetyltransferases along with its paralogue EP300. It is a transcriptional co-activator and 
histone acetyl transferase (HAT) located on chromosome 16 at p13.3. 
1.4.1 CREBBP Structure 
CREBBP is a large protein, around 265kDa in size and made up of numerous discrete 
functional domains (Figure 1.5). The SRCAP interaction domain (amino acids 227-410) 
allows interaction with the Snf2-Related-CBP activator protein (SRCAP) ATPase, which is 
able to enhance the ability of CREBBP to activate transcription (Johnston et al., 1999). The 
TAZ-type 1 zinc finger (amino acids 347-433) acts as a HIF1α and CITED2 interaction 
domain. HIF1α requires binding here to allow transcriptional activity during hypoxia (De 
Guzman et al., 2004). CITED2, induced by HIF1α, competes for binding and allows the 
HIF1α response to be attenuated due to negative feedback (De Guzman et al., 2004). The 
KIX domain (amino acids 587-666) provides an interaction site for the phosphorylated KID 
domain of CREB (Radhakrishnan et al., 1997). Like most histone modifiers, CREBBP has a 
bromodomain (amino acids 1103-1175), which allows interaction with acetylated lysine 
residues present on the N-terminal tails of histones (Giles et al., 1997; Zeng and Zhou, 
2002). The largest functional domain in the CREBBP protein is the HAT domain (amino 
acids 1173-1849), which functions to acetylate histone and non-histone proteins leading 
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to a variety of cellular effects (Bannister and Kouzarides, 1996; Ogryzko et al., 1996). The 
cysteine/histidine rich region in CREBBP (amino acids 1199-1487) contains a PHD-like zinc 
finger which is an important part of the enzymatic core of the HAT domain (Borrow et al., 
1996; Kalkhoven, 2004). The ZZ-type zine finger (amino acids 1701-1744) is linked to the 
TAZ-type 2 zinc finger (amino acids 1765-1846)  to form an E1A binding site (Kalkhoven, 
2004). This is the  binding site for the transactivation domain of p53 as well as the 
interaction site for the adenovirus E1A oncoprotein and numerous others including the 
anaphase promoting complex/cyclosome (APC/C) and proteins involved in cell cycle 
progression and transcription (De Guzman et al., 2000; Kalkhoven, 2004; Turnell et al., 
2005). EP300, the KAT3 family member and paralogue of CREBBP, is highly related, and 
shares a number of the domains described above (Bedford et al., 2010). 
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Figure 1.5. Map of CREBBP exons including locations of functional domains. Above nucleotide sequence (black); CREBBP exons (blue). Below 
nucleotide sequence; CREBBP functional domains. (Ensembl ID: ENST00000262367).
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1.4.2 CREBBP Function 
CREBBP plays a body-wide role in transcription and cell cycle control, interacting with the 
TATA-box binding protein (TBP) and transcription factor II B (TFIIB), both of which are involved 
in the formation of the RNA polymerase pre-initiation complex, as well as the E2F family of 
transcription factors and the APC/C (Kwok et al., 1994; Yuan et al., 1996; Martinez-Balbas et 
al., 2000; Marzio et al., 2000; Turnell et al., 2005). Further to this CREBBP is involved in HSC 
function and self-renewal, acting as a signal integrator in the haematopoietic system through 
interaction with transcription factors such as SFPI1/PI.1 and C/EBPα (Yamamoto et al., 1999; 
Blobel, 2000; Rebel et al., 2002; Kovacs et al., 2003; Iwasaki et al., 2005; Zimmer et al., 2011). 
CREBBP also acts as a co-activator for the transcription factor GATA-1, which is involved in 
erythroid cell maturation, coordinating the transcription of erythroid specific genes, blocking 
apoptosis in precursor cells and controlling the balance between cell proliferation and cell 
cycle arrest (Blobel et al., 1998). Both CREBBP and EP300 have been shown to be 
concentrated at the 5’ and 3’ ends of genes they are associated with, suggesting that they are 
also involved in pre-mRNA maturation (Ramos et al., 2010). 
CREBBP plays a crucial role in cAMP-dependent signalling, a ubiquitous form of signal 
transduction. Activation of protein kinase A (PKA) by increased levels of intracellular cAMP, 
leads to phosphorylation of the kinase inducible domain (KID) of CREB, which in turn allows 
CREBBP to bind through its KIX domain, activating CREB (Chrivia et al., 1993). CREB is a highly 
promiscuous transcription factor, with the ability to bind ~4000 different promoter start sites, 
so is important for the regulation of a wide range of genes throughout the body (Zhang et al., 
2005).   
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CREBBP is responsible for the acetylation of histone tails, which leads to an increase in 
transcriptional activation, as acetyl-lysine residues provide a binding site for chromatin 
remodelling factors which contain bromodomains (Loyola and Almouzni, 2004). Through 
bromodomain interactions, CREBBP is thought to play a role in the modulation of T regulatory 
(Treg) cells, more specifically, in differentiation of naïve Treg cells (Ghosh et al., 2016). CREBBP 
and EP300 are specifically required for global levels of histone 3, lysine 18 (H3K18) and histone 
3, lysine 27 (H3K27) acetylation, with knockout studies showing that acetylation of these two 
residues is dramatically reduced (Jin et al., 2011). This CREBBP/EP300 mediated acetylation 
of H3K18 and H3K27 is thought to be important for nuclear receptor-dependent transcription 
(Jin et al., 2011).  
CREBBP and EP300 have a large protein interactome, known to interact with at least 400 
proteins (Bedford et al., 2010). Through its HAT domain CREBBP is also able to acetylate non-
histone proteins, allowing modulation of their functions. Acetylation by CREBBP is vital for the 
activity of tumour suppressor p53, influencing its stability, DNA binding and recruitment of 
coactivators (Brooks and Gu, 2003; Tang et al., 2008). Conversely, acetylation of the 
oncoprotein BCL6, leads to its inactivation by disrupting interaction with histone deacetylases 
(HDACs), thereby reducing its ability to repress transcription (Bereshchenko et al., 2002). 
CREBBP also has intrinsic E4 polyubiquitin ligase activity and is involved in the rapid turnover 
of p53 in healthy cells (Shi et al., 2009). 
CREBBP plays a role in DNA damage repair through acetylation of base excision repair (BER) 
protein, PARP-1, which leads to enhanced activation of the anti-apoptotic NFκB pathway 
(Hassa et al., 2005). CREBBP also interacts with direct DNA repair protein, thymine DNA 
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glycosylase (TDG), and homologous recombination repair (HRR) protein, BRCA1 (Pao et al., 
2000; Tini et al., 2002; Leger et al., 2014). 
1.4.3 CREBBP Mutation 
Mullighan et al. (2011) identified that around 18.3% of relapsed childhood ALL cases were 
CREBBP mutant (Mullighan et al., 2011). These mutations were found to cause reduced 
acetylation of CREBBP target residues as well as impacting upon transcription of GC 
responsive and cAMP-dependent genes in CREBBP/EP300 double knockout mouse embryonic 
fibroblast (MEF) models, engineered to express different heterozygous CREBBP mutations 
(Mullighan et al., 2011). Importantly, acetylation was perturbed, but not lost in these CREBBP 
mutant models, and the intensity of this effect varied between mutations (Mullighan et al., 
2011). These results, coupled with the observation that CREBBP mutations can be seen in 
minor subclones at diagnosis, suggest that CREBBP mutation may play a role in drug resistance 
and thus increase the risk of relapse in childhood ALL patients (Mullighan et al., 2011). CREBBP 
mutations have been shown to be significantly enriched in relapse patients in the high 
hyperdiploid (HHD) (51-68 chromosomes) subgroup, with around 63% of CREBBP mutant 
relapse cases occurring in this cytogenetic subgroup (Inthal et al., 2012). CREBBP mutation as 
a frequent event in DLBCL and FL is becoming increasingly clear, with around 39% cases of 
DLBCL and 41-70% cases of FL identified as CREBBP mutant (Pasqualucci et al., 2011a; 
Pasqualucci et al., 2011b; Green et al., 2013; Pastore et al., 2015).  
The precise role of CREBBP mutation in the pathogenesis of these diseases is yet to be 
understood and, given the complex role played by CREBBP in a wide range of cellular 
functions, there are a number of possible mechanisms which could be affected. CREBBP 
mutations in relapsed childhood ALL, DLBCL and FL are primarily heterozygous, clustering in 
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and around, the HAT domain. This leads to attenuation or loss of function of the mutant 
protein, without altering the remaining wild type allele (Figure 1.6) (Mullighan et al., 2011; 
Pasqualucci et al., 2011a; Green et al., 2013). Importantly, CREBBP haploinsufficiency is 
known to be involved in the developmental condition, Rubinstein-Taybi syndrome (RSTS), 
which leads to an increased susceptibility to malignancies (Miller and Rubinstein, 1995; 
Roelfsema and Peters, 2007). 
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Figure 1.6. CREBBP mutations in acute lymphoblastic leukaemia (ALL) and lymphoma. CREBBP mutations documented in ALL and lymphoma 
(COSMIC) and their location in relation to the nucleotide sequence (black line) and functional domains. Multiple mutations at the same residue(s) 
are not depicted.
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One potential role of CREBBP mutation in the pathogenesis of lymphoid malignancies is in GC 
sensitivity. GCs are pivotal in the treatment of childhood ALL, DLBCL and FL, specifically 
inducing apoptosis in developing lymphocytes (Alnemri et al., 1992). CREBBP is known to 
interact with the GR and Mullighan et al. (2011) identified a link between CREBBP mutation 
and reduced expression of GC-regulated genes, with CREBBP-mutated T-ALL cell lines showing 
GC-resistance (Kino et al., 1999; Mullighan et al., 2011).  This suggests that CREBBP mutation 
may confer resistance to GC therapy. 
CREBBP plays a role in global acetylation and, with maintained expression of the wild type 
allele, it is likely that reduced HAT dosage plays a role in the pathogenesis of CREBBP-mutated 
disease (Mullighan et al., 2011; Pasqualucci et al., 2011a; Green et al., 2013). Importantly, it 
has been reported that small changes in HAT activity can lead to significant biological 
consequences (Legube and Trouche, 2003). To overcome this, treatment with HDAC inhibitors 
(HDACi) could be used in an attempt to rebalance levels of acetylation in CREBBP-mutated 
cells. Previous studies have shown that HDACi can lead to apoptosis in CREBBP mutant GC-
resistant ALL cells and in CREBBP/EP300 mutated DLBCL may be associated with increased 
sensitivity to HDACi (Tsapis et al., 2007; Mullighan et al., 2011; Andersen et al., 2012). Further 
to this, evidence suggests that histone acetylation deficits in RSTS cell lines can be reversed 
using HDACi and treatment with HDACi in CREBBP mutant mouse models was shown to 
ameliorate deficits in synaptic plasticity and cognition (Alarcon et al., 2004; Korzus et al., 
2004; Vecsey et al., 2007; Lopez-Atalaya et al., 2012). Haematological malignancies in general, 
seem to be particularly sensitive to HDACi, and this type of therapy tends to be well tolerated 
in patients (Stimson et al., 2009). 
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 A further approach could be to enhance the dysfunctional cAMP/PKA pathway. It is known 
that lymphocytes at different stages of development are susceptible to cAMP-induced 
apoptosis (Daniel et al., 1973; Coffino et al., 1975). There is known interplay between 
cAMP/PKA and the GC-induced apoptotic response, with the GR being required for cAMP/PKA 
induced apoptosis in lymphoma cells (Rickles et al., 2010). This suggests that 
phosphodiesterase (PDE) inhibitors (PDEi) could be beneficial in CREBBP-mutated lymphoid 
diseases. Certainly, PDEi has been shown to induce apoptosis in ALL and DLBCL cell lines and 
can enhance the GC-response in ALL cell lines (Ogawa et al., 2002; Smith et al., 2005). 
A study by Pasqualucci et al. (2011) showed that CREBBP mutation leads to reduced 
acetylation of p53 and BCL6 in vitro (Pasqualucci et al., 2011a). CREBBP mutation has also 
been associated with impaired BCL6 activity (Pasqualucci et al., 2011a; Green et al., 2013). 
P53 is a universally expressed tumour suppressor involved in apoptotic signalling and BCL6 is 
an oncogene involved in transcriptional repression able to inhibit p53, which leads to 
suppression of apoptosis and an environment tolerant of DNA breaks (Phan and Dalla-Favera, 
2004; Basso and Dalla-Favera, 2012). As acetylation is vital for p53 function and BCL6 
inactivity, this suggests that dysfunctional acetylation due to CREBBP mutation may lead to 
an imbalance between their activities, causing resistance to apoptosis and potentially 
induction of drug resistance. 
A recent study by Zimmer et al. found reduced activity of BER protein, PARP-1, as well as 
reduced protein levels of XRCC1 and APEX1 in CREBBP heterozygous mice (Zimmer et al., 
2012). BER is a vital pathway for the repair of single strand breaks (SSBs) in DNA (Curtin, 2012). 
Accumulation of SSBs in a cell contributes to genetic instability, a hallmark of cancer, so 
heterozygous loss of CREBBP may lead to the acquisition of a mutator phenotype (Loeb, 2001; 
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Nemec et al., 2010; Zimmer et al., 2012). This may also provide a target for therapeutic 
intervention, by way of inducing synthetic lethality in CREBBP-mutated cells. Synthetic 
lethality is a process by which cell death occurs when two pathways, or genes, are defective 
but not when a single defect occurs alone (Curtin, 2012). Given that BER appears to be 
defective in CREBBP-mutated lymphoid diseases, inhibition of the homologous recombination 
repair (HRR) pathway may lead to cell death in CREBBP-mutated cells, allowing the survival of 
healthy cells with functioning BER. 
Targeted therapies have had wide-spread success in a number of cancer types and are paving 
the way for personalised medicine for cancer therapy (Baudino, 2015). It is becoming clear 
that CREBBP mutations are a frequent event in a large number of solid tumours including; 
transitional cell carcinoma of the bladder, medulloblastoma, small cell lung cancer, adenoid 
cystic carcinoma, oesophageal squamous cell cancer, glioblastoma, squamous cell carcinoma 
and breast cancer (Gui et al., 2011; Peifer et al., 2012; Robinson et al., 2012; Ho et al., 2013; 
Gao et al., 2014a; Gao et al., 2014b; Han et al., 2014; Huether et al., 2014; Mukasa et al., 
2014; Song et al., 2014; Jansen et al., 2016; Watt et al., 2016). This suggests that 
understanding CREBBP mutations and developing therapies to rebalance its activity may 
benefit a wide range of cancer types. 
 
1.5 Aims and Hypotheses 
The key aim of the project was to investigate routes for the therapeutic targeting of CREBBP-
mutated lymphoid diseases. 
 Objective 1 - To investigate the molecular pathology of CREBBP mutations in ALL 
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o Characterise a BCP-ALL cell line with stable CREBBP knockdown 
o Validate data in additional BCP-ALL cell lines and primary derived samples with 
CREBBP knockdown 
o Study the effect of stable CREBBP knockdown on cell line growth in vivo 
 Objective 2 – Investigate the molecular pathology of CREBBP mutations in 
lymphoma 
o Create and characterise a DLBCL cell line with stable CREBBP knockdown 
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Materials and Methods 
2.1 General  
2.1.1 Equipment 
 7500 Fast Real-Time PCR System (Applied Biosystems, Warrington, UK) 
 Agarose Gel Electrophoresis Unit (BioRad, Hemel Hempstead, UK) 
 Analogue Tube Roller SRT9 (Stuart Scientific, UK) 
 Bead Bath (Gallenkamp/Weiss, Loughborough, UK)  
 BioRad Power Pac 200 (BioRad) 
 Class II microbiological safety cabinet (BIOMAT-2, Medical Air Technology Ltd., 
Manchester, UK) 
 EPI 2500 Elektroporations-impulsgenerator  
 FACSCalibur (Becton Dickinson, Oxford, UK) 
 FACSCanto II (Becton Dickinson) 
 FLUOStar Omega Microplate Reader (BMG Labtech, Aylesbury, UK) 
 Fujifilm Luminescent Image Analyzer (LAS-3000) (Fujifilm, Billingham, UK) 
 Gel Electrophoresis Tank (Pharmacia Biotech, Amersham Biosciences, UK) 
 Gene Amp PCR System 2700 (Applied Biosystems) 
 Gyro-Rocker STR9 (Fisher Scientific, Loughborough, UK) 
 Irradiation System RS320 (Gulway Medical, UK) 
 Microwave Oven (Sharp Electronics LTD., Burnley, UK) 
 Mini-PROTEAN 11 Electrophoresis Cell (BioRad) 
 Mini Trans-Blot Electrophoretic Transfer Cell (BioRad) 
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 Stirrer UC151 (Bibby Scientific Limited, Staffordshire, UK) 
 Techne Dri-Block DB-3D (Bibby Scientific Limited) 
 Water Bath (Grant Instruments, Cambridge, UK) 
 WhirliMixer (Fisons Scientific Equipment, Leicestershire UK) 
2.1.2 Centrifuges 
 Eppendorf refrigerated Centrifuge 5417R (Fisher Scientific) 
 Mistral 3000i Refrigerated Centrifuge (Fisher Scientific) 
2.1.3 Microscopes 
 Olympus transmitted light microscope (Olympus, Japan) 
 Zeiss transmitted light microscope (Carl Zeiss Ltd., Welwyn Garden City, Herts., 
UK) 
2.1.4 General Chemicals 
All chemicals and reagents were purchased from either Sigma Chemical Company (Dorset, 
UK) or Thermo Fisher (Loughborough, UK) unless otherwise stated. Phosphate buffered 
saline (PBS) was prepared from tablets (Invitrogen, Paisley, UK) and autoclaved before 
use.   
 
2.2 Cell Culture 
2.2.1 Cell Lines 
PreB 697: BCP-ALL cell line, established in 1979 from the bone marrow of a 12 year old 
male at relapse (Findley et al., 1982). 
Chapter 2 Materials and Methods 
 
 
52 
 
MHH-CALL-2: BCP-ALL cell line, established in 1993 from the peripheral blood of a 15 year 
old Caucasian girl with ALL at diagnosis (Tomeczkowski et al., 1995). 
SU-DHL-4: DLBCL cell line, established in 1975 from the peritoneal effusion of a 38 year 
old man (Epstein and Kaplan, 1979).  
2.2.2 Cell Line Maintenance 
Cell lines were grown as suspension cultures. PreB 697 cells were maintained in RF10 
(RPMI 1640 medium containing L-glutamine (Sigma Aldrich, Dorset, UK) supplemented 
with 10% foetal bovine serum (FBS) (Gibco, Rugby, UK). MHH-CALL-2 and SU-DHL-4 cells 
were maintained in RPMI 1640 medium containing L-glutamine (Gibco) supplemented 
with 20% FBS (Gibco). Tissue culture was performed in a Class II microbiological safety 
cabinet (Section 2.1.1) using sterilised glass and plasticware (Corning, High Wycombe, 
UK). Cells were grown in flasks or multi-well plates. Cell line incubation was carried out at 
37°C in a humidified tissue culture incubator at 5% CO2. 
2.2.3 Mycoplasma Testing 
Contamination of cell lines by mycoplasma can interfere with almost all parameters that 
are measured in cell culture, effects vary between cell lines and are not predictable 
(Drexler and Uphoff, 2002). All cell lines used in this project were routinely tested for 
mycoplasma infection using MycoAlert (Lonza, Basel, Switzerland). The MycoAlert assay 
exploits the activity of mycoplasmal enzymes to detect infection. Any viable mycoplasma 
are lysed and these enzymes react with MycoAlert substrate, catalysing the conversion of 
ADP to ATP. By measuring ATP levels in a sample before and after the addition of 
MycoAlert, a substrate ratio can be obtained which can effectively indicate the presence 
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or absence of mycoplasma infection. Cell lines were mycoplasma free throughout the 
project. 
2.2.4 Cells Counts and Viability Assessment 
Cell counting and viability assessment was carried out using trypan blue (Thermo Fisher) 
staining and a haemocytometer (Hawksworth, UK). Cell suspensions were mixed 1:1 (v/v) 
with a 0.4% solution of trypan blue in PBS and were counted using a haemocytometer 
with an Improved Neubauer counting chamber.  
2.2.5 Cell Harvesting 
Cells were harvested for RNA, DNA and protein studies when in exponential growth phase. 
The cell suspension was centrifuged at 1000 RPM (or 1200 RPM for primary cells) for 5 
minutes at room temperature. Supernatant was removed and the pellet washed by 
resuspending in PBS and pelleted again by centrifugation. The wash step was carried out 
twice and PBS was removed before pellets were stored at -80°C until required. 
2.2.6 Cryopreservation 
To cryopreserve cell stocks, cells in exponential growth phase were counted and assessed 
for viability (Section 2.2.4). Cells were then centrifuged at 1000 RPM (or 1200 RMP for 
primary and primary derived cells) for 5 minutes at room temperature and resuspended 
in freezing mixture made up of 10% (v/v) dimethyl sulphoxide (DMSO) (Sigma Aldrich) in 
FBS (Gibco) at 5x106-1x107/ml. Aliquots of 1ml were put into 2ml polypropylene cryotubes 
(Invitrogen) and placed in a polystyrene box filled with cotton wool, before being placed 
in a -80°C freezer. This ensured that the samples cooled at a rate of approximately 1°C per 
minute. After 2-14 days vials were transferred into storage in liquid nitrogen.  
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To recover cryopreserved cells, vials were rapidly thawed in a 37°C bead bath (Section 
2.1.1), diluted 1:10 with the relevant growth media and centrifuged at 1000 RPM for 5 
minutes. Freezing mixture was aspirated and the pellet resuspended in fresh growth 
media in a tissue culture flask. 
2.2.7 Formation of Primagrafts 
Principal  
Cell yield from patient material is often not great enough to carry out various downstream 
analyses, such as gene knockdown by small interfering RNA (siRNA) (Section 2.7.2). Mice 
have been developed with severe immunodeficiency (Non-obese diabetic, severe 
combined immunodeficiency (NOD-SCID), IL-2R common gamma chain null (NSG)) which 
allows injection of human haematopoietic cells without rejection (Shultz et al., 2005). NSG 
mice provide a superior platform for sustained engraftment of human hematopoietic 
stem cells and patient derived leukaemia (Shultz et al., 2005; Shultz et al., 2007; Agliano 
et al., 2008). Importantly, engrafted cells largely retain their leukaemic profile, in terms of 
phenotype, chromosomal aberrations, transcriptome and MRD marker expression 
(Woiterski et al., 2013). Leukaemia engraftment in mice can be assessed by analysing 
peripheral blood at frequent intervals for presence of human leukaemia by flow 
cytometry. Spleens taken from highly engrafted mice are enlarged and made up of a high 
percentage of human leukaemia cells which can be used for ex vivo analyses or can be re-
implanted into mice to generate further material. The key drawbacks of this technique 
are that it is time consuming and it is difficult to predict how long each patient sample will 
take to engraft in the spleen as well as how deleterious each sample will be to the health 
Chapter 2 Materials and Methods 
 
 
55 
 
of the mouse. Further to this, peripheral blood engraftment does not always closely 
correlate with spleen engraftment.  
Procedure 
Primary patient cells (Table 2.1) were thawed (Section 2.2.6) and resuspended in RF10 at 
5x107/ml (1x106 in 20µl). NSG were injected intrafemorally with 1x106 primary patient 
cells by a trained researcher with a home office licence. 
 
 
 
 
 
 
Table 2.1 Clinical details of patient samples used to generate primagrafts. G7578 NN, 
G7578 LN and G1062 RN primagraft samples were kindly donated by Paul Sinclair, and 
CREBBP status was assessed by SNP 6.0 arrays and genotyping console software 
(Affymetrix, High Wycombe, UK). 
 
2.2.7.1 Monitoring peripheral blood engraftment and assessment of spleen engraftment 
Around 50µl of mouse blood was taken from the tail vein, prepared for and analysed by, 
flow cytometry (Section 2.3.2). Once peripheral blood engraftment had reached >40%, 
mice were euthanised, spleens were removed and cells were resuspended in growth 
media to be assessed for engraftment by flow cytometry (Section 2.3.2) and other 
downstream analyses.  
Patient ID Age at 
Diagnosis 
CREBBP Status Other Mutations 
L779 5.5 yrs Wild type NRAS (Q61R) 
L829 
Relapse 
3.1 yrs Wild type (Wt 2) KRAS (G13D) 
L914 7.3 yrs Wild type CBL/FLT3 Large 
del/Δ836 
L885 2.2 yrs Wild type (Wt 1) - 
G7578 NN 12 yrs Wild type (Wt 3) - 
G7578 LN 12 yrs Mono-allelic deletion 
(Del 1) 
- 
G1062 RN 17 yrs Mono-allelic deletion 
(Del 2) 
- 
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2.2.8 In Vivo Growth of Cell Lines 
Principle 
Many of the complex growth factors and cell/tissue interactions are absent in an in vitro 
growth environment, and for this reason further insight into cell growth characteristics 
can be gained from the use of in vivo models. In order to assess cell line growth within the 
context of a whole organism, cell lines with lentiviral gene knockdown were implanted 
into NSG mice, and engraftment was studied. 
Procedure 
PreB 697 shCBP and shNEG cells (Section 2.7.1) were implanted into NSG mice (Section 
2.2.7) at 10 000 cells per mouse. Peripheral blood engraftment was monitored by tail vein 
bleed (Section 2.2.7). Mice were euthanised upon first signs of morbidity (weakness, loss 
of muscle tone, sedate behaviour etc.). Spleen and liver were weighed and a portion of 
the spleen was resuspended in growth medium for analysis of engraftment (Section 
2.2.7). GFP positivity was used to identify lentivirally transduced cells (Section 2.3.1). 
 
2.3 Flow Cytometry 
Principle  
Flow cytometry is a technique which is able to detect and enumerate specific cell types 
within a complex mixture. Flow cytometers are made up of three components; fluidics, 
optics and electronics. The fluidics system generates a stream of cells which individually 
and rapidly flow through an interrogation point (Henel and Schmitz, 2007). Cell attributes 
are then assessed by their ability to scatter laser light which intersects the cells at this 
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point. Standard flow cytometers have 1-2 lasers but more modern machines employ many 
more to detect a large number of parameters in parallel (Henel and Schmitz, 2007). 
Emitted light is given off in all directions and is subsequently collected by optics which 
direct the light into a series of filters and dichroic mirrors. Light signals are collected by 
photomultiplier tubes and digitised for analysis on a computer (Henel and Schmitz, 2007). 
The properties of cell size and granularity are determined by forward and side scatter 
respectively. To increase the number of parameters that can be detected by flow 
cytometry, antibodies conjugated to different fluorochromes are employed. 
Fluorochromes are molecules which absorb light of a given wavelength and emit light of 
a higher wavelength (Henel and Schmitz, 2007). Antibodies conjugated to different 
fluorochromes with similar excitation and different emission wavelengths can be used to 
allow analysis of several cellular properties simultaneously. 
2.3.1 Assessment of Lentiviral Transduction 
Between 1x105 and 1x106 cells were washed twice in PBS by centrifuging at 450 x g for 4 
minutes and the supernatant removed. Cells were then resuspended in 350µl PBS and 
analysed for GFP (FITC) expression on a BD FACSCalibur (Becton Dickinson) fitted with a 
488nm laser. 
2.3.2 Determining Peripheral Blood and Spleen Engraftment 
Around 50µl of mouse blood was taken and washed using 3ml of Dulbecco’s PBS (Thermo 
Fisher) made up to 0.2% bovine serum albumin (BSA) and filtered (termed PBSA) and 
spinning for 4 minutes at 450 x g. Cells were then stained using 5µl of patient dependent 
(anti-CD45, anti-CD38 or anti-Korsa) FITC conjugated antibody, 5µl anti-CD10 PE 
conjugated antibody, 5µl anti-CD34 Per-CP conjugated antibody, 2.5µl anti-CD19 APC 
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conjugated antibody and 2.5µl mouse anti-CD45 PE-Cy™7 conjugated antibody and left to 
incubate in the dark for 15 minutes. Red cell lysis was then carried out by adding 1.2ml of 
ammonium chloride red cell lysis solution to the cells and mixing by inversion for 5 
minutes. Two more washes were carried out before analysis by flow cytometry on a BD 
FACSCanto II (Becton Dickinson), fitted with 488nm and 633nm lasers. To assess spleen 
engraftment double the antibody volume was used and red cell lysis was omitted. 
2.3.3 HLA-DR Surface Expression 
Cells were harvested and washed in PBS (Section 2.2.5) before staining with a HLA-DR APC 
conjugated antibody (G46-6) (Becton Dickinson), isotype control (MOPC-21) (Becton 
Dickinson) or left unstained and incubated in the dark at room temperature for 15 
minutes. Two more washes were carried out before analysis by flow cytometry on a BD 
FACSCanto II (Becton Dickinson), fitted with 488nm and 633nm lasers. 
 
2.4 DNA Analysis 
2.4.1 DNA Extraction 
Principle 
All nucleic acid extraction and purification was carried out using solid phase methods 
involving silica matrices, which have unique nucleic acid binding properties (Tan and Yiap, 
2009). For DNA extraction samples are lysed using a protease-containing lysis buffer and 
binding buffers and ethanol are added to prepare the sample for binding to the silica 
membrane. Washing steps are carried out to remove contaminants and finally the DNA 
Chapter 2 Materials and Methods 
 
 
59 
 
sample is eluted using a buffer (or H20) under low ionic strength (pH ≥7) (Tan and Yiap, 
2009). 
DNA was extracted from cell pellets using a QIAamp DNA Mini kit (Qiagen, Crawley, UK).  
Reagents 
 Qiagen protease 
 Buffer AL 
 Buffer AW1 
 Buffer AW2 
 100% Ethanol 
 Buffer AE 
Procedure 
Between 5x106 and 1x107 cells in exponential growth phase were harvested and pelleted 
(Section 2.2.5). Cells were resuspended in 200µl of PBS in an eppendorf containing 20µl 
of Qiagen protease. Two hundred microliters of buffer AL was added and mixed by pulse 
vortexing for 15 seconds. The sample was then incubated at 56°C for 10 minutes before 
the addition of 200µl of absolute ethanol and being applied to a QIAamp mini spin column. 
Centrifugation was carried out at 8000 rpm for 1 minute and the flow through discarded. 
The column was then washed with 500µl buffer AW1 at 8000 rpm for 1 minute followed 
by 500µl buffer AW2 at 14 000 rpm for 3 min, the flow through discarded each time. To 
dry the column after washing, centrifugation was carried out again at 14 000 rpm for 1 
minute. Between 150 and 200µl of buffer AE was added directly to the silica membrane 
and left to incubate at room temperature for 1 minute before elution into a new 1.5ml 
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eppendorf was carried out at 8000 rpm for 1 minute. DNA purity was assessed by Nano 
Drop (Section 2.4.2) 
2.4.2 Quantification of DNA and RNA Samples 
DNA or RNA concentration was determined by assessing spectrophotometric absorbance 
at 260nm and 280nm, against a water blank using an ND-1000 Spectrophotometer 
(Nanodrop) (Nanodrop, Labtech International, UK). Purity was assessed by the ratio of 
260nm and 280nm readings, with a ratio of between 1.8 and 2.0 indicative of pure RNA 
or DNA, with lower ratios indicating protein contamination. 
2.4.3 Polymerase Chain Reaction 
Principle 
PCR is a well-established and widely used method for the rapid, exponential amplification 
of specific nucleotide sequences from a DNA target. Two oligonucleotide primers (15-30 
nucleotides) must be designed to flank the target sequence to be amplified. The forward 
primer is designed to be complimentary to the sense strand and the reverse primer is 
designed to be complimentary to the antisense strand to allow amplification in both 
directions. Template DNA is added to a mixture of forward and reverse primers with heat 
stable DNA polymerase (commonly, taq polymerase), DNA precursors (dGTP, dCTP, dATP, 
dTTP) and MgCl2. Through cycles of different temperatures, the DNA can be denatured 
and primers bind allowing the heat stable DNA polymerase to synthesise new DNA strands 
which are complimentary to the region of interest. PCR is known as a chain reaction 
because the newly synthesised strands act as templates for subsequent cycles in 
sequence. This way, the amount of newly synthesised target DNA increases exponentially 
with each heating cycle. An average PCR reaction consists of 30-40 cycles. After around 
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25 cycles the reaction mixture will contain enough copies of the target sequence (~105) to 
be visualised as a discrete band when resolved using agarose gel electrophoresis (Section 
2.4.4). The heating cycles of an average PCR are as follows: 
 Denaturation – 93-95°C 
 Reannealing – 50-70°C (depends on the annealing temperature of the primers 
(Tm)) 
 Extension – 70-75°C 
Touchdown PCR, the method used in this project, is a variation of the traditional PCR 
technique, designed to reduce the likelihood of primers binding to non-specific 
sequences. It involves starting the reaction with a higher than optimal annealing 
temperature and gradually approaching the desired temperature every 2 cycles. Varying 
MgCl2 concentration and the addition of betaine are also other common methods used to 
optimise PCR reactions to prevent non-specific binding.  
Reagents 
 MgCl2 (Invitrogen) 
 Forward and Reverse Primers (Table 2.2) (Invitrogen) 
 AmpliTaq Gold (Applied Biosystems) 
 dNTPs (Applied Biosystems) 
 PCR Buffer (Applied Biosystems) 
 RNase free water (Gibco) 
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Procedure 
PCR reaction mix was made up as follows; 1x PCR buffer, 100µM dNTPs, 1.5-3.5mM MgCl2, 
0.2µM forward and reverse primers, 1.25U AmpliTaq gold and ~50ng of DNA (Sections 
2.4.1) template. Reaction volumes were between 25 and 100µl depending on the 
downstream application. PCR conditions were as follows; 10 minute denaturation at 95°C, 
touchdown protocol of 20 seconds at 94°C followed by 1 minute at the Tm of the primers 
+7°C (reducing towards Tm every 2 cycles) and 1 minute at 72°C for 15 cycles followed by 
20 seconds at 94°C, 1 minute at Tm of primers and 1 minute at 72°C for 20 cycles with a 
final 7 minute extension at 72°C. All primers were purchased from Invitrogen (Table 2.2).  
 
 
Table 2.2. List of CREBBP primers used for genomic PCR, including sequence, annealing 
temperature and MgCl2 concentration. All primers were purchased from Invitrogen. 
 
2.4.4 Agarose Gel Electrophoresis 
Principle 
Agarose gel electrophoresis allows the separation of DNA by size. In this way, PCR 
products can be visualised in order to confirm the reaction was successful and to check 
product size. Agarose is a linear polymer and is used to form a porous matrix in which the 
DNA can be separated. The size of the pores are dependent on the concentration of 
agarose used. A current is passed through the agarose gel causing the DNA, which has a 
Target Forward Primer Reverse Primer Tm Product 
Size 
MgCl2 
Conc 
Exon 18 GACTGGCATTTGGATATTGGGG TCCAAGGGACTGCATGACAG 55°C 280bp 1.5mM 
Exon 21 GATTTTAAGGGGCCATCATGTC CCCACAACCCACTCCATAAG 50°C 267bp 1.5mM 
Exon 25 AGCACCTTGTCAGCAACAGC ACACGGCTCACTGAATGACAC 56°C 247bp 2.5mM 
Exon 26 AACATGTGCCTCCTTCCCAC AAAGAGCTTGCTACGTGCCC 56°C 338bp 2.5mM 
Exon 27 CCTTAAAGGCAGGGCCGATTTC TGACAAAAGCCACCACCTTCC 56°C 264bp 2.5mM 
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negatively charged backbone at neutral pH, to migrate towards the positive anode. 
Smaller DNA fragments move through the matrix faster than larger ones, allowing 
separation. Separated DNA fragments are commonly visualised using a DNA intercalating 
dye such as ethidium bromine, or a modern, less toxic alternative such as gel red. 
Reagents 
 Electrophoresis grade agarose (Invitrogen) 
 GelRed DNA Stain (10 000x) (Biotium, Cambridge Bioscience, Cambridge, UK ) 
 Tris borate ethylenediaminetetraacetic acid (EDTA) (TBE) Buffer (10x stock) - 1M 
Tris base, 1M boric acid and 20ml/litre 0.5M EDTA (pH 8.0) 
 Gel Loading Buffer (6x) (Promega, Southampton, UK)  
 PCR Markers 50-1000bp ladder (Promega)  
Procedure 
The agarose gel was formed by melting electrophoresis grade agarose in 40ml TBE (1x 
stock) to give a 0.4% (w/v) gel. Four microliters of 10 000 x GelRed DNA stain was then 
added to the molten gel mixture. The gel was poured into a casting tray with a well comb 
and allowed to set for at least 15 minutes. For sample loading, 10µl of PCR product was 
mixed with 2µl of 6x loading buffer and pipetted into a well of the agarose gel. For 
estimation of product size, 5µl of PCR markers were mixed with 1µl of 6x loading buffer 
and pipetted into a well of the agarose gel. Electrophoresis was carried out in a gel 
electrophoresis tank (Pharmacia Biotech) (Section 2.1.1) in TBE (1x stock) at 80V for 40-
120 minutes. Gels were visualised using a BioRad Transilluminator (GelDoc) (Section 
2.1.1). 
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2.4.5 Purification of PCR products 
Principle  
As described in section 2.4.1.  
PCR products were purified using a QIAquick PCR purification kit (Qiagen). 
Reagents 
o Buffer PB1 
o Buffer PE 
o Buffer EB 
Procedure 
The PCR sample was mixed with buffer PB1 (5 volumes PB1 to 1 volume PCR sample) and 
vortexed briefly, ensuring that the colour of the mixture remains yellow (indicative of pH 
<7.5, the optimal pH for the buffers to work). Addition of 3M sodium acetate (pH 5.0) can 
be carried out to correct the pH if required. The sample was then added to a QIAquick 
column and centrifuged at 13 000 RPM for 30-60 seconds to allow DNA to bind to the 
column. The flow-through, collected in a collection tube, was then discarded and the spin 
column was washed with 750µl buffer PE by centrifugation at 13 000 RPM for 30-60 
seconds. The flow-through was again discarded and the column was centrifuged once 
more for 60 seconds. The column was then placed into a clean 1.5ml microcentrifuge tube 
and 30-50µl of elution buffer (buffer EB) was added directly to the silica membrane and 
left to stand for 60 seconds. Elution was carried out by centrifugation at 13 000 RPM for 
60 seconds into a new 1.5ml eppendorf. The concentration and purity of the DNA was 
checked by Nano Drop (Section 2.4.2). DNA was stored at 4°C for short term or -80°C long 
term. 
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2.4.6 Sanger Sequencing 
Principle 
Sequencing of DNA was carried out using the dideoxynucleotide chain termination 
method (Sanger et al., 1977). This method is based on the selective incorporation of chain-
terminating 2’,3’-dideoxynucleotide triphosphates during in vitro DNA replication. The 
DNA sample to be sequenced is mixed with normal deoxynucleotides as well as 
dideoxynucleotides, each of which is coupled to a different fluorescent tag and DNA 
polymerase. The dideoxynucleotides lack a 3’OH group and so prevent any further 
elongation of DNA after incorporation; this results in different strand lengths. Automated 
DNA sequencers carry out DNA size separation by capillary electrophoresis and detection 
and recording of dye fluorescence, with data output in the form of a chromatogram.   
Procedure 
Sanger sequencing of PCR products was outsourced to Source Bioscience (Cambridge, UK). 
Sample requirements for this service were; 1ng/µl per 100bp to be sequenced and 
primers at 3.2pmol/µl. Results were received as chromatograms and analysed using 
FinchTV (Geospiza, Seattle, USA) and DSgene software (Accelrys, San Diego, USA). 
2.4.7 Quantitative Reverse-Transcriptase Polymerase Chain Reaction 
Quantitative reverse-transcriptase polymerase chain reaction (QRT-PCR) is a rapid and 
sensitive method used for measuring relative mRNA expression within cells. The 
procedure is made up of three stages: 
1. Extraction of RNA from cells 
2. Synthesis of copy DNA (cDNA) by reverse transcription of the RNA 
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3. Real-time PCR reaction using the cDNA 
2.4.7.1 RNA Extraction 
Principle 
As described in section 2.4.1. For RNA extraction, samples are lysed and homogenised in 
the presence of a highly denaturing guanidine-thiocyanate-containing buffer, which leads 
to the immediate inactivation of RNases, keeping the RNA intact. Ethanol is added to 
provide the appropriate binding conditions, before applying the sample to a silica 
membrane. Contaminants are washed away and RNA is eluted using RNase free water 
(Tan and Yiap, 2009). 
Total RNA was extracted using a Qiagen RNeasy Mini kit (Qiagen). 
Reagents 
 Buffer RLT 
 Buffer RW1 
 Buffer RPE 
 2-Mercaptoethanol 
 70% ethanol 
 RNase free water 
Procedure 
Between 1x106 and 1x107 cells in exponential growth phase were harvested and pelleted 
(Section 2.2.5). Pellets were then lysed by using the appropriate volume of buffer RLT 
(containing 2-Mercaptoethanol) and pipetting up and down to break up the pellet. 
Homogenisation was carried out by passing the sample though a 20-gauge needle fitted 
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to a 1ml hypodermic syringe 5-10 times. An equal volume of 70% ethanol was added to 
the sample and mixed before transfer into an RNeasy mini spin column, placed into a 2ml 
collection tube and centrifuged for 15 seconds at 10 000 RPM. The flow through was 
discarded and the column washed by the addition of 700µl of buffer RW1 and 
centrifugation at 10 000 RPM for 15 seconds. The flow through was again discarded and 
further washing was carried out by the addition of 500µl of buffer RPE followed by 
centrifugation for 15 seconds at 10 000 RPM. Flow through was discarded and a further 
wash step with RPE buffer carried out, this time with 2 minute centrifugation at 10 000 
RPM. After discarding the flow through the column was centrifuged for a further 1 minute 
to remove any excess ethanol. RNA was eluted by transferring the RNeasy mini spin 
column to a new 1.5ml collection tube, before adding 30-50µl RNase free water and 
centrifuging at 10 000 RPM for 1 minute. RNA concentration and purity was determined 
by Nano Drop (Section 2.4.2). Samples were stored at -80°C until required. 
2.4.7.2 Copy DNA Synthesis 
Principle 
This method allows the formation of complementary copy DNA (cDNA) by a reverse 
transcriptase enzyme, which uses cellular mRNA as a template. This cDNA can then be 
used in quantitative reverse transcriptase PCR (QRT-PCR) reactions. 
Synthesis of cDNA was carried out using a High-Capacity Reverse Transcription Kit (Applied 
Biosystems, Thermo Fisher) and the provided protocol. 
Reagents 
 10x RT Buffer 
 10x RT Random Primers 
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 25x dNTP Mix (100mM) 
 Multiscribe™ Reverse Transcriptase (50U/µl) 
 RNase Inhibitor 
 RNase free water 
Procedure 
Each RNA sample was made up to a final concentration of 70-200µg/ml in RNase free 
water. The reaction buffer was prepared on ice as outlined in table 2.3. 
Component Volume/Reaction (µl) 
10x RT Buffer 2.0 
25X dNTP Mix (100mM) 0.8 
Random Primers 2.0 
MultiScribe™ Reverse 
Transcriptase 
1.0 
RNase Inhibitor 1.0 
Nuclease-free H2O 3.2 
 
Table. 2.3 Reaction buffer used in cDNA synthesis. 
 
The final reaction mix was made by adding 10µl of reaction buffer with 10µl of RNA (at 
70-200µg/ml) in a PCR reaction tube (Applied Biosystems) and mixed by pipetting. Any 
tubes with bubbles were briefly centrifuged to remove them. To complete the reaction 
tubes were incubated in a thermal cycler (Gene Amp PCR System 2700, Applied 
Biosystems) at 25°C for 10 minutes, followed by 37°C for 120 minutes and 85°C for 5 
seconds. cDNA was stored at 4°C for short term storage or -20°C for long term storage. 
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2.4.7.3 QRT-PCR 
Principle 
QRT-PCR relies on the measurement of PCR product after each cycle via fluorescent dyes 
that yield increasing fluorescent signal directly in proportion with the number of PCR 
product molecules. QRT-PCR provides a high degree of sensitivity and reproducibility, with 
accuracy within a two-fold range and a direct range of input material that covers 6 to 8 
orders of magnitude.  
The commercially available TaqMan® real-time PCR method was used in this project. This 
method allows accurate quantification of PCR product by inclusion of a fluorogenic 
oligonucleotide probe to components of the standard PCR product. TaqMan® probes 
consist of two types of fluorescent label; the reporter (6-carboxyfluorescein or FAM), 
attached at the 5’ end and a quencher (6-carboxy-tetramethyl-rhodamine or TAMRA) 
attached at the 3’ end. 
During the PCR reaction, samples are exposed to ultra violet (UV) light after each cycle. 
Fluorescent output following this exposure is determined by a charge-coupled device 
(CCD) camera and logged by a computer. Whilst the probes are intact, the close proximity 
of the reporter to the quencher significantly decreases the fluorescence output. Cleavage 
of the probe causes a fluorescent signal to be omitted based on the fluorescence 
resonance energy transfer (FRET) principle (Cardullo et al., 1988). If the target is present, 
the probe anneals downsteam and is cleaved by 5’ nuclease activity of Taq polymerase 
during the extension phase of PCR. Importantly, this cleavage removes the probe from 
the target strand, allowing primer extension to continue to the end of the template 
strand. Reporter dye molecules are cleaved from their quencher probes with each 
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additional cycle, leading to an increase in the intensity of the fluorescent signal which is 
proportional to the amount of PCR product formed.  
During amplification the fluorescence intensity is measured and an amplification plot 
formed. At the beginning is a linear phase (first 10-15 cycles), when the fluorescence signal 
has not risen above background levels, this is when the baseline fluorescence is 
calculated. An arbitrary threshold is chosen by the computer, it is ten times the standard 
deviation of the average signal of the baseline fluorescence between cycles 5 and 15. The 
comparative threshold (CT) is the fractional PCR cycle number at which the reporter 
emission is above the threshold value.  
The comparative CT threshold method (ΔΔCT) can be used to quantify mRNA expression 
relative to the expression of an endogenous control, without the need for a standard 
curve (Schmittgen and Livak, 2008). The formula used for this method is as follows; 
ΔCT = CT Target Gene – CT Reference Gene 
ΔΔCT = ΔCT Treated – ΔCT Untreated 
Reagents 
 2 x TaqMan Universal PCR MasterMix (Applied Biosystems) 
 Primer/probe set (Assays-on-Demand, Applied Biosystems) (Table 2.4) 
 RNase free water 
Procedure for assessment of basal gene expression 
Total RNA was isolated from pellets of cells growing in exponential phase and cDNA 
synthesised (Sections 2.4.7.1 & 2.4.7.2). QRT-PCR was carried out using the relevant 
primer/probe sets (Table 2.4). 
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Procedure for assessment of cAMP-dependent targets 
Cells in exponential growth phase were treated with 100µM 3-isobutyl-1-methylxanthine 
(IBMX) and 10µM forskolin to maximally increase intracellular cAMP levels or control 
vehicle (CV) (0.002% ethanol and 0.0008% DMSO). IBMX is a phosphodiesterase (PDE) 
inhibitor, which prevents the breakdown of cAMP within the cell. Forskolin is an adenyly 
cyclase agonist, causing an upregulation of cAMP production. Following 90 minutes of 
IBMX and forskolin treatment, cells were harvested for RNA and cDNA was subsequently 
synthesised (Sections 2.4.7.1 & 2.4.7.2). QRT-PCR was then carried out using the relevant 
primer/probe sets (Table 2.4). 
Procedure for assessment of glucocorticoid receptor targets 
Cells in exponential growth phase were treated with dexamethasone (17nM for cell lines 
or 1µM for primagrafts) to cause GR activation and transcription of downstream targets, 
or CV (9.0E-05% ethanol for cell lines, 0.005% ethanol for primagrafts). Following 24 hours 
incubation cells were harvested for RNA and cDNA was synthesised (Sections 2.4.7.1 & 
2.4.7.2). QRT-PCR was then carried out using the relevant primer/probe sets (Table 2.4). 
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Experiment Gene Product Number 
Assessment of CREBBP Knockdown CREBBP Hs00231733_m1 
GR Targets GILZ 
(TSC22D3) 
Hs00608272_m1 
FKBP5 Hs00188025_m1  
NR3C1 (GR) Hs00230813_m1 
ITGA9 Hs00174408_m1 
cAMP Targets CXCR4 Hs00607978_s1 
MKNK2 Hs00179671_m1 
DUSP10 Hs00200527_m1 
RGS16 Hs00892674_m1 
DUSP5 Hs00244839_m1 
Endogenous Control TBP 4310891E 
 
Table. 2.4 List of primer/probe sets used. All primer/probe sets were purchased from 
Applied Biosystems. 
 
2.4.8 Gene Expression Microarray 
Principle 
This method involves the synthesis and fluorescent labelling of cDNA before hybridising 
to a gene chip containing synthetic oligonucleotides, representing all of the expressed 
genes in the human genome. Sequences of 16-20 short oligonucleotides are chosen from 
the mRNA reference sequence of each gene, and light-directed in situ oligonucleotide 
synthesis is used to generate high-density probe arrays containing over 300 000 individual 
elements. In vitro transcription of double stranded cDNA from sample RNA is carried out, 
during which biotin-labelled nucleotides are incorporated into the synthesised cRNA 
molecules. The sample is then hybridised to a probe array and target binding is detected 
by staining with a fluorescent dye coupled to streptavidin. Signal intensities from probe 
array elements are used to calculate the mRNA abundance for each gene and 
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subsequently the relative gene expression. The amount of fluorescence emitted 
corresponds to the amount of bound nucleic acid. This process is summarised in Figure 
2.1. 
The data output from gene expression microarray analyses are stored as .CEL files, 
containing all of the raw signal intensity data from the array chip. These data must then 
be assessed for quality and normalised to ensure comparability across arrays. Data from 
samples from each condition are then assessed for differential gene expression. These 
data can be analysed for enrichment of gene sets by gene set enrichment analysis (GSEA) 
and predictions of effects on pathways can be generated using ingenuity pathway analysis 
(IPA) software (Qiagen).  
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Figure 2.1. Summary of gene expression microarray analysis using high-density 
oligonucleotide arrays. 
 
 
 
 
 
 
 
 
 
 
Chapter 2 Materials and Methods 
 
 
75 
 
Procedure 
Untreated cells, or cells treated with either 100µM 3-isobutyl-1-methylxanthine (IBMX) 
and 10µM forskolin or CV for 90 minutes were harvested in exponential growth phase, 
pelleted and RNA was isolated (Section 2.4.7.1). RNA samples were sent to Source 
Biosciences for analysis on the Affymetrix U133 Plus 2.0 platform. Raw data was then 
normalised and subsequently analysed for statistically significant differential gene 
expression.  
Raw data files (.CEL) were read into ‘R’ software using the ‘read.affy’ function provided by 
the ‘simpleaffy’ R package. Expression values were obtained using GC robust multi-array 
average (GCRMA), which applies optical background correction to the raw data and 
adjusts for non-specific binding, then applies quantile normalisation to ensure that 
expression values across the array are comparable. Data were normalised and corrected 
through principle component analysis (PCA) and visual inspection of images. PCA, is a 
technique used to find patterns in data sets with high dimensions, reducing dimensionality 
by transforming the data into a new set of data (the principal components) and 
summarising the features. Probes with low variation or low signal across arrays were 
discarded. Gene symbols for probes were obtained from the ‘hgu133plus2.db’ R package, 
a database linking Affymetrix probe IDs to known annotation. Differential gene analysis 
was carried out using the ‘limma’ R software package. Linear models were fitted for each 
probe across the experimental groups and differences in gene expression between groups 
were determined using a moderated t-test. Genes were considered to be significantly 
differentially expressed where the p-value was <0.05 and the fold change between groups 
was ≥2. 
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2.4.8.1 Gene Set Enrichment Analysis  
GSEA is a method of analysis for gene expression data which allows the assessment of 
groups of genes which share common biological functions, termed ‘gene sets’ 
(Subramanian et al., 2005). These gene sets are defined based on prior biological 
knowledge from published data. GSEA is made up of three key elements; 
1. Calculation of an enrichment score – reflects the degree to which the set is 
overrepresented at the extremes (top or bottom) of the list 
2. Estimation of significance of enrichment score 
3. Adjustment for multiple hypothesis testing 
Gene ontology (GO) is used to perform enrichment analysis on gene sets, aiming to 
identify GO terms which are over or under represented within a data set. GO terms are a 
controlled vocabulary of terms for describing gene products and characteristics. 
2.4.8.2 Ingenuity Pathway Analysis 
IPA (Qiagen) is a web based software for analysing large ‘omics’ type data sets. This 
software takes raw data from gene expression microarray experiments and can make 
predictions pathways which may be altered, diseases and functions that have similar gene 
expression changes and upstream genes whose expression may be altered.  
 
 
 
 
 
 
 
Chapter 2 Materials and Methods 
 
 
77 
 
2.5 Protein Analysis 
2.5.1 Western Blotting 
Principle 
This method involves the separation of proteins using a polyacrylamide gel, and 
visualisation of specific proteins using antibodies. There are four major stages to the 
process of western blotting; 
1. Preparation of protein 
2. Gel electrophoresis 
3. Electroblotting 
4. Immunodetection 
2.5.1.1 Preparation of Protein Samples for Western Blotting 
Principle 
Before they can be separated by gel electrophoresis, cells must be lysed, proteins must 
be denatured into their individual polypeptide units and protein concentration 
determined to allow equal loading of samples. A denaturing agent containing sodium 
dodecyl sulphate (SDS) is used, which as well as denaturing proteins, binds polypeptides 
and gives them an overall negative charge, so electrophoretic separation can occur based 
on size. The denaturing agent also contains 2-mercaptoethanol which cleaves the intra 
and inter-molecular disulphide bonds, and bromophenol blue which serves as a dye front, 
allowing the user to visualise the sample running. 
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Reagents 
 Cell Lysis Buffer – 50mM Tris-HC, pH 7.5, 150mM NaCl, 1% (v/v) Triton X-100, 0.5% 
(w/v) Na-deoxycholate, 0.1% SDS, cocktail of protease inhibitors (Roche, Welwyn 
Garden City, UK) 
 Laemmli Buffer – 62.5mM Tris-HCL, pH 6.8, 4% SDS, 20% (v/v) glycerol, 5% 2-
mercaptoethanol, 0.005% bromophenol blue 
 BCA Reagent A – contains sodium carbonate, sodium bicarbonate, bicinchoninic 
acid and sodium tartrate in 0.1M NaOH 
 BCA Reagent B – contains 4% cupric sulphate 
 Albumin Standard (Invitrogen) – bovine serum albumin at 2mg/ml in 0.9% NaCl 
solution containing sodium azide 
Procedure 
Cell pellets were thawed on ice and flicked to loosen. Between 30 and 100µl cell lysis 
buffer was added based on cell number (1x106 cells = 40µl, 5x106 = 70µl) and incubated 
on ice for 20 minutes with frequent vortexing. Cell debris was removed by centrifugation 
at 12 000 RPM for 7 minutes at 4°C. Protein containing supernatant was then removed 
into 1.5ml eppendorfs which had been cooled on ice. Protein concentration was 
determined using the bicinchoninic acid (BCA) method. 
The BCA method was carried out according to the manufacturer’s instructions. An aliquot 
of the protein sample was diluted 1:10 and plated out in quadruplicate in 10µl volumes, 
into a 96 well plate. Protein standards between 0.2 and 1.2mg/ml were made by diluting 
bovine serum albumin standard (at 2mg/ml) with dH2O. Protein standards were also 
plated in quadruplicate in 10µl volumes along with dH2O blank. A working BCA reagent 
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was made by mixing 50 parts BCA reagent A with 1 part BCA reagent B. To each well, 190µl 
of working reagent was added before being sealed and incubated at 37°C for 30 minutes. 
Absorbance at 562nm was measured using an Omega FLUOStar plate reader (Section 
2.1.1). Data were analysed using Omega software (BMG Labtech) to generate a standard 
curve and unknown protein concentrations were determined based on extrapolation 
from this curve, taking into account the 10 fold dilution factor. Protein samples were made 
up to 0.5-2mg/ml using laemmli buffer and denatured by heating to 100°C for 5 minutes. 
Samples were stored at -20°C until required. 
2.5.1.2 Polyacrylamide Gel Electrophoresis 
Principle 
This scientific method is based on the fact that charged molecules will migrate through a 
matrix upon application of an electric field. Polyacrylamide gel is used as this matrix as it 
is chemically inert, electrically neutral, hydrophilic and transparent. Separation of proteins 
in this way is based on size, with larger proteins migrating more slowly than smaller 
proteins. Polyacrylamide gels are formed by the polymerisation of acrylamide monomers 
into long chains which are then cross-linked by the reaction of N,N-methylene-
bisacrylamide with free functional groups at the chain termini. The size of the pores in the 
polyacrylamide gel determines the rate at which proteins travel, and can be varied 
according to the protein size range of interest. Gels with a gradient of pore size (e.g 4-
20%) are commonly used to resolve large sized proteins on the same gel as small sized 
proteins.  
Reagents 
 Electrode Buffer – 41.2nM Tris, 192mM glycine, 0.1% (w/v) SDS 
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 4-20% Mini Protean TGX gels (BioRad) 
 Precision Plus Dual Color protein standards (BioRad) 
 Spectra Multicolour High Range Protein ladder (Thermo Fisher) 
Procedure 
Fifteen microliters of prepared protein sample (at 0.5-2mg/ml in laemmli buffer) was 
loaded per well into a BioRad mini 4-20% TGX gel. Eight to ten microliters of the relevant 
protein ladder for the protein of interest, was also loaded in the first well. Separation of 
proteins was carried out using a constant voltage of 250V for 25-60 minutes depending 
on the protein of interest.  
2.5.1.3 Electroblotting 
Principle 
In order for proteins of interest to be detected by immunodetection, they must be 
transferred from the polyacrylamide gel to the surface of an immobilized matrix with a 
high capacity for protein binding e.g. polyvinylidine difluoride (PVDF) or nitrocellulose. 
This is carried out by sandwiching the membrane and the gel surface together, with filter 
paper and sponge on the outside to protect them. An electric field is then applied 
perpendicular to the surface of the gel, causing the proteins to move out of the gel and 
onto the surface of the membrane. The buffer used for transferring proteins in this way 
contains methanol to counteract the swelling of the gel and increase the binding affinity 
of the PVDF membrane for proteins. 
Reagents 
 Transfer Buffer – 10mM CAPS, 10% (v/v) methanol 
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 PVDF Membrane (BioRad) 
 3mm Filter Card (Thermo Fisher) 
 Sponge (BioRad) 
Procedure 
Electroblotting was carried out using mini-blot equipment (BioRad) (Section 2.1.1). Filter 
card, sponges and PVDF membrane were briefly soaked in transfer buffer before 
construction of the sandwich. Before being soaked in transfer buffer, the PVDF membrane 
was soaked in methanol to hydrate the membrane and overcome its hydrophobicity. The 
electroblotting sandwich was constructed within the cassette as follows; sponge, 2 x filter 
card, gel, PVDF membrane, 2 x filter card, sponge. The sandwich was compressed by 
rolling a 5ml pipette tip over it in order to remove any bubbles. The transfer was carried 
out at either 25V overnight or 100V for 1 hour depending on the protein of interest. For 
transfers at 100V for 1 hour, an ice pack was added to the tank to prevent overheating. 
2.5.1.4 Immunodetection 
Principle 
This process involves the detection of specific proteins by probing with mono- or 
polyclonal antibodies. To prevent the non-specific binding of antibodies to sites on the 
PVDF membrane, these sites are blocked using a buffer which contains non-fat milk 
powder before probing with antibodies. The antibodies themselves are also diluted in this 
blocking buffer. This buffer, as well as the buffer used for washing the membrane, 
contains Tween-20, to reduce non-specific binding of protein. Following blocking, 
membranes are probed with a primary antibody specific for the protein of interest. 
Membranes are then washed to remove any unbound primary antibody before being 
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probe with a secondary antibody produced in a different species of animal, raised against 
the immunoglobulins (Ig) of the species used to produce the primary antibody. The 
secondary antibody is conjugated to the horseradish peroxidase (HRP) enzyme which 
catalyses the oxidation of luminol (cyclic diacylhydrazide) to form acrinidium ester 
intermediates. These intermediates react with peroxide under slightly alkaline conditions 
to produce chemiluminescence with a maximal emission at 430nm. This 
chemiluminescence is subsequently detected by exposure of X-ray film and developing. 
Reagents 
 Tris-Buffered Saline (TBS) with Tween-20 (TBST) – 0.154M NaCl, 0.05M Tris, 0.5% 
(v/v) Tween-20 
 Blocking Buffer – TBST, 5% (w/v) dried skimmed milk powder 
 ECL Prime Western Blotting Detection Reagents (Amersham Biosciences) 
Procedure 
PVDF membranes were blocked for 30 minutes in blocking buffer following 
electroblotting. The membranes were then cut and probed with the relevant primary 
antibody at the given concentration (Table 2.5) for one hour at room temperature, in a 
50ml falcon tube on a roller or overnight at 4°C on a rocking platform. Following primary 
antibody probing, the membrane was rinsed 3 times in TBST before a final 12 minute wash 
in TBST on a rocking platform. Membranes were then incubated with the relevant 
secondary HRP-conjugated antibody (Table 2.5) for 30 minutes at room temperature on a 
rocking platform. Following secondary antibody probing, the membranes were washed in 
TBST for 20 minutes, with TBST refreshed every 5 minutes, again on a rocking platform. 
Membrane bound HRP was then detected using ECL Prime western blotting detection 
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reagents (Amersham Biosciences) according to the manufacturer’s instructions. ECL Prime 
reagent A was mixed 1:1 with reagent B and pipetted onto membranes and incubated at 
room temperature for five minutes. Membranes were then dried, wrapped in Saran Wrap 
(Thermo Fisher) and placed in an autoradiography cassette. For detection of 
chemiluminescence, membranes were exposed to X-ray film (Fuji Medical X-ray film, HA 
West, Gateshead, UK) for an appropriate amount of time to give visible protein bands. 
Where relative quantification of protein expression was required, exposed x-ray film was 
scanned using a Luminescent Image Analyzer (LAS-3000) (Fujifilm) and densitometry 
carried out using AIDA image analysis software (Raytest, Straubenhardt, Germany). 
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Protein Molecular 
Weight 
(kDa) 
Catalogue 
Number 
Species & 
Clonality 
Supplier Dilution 
Used 
Dilution of 
Secondary 
Ab 
P
ri
m
ar
y 
CREBBP 265 sc-369 Rabbit 
polyclonal 
Santa Cruz, 
Wembley, 
UK 
1:1000 1:2000 
Acetyl Histone 
3 Lysine 18 
17 ab1191 Rabbit 
polyclonal 
Abcam, 
Cambridge, 
UK 
1:1000 1:2000 
Acetyl Histone 
3 Lysine 27 
17 ab4729 Rabbit 
polyclonal 
Abcam 1:500 1:1000 
Acetyl p53 50 06-758 Rabbit 
polyclonal 
Millipore, 
Consett, UK 
1:800 1:6000 
p53 50 sc-126 Mouse 
monoclonal 
Santa Cruz 1:8000 1:10 000 
p21 18 556430 Mouse 
monoclonal 
Becton 
Dickinson 
1:600 1:2000 
BCL6 75 14-9887-82 Mouse 
monoclonal 
eBioscience
, Cheshire, 
UK 
1:10 000 1:5000 
MGMT 26 MAB16200 Mouse 
monoclonal 
Millipore 1:1000 1:1000 
Phosphorylate
d ERK 
42 9101 Rabbit 
polyclonal 
Cell 
Signalling 
1:3000 1:2000 
ERK2 42 sc-153 Rabbit 
polyclonal 
Santa Cruz 1:3000 1:2000 
PARP1/2 116 Sc-7150 Rabbit 
polyclonal 
Santa Cruz 1:1000 1:2000 
Alpha tubulin 50 T6074 Mouse 
monoclonal 
Sigma-
Aldrich 
1:500 000 1:10 000 
Se
co
n
d
ar
y Rabbit-Ig - P0448 Goat Dako, 
Glosturp, 
Denmark 
- - 
Mouse Ig -  Goat Dako - - 
 
Table 2.5 List of antibodies used with corresponding dilutions. All antibodies were 
diluted in blocking buffer (described previously) except anti-ERK2 which was diluted in 
TBST made up to 5% bovine serum albumin (w/v) and anti-p21 which was diluted in 
SuperBlock (Thermo Fisher) with 1% Tween-20 (v/v). 
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2.5.2 Irradiation of Cells 
Principle 
To study p53 response by western blotting, a DNA damage response must be induced. 
This can be achieved by sub-lethally irradiating cells. 
Procedure 
Cells were exposed to 5 Gray (Gy) radiation using an RS320 Irradiation System (Gulway 
Medical), whilst in exponential growth phase. Cell pellets were harvested (Section 2.2.5) 
at 0, 4 and 8 hours post-irradiation, and western blotting was carried out for p53, Ac-p53 
and p21 (Section 2.5.1). 
2.5.3 Histone Deacetylase Inhibition of Cells 
Principle 
Vorinostat (SAHA) is a pan histone deacetylase (HDAC) inhibitor. Vorinostat treatment 
leads to a significant increase in pan histone acetylation within cells. 
Procedure 
Cells growing in exponential phase were treated with 500nM vorinostat or DMSO CV for 
1 hour before cell pellets were harvested (Section 2.2.5), and western blotting for 
AcH3K18 was carried out (Section 2.5.1).  
2.5.4 Poly(ADP) Ribose Polymerase Assay  
Principle 
Poly(ADP) ribose polymerase (PARP) 1, is involved in DNA damage repair, acting in the 
base excision repair pathway. It attaches to regions of damaged DNA and catalyses the 
synthesis of poly(ADP) ribose (PAR) chains on itself and nuclear proteins. Synthesis of PAR 
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utilises nicotinamide adenine dinucleotide (NAD+) (Morales et al., 2014). Immunoblotting 
for the PAR product following maximum stimulation of PARP can be used to determine 
PARP activity. 
Procedure 
This procedure was carried out by Ashleigh Herriott and is outlined here (Herriott et al., 
2015). 
 
2.6 Cell Growth and Drug Sensitivity 
2.6.1 Growth Curves 
Principle 
In order to assess the effects of exongenous compounds on cell growth and apoptosis, 
information about the growth rate of cells under normal conditions must be gathered. 
This method simply involves periodically counting cells over time to establish a growth 
curve. Cell growth follows a characteristic pattern of lag phase, exponential phase and 
plateau phase.  
Reagents 
 Trypan blue reagent (Sigma Aldrich) 
Procedure 
Cells were seeded at a range of densities at time 0. Every 24 hours for 120 hours an aliquot 
of cells was taken and counted using trypan blue exclusion on a haemocytometer (Section 
2.2.4). A growth curve of the data was plotted using GraphPad Prism software (GraphPad 
Software Inc., San Diego, CA, USA).  
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2.6.2 Drug Sensitivity 
Principle  
Drug sensitivity assays allow the effect of drug treatment on live cells to be measured. The 
alamar blue (Resazurin) (Thermo Fisher) assay was chosen for this application. In this 
assay, the non-fluorescent Resazurin is converted into bright red resorufin by diaphorase, 
a mitochondrial enzyme. The amount of fluorescence produced is proportional to the 
number of living cells, as dead/dying cells will be less metabolically active.  
Reagents 
 Alamar blue reagent (Thermo Fisher) 
Procedure 
Cells growing in exponential growth phase were seeded at 2x105/ml (cell lines) or 
4x106/ml (primagraft/primary cells) and plated into 96 well plates at 100µl per well 
(2x104-4x105 cells per well). Drug concentrations or CV were added to each well as stated 
in Table 2.6. Drugs were diluted in growth media corresponding to the cells used. This 
dilution media was made up with CV to ensure a constant CV concentration across all drug 
concentrations. Outer wells were filled with media to prevent the evaporation of outer 
samples. Cells were incubated for 3 cell doublings (96 hours) before the addition of 20µl 
of alamar blue to each well. Following 4-6 hours incubation with alamar blue, fluorescence 
intensity was assessed using a FLUOstar Omega plate reader (Section 2.1.1) and Omega 
data analysis software (BMG Labtech). Absorbance readings were expressed as a 
percentage of CV treated cells and plotted as a survival curve using GraphPad Prism 
software (GraphPad Software Inc.). 
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The same method was used to assess sensitivity to ionising radiation (IR). Cells were 
subjected to a range of IR doses and plated out as described above. PreB 697 cells were 
exposed to between 0.292 and 6.132 Gy and SU-DHL-4 cells were exposed to between 
0.876 and 8.76 Gy using an RS320 Irradiation System (Gulway Medical). 
Cells Drug Concentration 
Range 
Control 
Vehicle (CV) 
PreB 697 Dexamethasone (Sigma-Aldrich) 0.1-100nM 0.2% ethanol 
Vorinostat (Selleckchem) 0.05-1.5µM 0.01% DMSO 
Dexamethasone and Vorinostat 0.01-1.25µM 
Vorinostat 
17nM 
Dexamethasone 
0.005% DMSO 
0.1% ethanol 
Daunorubicin (Tocris Bioscience) 1-100nM 0.05% 
methanol 
Vincristine (Tocris Bioscience) 0.01-1nM N/A (H2O) 
Methotrexate (Sigma-Aldrich) 0.1-50nM 0.0001N NaOH 
6-thioguanine (Sigma-Aldrich) 0.1-50µM 0.02% DMSO 
BCL6 Inhibitor 79-6 (Merck Millipore) 10-1000µM 1% DMSO 
HAT Inhibitor C646 (Tocris Bioscience) 0.1-30µM 0.4% DMSO 
Temozolomide (Sigma-Aldrich) 25-257.5µM 1% DMSO 
U0126 MEK Inhibitor (Calbiochem) 0.1-50µM 1% DMSO 
Selumetinib (Sellekchem) 0.001-100µM 0.6% DMSO 
MHH-CALL-2 Dexamethasone 0.1-1000nM 0.1% ethanol 
Temozolomide 50-257.5µM 1% DMSO 
U0126 MEK Inhibitor (Calbiochem) 0.1-50µM 1% DMSO 
Primagraft Dexamethasone 0.001-10µM 0.2% ethanol 
SU-DHL-4 Dexamethasone 1-100µM 1% ethanol 
Vorinostat 0.25-6µM 0.05% DMSO 
Temozolomide 1-257.5µM 1% DMSO 
Vincristine 1-10nM N/A (H2O) 
Daunorubicin 0.0001-10µM N/A (H2O) 
 
Table 2.6 List of drugs used and concentration ranges for each cell line and primagraft 
cells. 
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2.7 Gene Knockdown by RNA Interference (RNAi) 
RNA interference (RNAi) is a method which allows selective repression in the expression 
of genes of interest.   
Two forms of RNA interference (RNAi) were used in this project: 
1. Small interfering RNA (siRNA) 
2. Small hairpin RNA (shRNA) 
Principle 
Both methods of RNAi used in this project rely on the formation of a protein complex 
called the RNA-induced silencing complex (RISC). Multi-functional protein argonaute 2 
unwinds double-stranded siRNA and the sense strand is cleaved. This leaves the antisense 
strand, complimentary to the target mRNA. This strand is loaded into the RISC and 
selectively seeks the target mRNA for degradation, exactly 10 nucleotides upstream from 
the first complementary nucleotide at the 5’ end of the siRNA. The cleaved mRNA does 
not contain a poly-A tail and is degraded by exonucleases, leading to reduced gene 
expression. Activated RISC can move on to degrade multiple targets, accentuating gene 
silencing. For transient gene silencing, siRNA can be delivered to the cell directly. For 
stable knockdown, shRNA is used. Lentiviral transduction is used to deliver a shRNA 
containing vector to the cell. This vector fuses with the host DNA and so leads to the 
continual nuclear synthesis of this shRNA. ShRNA produced by the nucleus must undergo 
further processing to become siRNA and effect RNAi. The primary transcript generated 
from transcription is processed by the RNase enzyme Drosha and double-stranded RNA-
binding protein DGCR8 into pre-mRNA. Pre-mRNA is then loaded into another complex 
containing the enzyme Dicer, which cleaves the double-stranded RNA into shorter 
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fragments (21-23 nucleotides). The process then continues as described for siRNA (Wilson 
and Doudna, 2013). 
 
 
 
 
 
 
 
 
Figure 2.2. Mechanism of gene silencing using shRNA and siRNA. Adapted from (Chen et 
al., 2008). 
 
2.7.1 Lentiviral Transduction of Small Hairpin RNA (shRNA) 
RNAi by shRNA transduction was carried out using pGIPZ Lentiviral shRNA (Thermo Fisher) 
allowing the formation isogenic cell lines with reduced expression of CREBBP, which is 
maintained indefinitely throughout the cell culture process. This construct contains; 
 TurboGFP, allowing the visual marking of transduced cells 
 Puromycin drug resistance, allowing positive selection of transduced cells 
 ShRNA construct targeting CREBBP 
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Reagents 
 Virus containing pGIPZ shRNA construct targeting CREBBP (V3LHS_358935, 
Thermo Fisher) and negative control shRNA (Thermo Fisher) 
 Puromycin at 10mg/ml (Gibco).  
Procedure 
2.7.1.1 Puromycin Kill Curve 
Cells were first assessed for sensitivity to puromycin by carrying out a puromycin kill curve. 
Cells were plated at 5x104 cells per well in a 24 well plate and incubated overnight. They 
were then exposed to a range of puromycin (1-10µg/ml) and viability was assessed by cell 
counting (Section 2.2.4) for 3-6 days. The lowest concentration to kill 100% of cells within 
the 3-6 day time period was chosen as the concentration to use for selection of 
transduced cells. 
2.7.1.2 Lentiviral Transduction 
Twenty four hours before transduction, cells in exponential growth phase were seeded at 
5 x 104 cells per well in a 24-well plate and incubated overnight. On the day of transduction 
growth medium was removed and virus containing a lentiviral construct targeting CREBBP 
or control construct, was added to the cells at multiplicities of infection (MOI) of between 
5 and 30. MOI is the ratio of agent (i.e virus) to infection targets (i.e cells). MOI was 
calculated using the following formula; 
 MOI = plaque forming units (pfu) of virus / number of cells 
4-6 hours post transduction, 1ml of growth media was added to cells followed by an 
overnight incubation. After 48 hours cells were assessed by flow cytometry to determine 
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the percentage of cells expression GFP (Section 2.3.1). Cells were then put onto puromycin 
selection for 3-6 days to remove any non-transduced populations. Cells were monitored 
routinely by flow cytometry (Section 2.3.1) until GFP expression reached >90, indicating a 
pure transduced population. Cells were amplified and cryopreserved (Section 2.2.6) for 
use in downstream applications.  
2.7.2 Transfection of Small Interfering RNA (siRNA) 
Principle 
Knockdown of gene expression by siRNA involves the delivery of siRNA particles to a cell, 
leading to a reduced expression of target mRNA and thus protein expression. As the siRNA 
molecules delivered are subjected to the same procedures of degradation of endogenous 
mRNA, the knockdown achieved is transient. The application of an electrical impulse 
across cells membranes leads to transient pore formation, which in turn leads to greater 
uptake of exogenous molecules, such as RNA or DNA, into the cells (Neumann et al., 1982; 
Sugar and Neumann, 1984). This process can be used for efficient delivery of siRNA to 
cells. Electroporation can be associated with a reduction in viability on a cell line basis, so 
whether or not cells are amenable to electroporation should be determined before 
attempting siRNA knockdown using this method. 
Reagents 
 Pooled siRNAs targeting CREBBP from (CBP siRNA (h)) (Santa Cruz). 
 Non-targeting control siRNA pool (Control siRNA-A) (Santa Cruz). 
Procedure 
Cells in exponential growth phase were centrifuged at 1000 RPM for 5 minutes and 
resuspended at 1x107/ml. Cells were then pipetted into a 4mm electroporation cuvette 
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(Eurogentec, Southampton, UK). For cell lines, 500µl of cells at 1x107/ml were added to 
each cuvette (5x106 cells/cuvette) and for primagraft and primary cells 800µl of cells at 
1x107/ml were added (8x106 cells/cuvette). SiRNA was reconstituted using RNase free 
water to give a 10µM solution. Reconstituted siRNA was then added to each cuvette to a 
final concentration of 120-500nM. For optimisation experiments, one cuvette of cells 
without any siRNA added was included as a ‘Mock’ condition. To deliver the siRNA to cells, 
each cuvette was subjected to electroporation in an EPI 2500 Elektroporations-
impulsgenerator (Section 2.1.1) at 350V for 10ms. Cells were subsequently incubated at 
room temperature for 15 minutes. Cells were then diluted 10 fold in culture medium in 6 
well plates and incubated for 24 hours before use in downstream applications. 
Knockdown was confirmed for each discrete experiment by QRT-PCR (Section 2.4.7.3) and 
western blotting for CREBBP (Section 2.5). 
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Characterisation of a BCP-ALL Cell Line with Stable CREBBP 
Knockdown 
 
3.1 Introduction 
In order to assess the effect of CREBBP haploinsufficiency on the propensity to relapse in 
childhood ALL, an understanding of the molecular effects of CREBBP haploinsufficiency in 
cells must be gained. As discussed in Chapter 1, CREBBP is involved in a wide array of 
cellular functions, many of which could reasonably provide mechanisms for relapse 
establishment/development. In order to study the effect of CREBBP haploinsufficiency on 
multiple cellular processes, an isogenic model with stable CREBBP knockdown was 
required. To this end, a previously generated, CREBBP knockdown PreB 697 ALL cell line 
was studied. This enabled assessment of the effects of CREBBP knockdown on a range of 
cellular phenotypes in a B-ALL setting.  
The aim of this chapter was to study CREBBP deficiency and its impacts on gene 
expression, sensitivity to ALL chemotherapeutics, tumour suppressor/oncogene balance, 
DNA damage repair, RAS pathway signalling and antigen presentation. 
 
3.2 Characterisation of PreB 697 Cells with Stable CREBBP Knockdown 
Previously (submitted as part of MRes dissertation), an isogenic CREBBP knockdown 
model was created in a BCP-ALL cell line. PreB 697 cells were selected as they had been 
shown to have expression of wild type CREBBP by PCR and western blotting. To achieve 
knockdown, cells were stably transfected with shRNA, targeting CREBBP or non-targeting 
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control, using a pGIPZ lentiviral vector. Following puromycin selection, CREBBP 
knockdown was confirmed at the protein level by western blotting. Cells with a stable 
knockdown in CREBBP (shCBP) showed around 40% reduction in CREBBP mRNA 
expression (p=0.005) and a much greater reduction at the protein level (Figure 3.1 A & B). 
These cells (shCBP) showed reduced acetylation of CREBBP target, histone 3 lysine 18 
(H3K18) compared to controls (shNEG) showing that the knockdown had functional 
relevance (Figure 3.1 C). CREBBP knockdown was shown to have no effect on growth rate 
(Mean growth rate ±SD; shCBP 32.4 hours ±5.4; shNEG 30.7 hours ±4.8; p=0.7) (Figure 3.1 
D), but led to a statistically significant reduction in GC induced expression of glucocorticoid 
receptor (GR) targets GILZ, FKBP5 and NR3C1 (p=0.009, p=0.03 and p=0.0003 respectively) 
(Figure 3.1 E), suggesting an impact of CREBBP haploinsufficiency on glucocorticoid (GC) 
receptor (GR) function. Despite this observation, and contrary to previous observations 
(Mullighan et al., 2011), CREBBP knockdown was shown to have no effect on sensitivity 
to dexamethasone (GI50 values, mean ±SD; shCBP 16.6nM ±5.5 and shNEG 16.7nM ±3.1; 
p=0.9) or the HDACi vorinostat (GI50 values, mean ±SD; shCBP 485nM ±27.8 and shNEG 
471nM ±48.75; p=0.9), alone or in combination (p=0.8) (Figure 3.1 F-H). 
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Figure 3.1. Summary of previous data outlining the creation and characterisation of a 
BCP-ALL cell line with stable knockdown of CREBBP. A. Cells were harvested in log growth 
phase and QRT-PCR was carried out for CREBBP expression. Expression levels were 
normalised to TBP by the ΔΔCT method. Histogram shows mean expression ±SD (n=3). 
Whole cell lysates from PreB 697 shCBP and shNEG were assessed for B. CREBBP protein 
expression and C. AcH3K18 expression, by western blotting. Alpha tubulin was included 
as loading control. D. Growth rate of shCBP and shNEG cells was determined by seeding 
cells at 3 different starting densities and counting using trypan blue exclusion every 24 
hours for 120 hours. E. SiCBP and control cells were treated with either control vehicle 
(CV) or dexamethasone (Dex) for 24 hours before determining expression of GR target 
genes by QRT-PCR relative to endogenous TBP expression by the ΔΔCT method. 
Histograms show mean expression ±SD (n=3). F, G, H. ShCBP and shNEG cells were treated 
with a range of dexamethasone or vorinostat concentrations or a combination of the two 
and their survival compared to CV treated cells was determined by alamar blue assay. 
Values plotted represent the mean % survival ±SD (n=3). 
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CREBBP protein expression in primagraft ALL samples with mono-allelic CREBBP deletion 
compared to wild type was assessed by western blotting (Section 2.5). Expression of 
CREBBP was reduced but not absent in samples with mono-allelic deletions, in line with 
previous studies (Mullighan et al., 2011; Pasqualucci et al., 2011) (Figure 3.2 A & B). 
Crucially, the protein reduction seen in PreB 697 cells with stable CREBBP knockdown is 
in line with what is shown in these primary derived samples (Figures 3.1 B). 
 
 
 
 
 
 
Figure 3.2. CREBBP protein expression in primagraft samples with mono-allelic CREBBP 
deletion. A. Whole cell lysates from primagraft ALL cells with expression of CREBBP with 
mono-allelic deletions (Del) or wild type (Wt) were assessed for CREBBP expression. 
Alpha-tubulin was included as loading control. B. Histogram of the relative expression of 
CREBBP in PreB 697 cells with and without stable CREBBP knockdown (left two bars) and 
primagraft samples normalised to α-tubulin after densitometric analyses. 
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3.3 cAMP response in PreB 697 Cells with Stable CREBBP Knockdown 
As discussed in Chapter 1, CREBBP plays a key role in the cAMP-dependent signalling, 
acting as binding partner and co-activator of CREB (Radhakrishnan et al., 1997). Given that 
cAMP-dependent signalling represents a major function of CREBBP, the effect of its 
knockdown on cAMP-dependent transcription was assessed.  
Firstly, to determine relevant cAMP-dependent genes in PreB 697 cells, gene expression 
profiling was carried out using the Affymetrix U133 Plus 2.0 platform. RNA from PreB 697 
cells transduced with non-silencing shRNA (shNEG) and treated with 3-Isobutyl-1-
methylxanthine (IBMX) and forskolin for 90 minutes to induce a maximum intracellular 
cAMP response or CV was analysed by Source Bioscience as described in section 2.4.8. 
Data were analysed using R software and differentially expressed genes between IBMX 
and forskolin treated and control cells were compared. To select the genes which cAMP 
had the greatest effect on, genes which were upregulated in IBMX and forskolin treated 
cells were first ordered by average expression, the top 50 genes in this list were then 
sorted by statistical significance of differential expression and genes whose expression 
was reduced by IBMX & FSK treatment were removed. CXCR4 and MKNK2 were selected 
for further study as they appeared at the top of the list and were apparent with alternative 
probe sets, validating their significance (Table 3.1). DUSP10 and RGS16, identified as 
cAMP-dependent in MEF cells, also appeared in this list and were also selected for further 
study (Mullighan et al., 2011).  
To assess the effect of CREBBP haploinsufficiency on cAMP-dependent signalling, cells 
were treated with IBMX and forskolin for 90 minutes to induce a maximum intracellular 
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cAMP response or CV (Section 2.4.7.3). Quantitative reverse transcriptase PCR (QRT-PCR) 
was then used to assess expression of genes identified as cAMP-dependent targets. All 
genes assessed were shown to be significantly upregulated by cAMP stimulation in both 
shCBP and shNEG cells (Fold induction; CXCR4 ~14 fold, p values <0.007, MKNK2 ~6 fold, 
p values <0.001, DUSP10 ~3 fold, p values <0.05, RGS16 ~5 fold, p values <0.02). CREBBP 
knockdown led to a small, statistically significant, reduction in basal MKNK2 expression 
(p=0.005) and increase in basal RGS16 expression (p=0.04), with no effect on basal CXCR4 
or DUSP10 expression (p=0.7 and p=0.3 respectively) (Figure 3.3). Importantly, CREBBP 
knockdown had no effect on the level of cAMP induced gene expression achieved for any 
gene assessed (p values >0.3), suggesting that CREBBP knockdown does not impact on 
cAMP-dependent gene expression. 
Feature Gene log2 Fold 
Change 
Average 
Expression 
P.Value 
217028_at CXCR4 3.964 10.779 7.90E-08 
218205_s_at MKNK2 2.544 10.695 2.10E-09 
215111_s_at TSC22D1 2.151 9.002 1.07E-08 
209201_x_at CXCR4 4.618 8.848 1.90E-09 
202284_s_at CDKN1A 1.260 8.406 4.63E-08 
211919_s_at CXCR4 4.697 8.163 6.30E-09 
201751_at JOSD1 1.927 8.152 4.07E-08 
208622_s_at EZR 2.343 8.117 6.80E-08 
201368_at ZFP36L2 3.152 7.895 5.70E-09 
212430_at RBM38 2.511 7.439 1.06E-07 
223199_at MKNK2 2.736 7.426 4.41E-08 
227846_at GPR176 1.734 7.424 3.33E-08 
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209324_s_at RGS16 4.134 7.118 2.22E-08 
201473_at JUNB 3.488 7.076 2.00E-10 
201531_at ZFP36 2.975 6.723 3.46E-08 
202499_s_at SLC2A3 4.614 6.176 2.06E-08 
205289_at BMP2 4.636 5.992 3.50E-09 
227410_at FAM43A 4.165 5.698 5.10E-09 
202815_s_at HEXIM1 2.343 5.561 9.96E-08 
41577_at PPP1R16B 2.960 5.436 1.45E-08 
203910_at ARHGAP29 5.476 5.421 3.93E-08 
207630_s_at CREM 4.677 5.327 3.60E-09 
201236_s_at BTG2 4.681 4.624 2.68E-08 
208763_s_at TSC22D3 5.218 4.599 2.00E-10 
202340_x_at NR4A1 3.749 4.432 4.55E-08 
216236_s_at NA 3.165 4.374 6.00E-10 
204491_at PDE4D 4.680 4.244 4.00E-09 
214508_x_at CREM 5.503 4.231 3.00E-10 
217875_s_at PMEPA1 3.738 4.147 5.14E-08 
209967_s_at CREM 4.776 4.094 7.10E-09 
205463_s_at PDGFA 4.373 4.082 0.00E+00 
221563_at DUSP10 1.475 4.040 3.29E-08 
216268_s_at JAG1 2.661 4.007 2.02E-08 
214873_at LRP5L 1.481 3.837 5.43E-08 
222088_s_at NA 4.718 3.761 2.73E-08 
209189_at FOS 5.394 3.756 3.20E-08 
202497_x_at SLC2A3 4.615 3.713 1.00E-10 
209305_s_at GADD45B 3.376 3.507 7.29E-08 
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209099_x_at JAG1 3.574 3.365 1.90E-09 
230233_at NA 3.181 3.292 0.00E+00 
229072_at RAB30 3.367 3.229 5.22E-08 
223217_s_at NFKBIZ 2.235 2.962 7.00E-10 
223887_at GPR132 2.057 2.896 2.59E-08 
201883_s_at B4GALT1 2.685 7.103 1.15E-07 
224797_at ARRDC3 2.521 6.437 1.15E-07 
202498_s_at SLC2A3 3.375 3.926 1.17E-07 
200605_s_at PRKAR1A 1.399 9.717 1.33E-07 
223218_s_at NFKBIZ 3.467 3.300 1.42E-07 
227558_at CBX4 3.113 9.107 1.49E-07 
 
Table 3.1. Genes upregulated by cAMP in PreB 697 cells. List shows 50 of the genes with 
the highest change in expression by cAMP stimulation in PreB 697 shNEG cells ordered by 
statistical significance. CXCR4 and MKNK2 (highlighted in green) were chosen for further 
analysis as they appear at the top of the list and more than once. DUSP10 and RGS16 
(highlighted in orange) were previously identified as dependent on cAMP and were also 
chosen for further analysis (Mullighan et al., 2011). Extended gene list in appendix 1. 
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Figure 3.3. Effect of CREBBP shRNA knockdown in PreB 697 cells on cAMP-dependent 
gene expression. ShCBP and shNEG cells were treated with either control vehicle (CV) or 
IBMX and forskolin (I&F) before determining expression of cAMP-dependent genes by 
QRT-PCR, relative to endogenous TBP expression by the ΔΔCT method. Histograms show 
mean ±SD (n=3). 
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3.4 Gene Expression Profiling of stable CREBBP Knockdown in PreB 697 Cells  
CREBBP plays a role in body wide transcription through its interaction with TBP, TFIIB and 
CREB, as discussed in Chapter 1 (Kwok et al., 1994; Yuan et al., 1996).   To determine the 
effect of CREBBP knockdown on total gene transcription in PreB 697 cells, the Affymetrix 
U133 Plus 2.0 gene expression array platform was used. RNA was collected from cells 
growing exponentially on 3 separate occasions before sending to Source Bioscience for 
Affymetrix U133 Plus 2.0 analysis (Section 2.4.8). Data were normalised (section 2.4.8) 
and PCA was carried out to allow visual inspection of the variation between experimental 
replicates (Figure 3.4). Inter-assay variation was low, with data from shCBP and shNEG 
cells clustering closely within their groups. ShCBP_1 and shCBP_2 clustered together more 
closely than shCBP_3, and the same was true for shNEG_1, shNEG_2 and shNEG_3. As 
expected, data from shCBP and shNEG cells clustered separately, representing the altered 
gene expression induced by CREBBP knockdown. Analysis of differentially expressed 
genes between shCBP and shNEG cells identified 28 genes which were significantly 
differentially expressed (p=<0.05, fold change ≥2) (Table 3.2). Gene set enrichment 
analysis was carried out and showed that no gene sets were enriched in CREBBP 
knockdown cell compared to control. SSBP1, POLE2, MCM7, RFC2 and MCM5 were all 
downregulated in shCBP cells compared to shNEG, with gene ontology (GO) analysis 
suggestive of DNA replication pathway perturbation (Adjusted p value 3.88x10-2) (Figure 
3.4). GO analysis also identified a potential effect on the cell cycle pathway in CREBBP 
knockdown cells, with 7 genes in this pathway differentially expressed (Adjusted p values 
<3.88x10-2) (Figure 3.5). Further to this, the data set was analysed using Ingenuity Pathway 
Analysis (IPA) software (Quiagen, UK). This analysis identified that, based on the 
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differential expression of SCG2, OAT, and DNAJC15, that upstream expression of NR3C1, 
the gene encoding the GR, would be altered, hinting at a link between CREBBP knockdown 
and GC response (p=0.04) (Table 3.2).  
 
 
 
 
 
 
 
 
 
Figure 3.4. Principal component analysis of gene expression data from PreB 697 shCBP 
and shNEG cells. PCA scatterplot representing individual experimental replicates from 
PreB 697 shCBP (red) and shNEG cells (blue). 
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Feature Gene log2FC P.Value 
  
204035_at SCG2 2.81E+00 3.30E-05 
 
Increased 
232327_at THSD7B 2.64E+00 1.60E-04 
 
Decreased 
201599_at OAT 2.59E+00 1.70E-04 
  
234987_at SAMHD1 1.37E+00 1.60E-04     
235048_at FAM169A 1.23E+00 8.50E-05 
  
210933_s_at FSCN1 1.17E+00 1.10E-05 
  
204048_s_at PHACTR2 1.16E+00 2.60E-06 
  
229103_at WNT3 1.11E+00 3.00E-04 
  
227819_at LGR6  1.05E+00 8.20E-05 
  
213316_at KIAA1462 -1.01E+00 6.30E-07 
  
209422_at PHF20 -1.13E+00 1.20E-04 
  
217485_x_at PMS2P1 -1.13E+00 6.40E-05 
  
204140_at TPST1 -1.15E+00 2.40E-04 
  
209970_x_at CASP1 -1.16E+00 2.30E-05 
  
222288_at NA -1.17E+00 1.80E-05 
  
200636_s_at PTPRF -1.17E+00 1.60E-04   
209321_s_at ADCY3 -1.19E+00 7.00E-05   
208050_s_at CASP2 -1.28E+00 6.00E-05   
223197_s_at SMARCAD1 -1.33E+00 1.80E-05   
212589_at RRAS2  -1.38E+00 2.70E-04   
203857_s_at PDIA5 -1.50E+00 1.00E-04   
228843_at ARL10  -1.56E+00 2.20E-05   
238029_s_at SLC16A14 -1.61E+00 2.20E-04   
211368_s_at CASP1 -1.61E+00 5.80E-05   
232232_s_at SLC22A16 -1.70E+00 3.30E-05   
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223204_at FAM198B -2.26E+00 3.10E-06   
204897_at PTGER4 -2.48E+00 1.30E-05   
218435_at DNAJC15 -2.50E+00 2.60E-06   
 
Table 3.2. Analysis of differentially expressed genes between PreB 697 shCBP and shNEG 
cells. RNA samples isolated from shCBP and shNEG on three separate occasions were 
analysed using the Affymetrix U133 Plus 2.0 platform. Data was normalised and genes 
whose expression was significantly altered in shCBP compared to shNEG control were 
identified. Twenty eight genes in total were found to be significantly differentially 
expressed in shCBP cells compared to shNEG. Log2FC: log2 of the fold change. 
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Figure 3.5. Gene Ontology (GO) pathways predicted to be affected by CREBBP 
Knockdown in PreB 697 cells. Pathways highlighted in red are predicted to be perturbed 
in cells with CREBBP knockdown. 
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3.5 Further Analysis of Cell Proliferation in PreB 697 Cells with Stable CREBBP 
Knockdown 
To confirm results obtained by growth curve analysis (Section 3.3) fluorescence output 
readings from the control groups for each drug sensitivity experiment conducted using 
shCBP and shNEG cells were compared as a measure of cell proliferation over 96 hours 
(Section 3.3 & 3.5). The average fluorescent output for shCBP compared to shNEG cells 
was not significantly different (Mean fluorescent output ±SD; shCBP 1.05x105 ±2.45x104, 
shNEG 1.01x105 ±2.21x104; p=0.5) (Figure 3.6), suggesting that, despite GO term 
predictions (Section 3.4), CREBBP knockdown in PreB 697 cells does not influence cell 
proliferation over 96 hours. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Stable CREBBP knockdown in PreB 697 cells and survival at 96 hours. The raw 
fluorescence output values from control treated cells from previous drug sensitivity 
experiments were combined and compared. Graph shows average relative fluorescence 
±SD (n=15). 
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3.6 Chemosensitivity of PreB 697 Cells with Stable CREBBP Knockdown 
Given that CREBBP knockdown in PreB 697 cells was shown to have no effect on sensitivity 
to dexamethasone treatment, we hypothesised that it may lead to reduced sensitivity to 
other ALL chemotherapeutics, thus explaining the propensity to relapse with CREBBP 
mutation in childhood ALL (Mullighan et al., 2011; Inthal et al., 2012). To this end, shCBP 
and shNEG cells were assessed for sensitivity to; daunorubicin, vincristine, methotrexate 
and 6-thioguanine by alamar blue drug sensitivity assay (Section 2.6.2). CREBBP 
knockdown in PreB 697 cells showed no significant effect on sensitivity to any of the 
chemotherapy agents tested compared to shNEG control (GI50 values, mean ±SD; 
daunorubicin shCBP 10.4nM ±1.5 versus shNEG 11.3nM ±0.52; p=0.4, vincristine shCBP 
0.3nM ±0.02 versus shNEG 0.3nM ±0.04; p=0.07, methotrexate shCBP 9.4nM ±1.6 versus 
shNEG 9.8nM ±1.8; p=0.7 and 6-thioguanine shCBP 2.4μM ±0.58 versus shNEG 2.6μM 
±0.32; p=0.6) (Figure 3.7 A-D). 
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Figure 3.7. Effect of stable CREBBP knockdown in PreB 697 cells on sensitivity to 
common ALL chemotherapeutics. ShCBP and shNEG cells were assessed for sensitivity to 
common ALL chemotherapies; A. daunorubicin, B. vincristine, C. methotrexate, D. 6-
thioguanine, by alamar blue drug sensitivity assay over 96 hours. Histograms show mean 
survival ±SD (n=3). 
 
 
 
 
 
 
 
 
                                                                                     Chapter 3 Stable CREBBP Knockdown in BCP-ALL 
 
 
 
112 
 
3.7 Expression and Activity of P53 and BCL6 in PreB 697 Cells with Stable 
CREBBP Knockdown 
Alongside its role as a HAT, CREBBP is also able to acetylate and regulate the activity of 
non-histone proteins (Chapter 1). Acetylation by CREBBP is vital for the activity of tumour 
suppressor p53, influencing stability, DNA binding and recruitment of co-activators 
(Brooks and Gu, 2003; Tang et al., 2008). CREBBP acetylation is also important in the 
inactivation of oncoprotein BCL6 by disrupting interaction with HDACs, reducing the 
ability to repress transcription of anti-apoptotic genes including p53 (Bereshchenko et al., 
2002). CREBBP is important for balancing the activity of this tumour suppressor/oncogene 
pair, and CREBBP mutation could potentially disrupt this balance, contributing to relapse 
in childhood ALL.  
3.7.1 CREBBP knockdown and p53 Expression and Acetylation 
The effect of CREBBP knockdown in PreB 697 cells, on p53 acetylation and expression of 
downstream target, p21, was assessed. Cells were exposed to 5 Gray (Gy) radiation, to 
induce DNA damage and trigger a p53 response, and harvested at 0, 4 and 8 hours post-
irradiation (Section 2.5.2). Western blotting for the acetyl-p53 (CREBBP target residues; 
Lysine 373 and Lysine 382) (Ac-p53), p53 and p21 expression was carried out. The effect 
of CREBBP knockdown on acetylation of p53 in PreB 697 cells was unclear; in 2 of 4 repeats 
(C and D), Ac-p53 expression was unaffected, whereas the other repeats show a clear 
reduction of Ac-p53 levels in CREBBP knockdown cells following irradiation (A and B) 
(Figure 3.8). Importantly, CREBBP knockdown had no effect on p21 expression, a 
transcriptional target of p53 in any experiment. Taken together these data suggest that 
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CREBBP knockdown in PreB 697 cells may cause a small impairment of p53 acetylation, 
but that this is not sufficient to affect p53 activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Expression of acetyl p53 (Ac-p53), p53 and p21 in PreB 697 cells with stable 
CREBBP knockdown. PreB 697 shCBP and shNEG cells were subjected to 5Gy radiation 
and whole cell lysates were harvested at 0, 4 and 8 hours on four separate occasions (A-
D). Western blotting was carried out for Ac-p53, p53 and p21. Alpha tubulin was included 
as loading control. 
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3.7.2 CREBBP Knockdown and BCL6 Expression 
To study the effect of CREBBP knockdown on BCL6 protein expression, western blotting 
was carried out using whole cell lysates from PreB 697 shCBP and shNEG cells (Section 
2.5). This showed that CREBBP knockdown did not influence basal BCL6 expression in PreB 
697 cells (Figure 3.9). Unfortunately, there was no commercially available antibody for 
acetyl-BCL6 at the time this study was carried out.  
 
 
 
 
 
 
Figure 3.9. BCL6 protein expression in PreB 697 cells with stable CREBBP knockdown. 
Whole cell lysates were taken from PreB 697 shCBP and shNEG cells on four separate 
occasions (A-D) and western blotting was carried out for BCL6 expression. Alpha-tubulin 
was included as loading control. 
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To study the effect of CREBBP knockdown and BCL6 expression at the mRNA level, gene 
expression microarray data (Section 3.4) was mined to determine expression of BCL6 and 
a number of BCL6 targets in PreB 697 shCBP compared to shNEG cells. BCL6 expression 
was unaffected by CREBBP knockdown, and only 3 of 19 BCL6 target genes assessed 
showed significant differential expression (Figure 3.10). Cells with CREBBP knockdown 
showed reduced expression of some IFITM1, IFITM3 and ATR probes (p=<0.04, p=0.0008 
and p=0.02 respectively) and increased expression of an ID2 probe (p=0.02). Given that 
only a small number of BCL6 targets were differentially expressed and BCL6 mRNA and 
protein expression were unaffected, this would suggest that CREBBP knockdown does not 
significantly alter BCL6 function.  
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Figure 3.10. BCL6 and BCL6 target expression in PreB 697 cells with stable CREBBP 
knockdown. Gene expression microarray data from PreB 697 shCBP and shNEG cells was 
mined to assess the expression of BCL6 and its targets. Graphs represent raw expression 
values from individual probes for each gene. Where more than 3 probes were available, 
the 3 with the highest relative expression values were plotted. Statistical significance was 
determined using the student’s t test.  
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3.8 DNA Damage Repair in PreB 697 Cells with Stable CREBBP Knockdown 
CREBBP is known to play a role in numerous DNA damage repair pathways, including; base 
excision repair (BER), homologous recombination repair (HRR) and direct DNA damage 
repair by thymine DNA glycosylase (TDG) (Chapter 1) (Pao et al., 2000; Teo et al., 2001; 
Tini et al., 2002; Hassa et al., 2005; Zimmer et al., 2012; Leger et al., 2014). Therefore, 
DNA damage repair mechanisms were assessed in the PreB 697 isogenic CREBBP 
knockdown model.  
3.8.1 CREBBP Knockdown and Expression of BER Components 
To assess the effects of CREBBP knockdown on BER, microarray data from PreB 697 shCBP 
and shNEG cells (Section 3.4) was mined for probes relating to BER components. None of 
the probes for the BER components analysed were found to be significantly differentially 
regulated in shCBP compared to shNEG cells (Figure 3.11). These data suggest that 
CREBBP knockdown does not impact on BER function in PreB 697 cells. 
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Figure 3.11. Expression of BER components in PreB 697 cells with stable CREBBP 
knockdown. Gene expression microarray data from shCBP and shNEG cells was mined to 
assess the expression of important BER components. Graphs represent raw expression 
values from individual probes for each gene. Where more than 3 probes were available, 
the 3 with the highest expression values were plotted. 
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3.8.2 CREBBP Knockdown and PARP Expression and Activity 
CREBBP is known to acetylate BER protein, poly(ADP) ribose polymerase (PARP) 1 allowing 
interaction with p50 and synergistic co-activation of NF-κB by p300 (Hassa et al., 2005). 
Firstly, western blotting for basal PARP-1 protein expression in PreB 697 shCBP and shNEG 
cells was carried out (Section 2.5). This showed that CREBBP knockdown had no effect on 
PARP-1 protein levels in PreB 697 cells (Figure 3.12). Maximally stimulated PARP activity 
was assessed by Ashleigh Herriott as described here (Plummer et al., 2005). Whilst cells 
with CREBBP knockdown showed slightly higher basal PAR levels, there was no significant 
difference in PARP activity between shCBP and shNEG cells (Figure 3.13). This further 
suggests that CREBBP knockdown is not sufficient to impair BER in PreB 697 cells. 
 
 
 
 
 
 
 
Figure 3.12. PARP-1 expression in PreB 697 cells with stable CREBBP knockdown. Whole 
cell lysates from PreB 697 shCBP and shNEG cells were collected on three separate 
occasions (A-C) and western blotting for PARP-1 expression was carried out. Alpha tubulin 
was included as loading control.  
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Figure 3.13. Basal PAR expression and maximally stimulated PARP activity in PreB 697 
cells with stable CREBBP knockdown. Basal PAR levels and maximally stimulated PARP 
activity was assessed in PreB 697 shCBP and shNEG cells. Maximally stimulated PARP 
activity was determined based on ability to form PAR using an immunoblot assay. Graphs 
show mean recalculated PAR [pmol] per 106 cells ±SD (n=1). 
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3.8.3 CREBBP Knockdown and Temozolomide Sensitivity 
To further assess the effect of CREBBP knockdown on DNA damage repair, PreB 697 shCBP 
and shNEG cells were analysed for sensitivity to the alkylating agent, temozolomide. 
Temozolomide rapidly undergoes pH-dependent degradation to the active intermediate 
5-(3-methyltriazen-lyl)imidazole-4-carboxamide, which can add methyl adducts to N7 
guanine, O6 guanine and N3 adenine (Horspool et al., 1990; Cheng et al., 2005). Unrepaired 
O6-methylguanine is a mutagenic lesion as it leads to mispairing of cytosine or thymidine, 
which in turn leads to G:C to A:T transitions upon DNA replication (Saffhill et al., 1985). 
This can trigger the mismatch repair (MMR) pathway, eventually leading to double strand 
breaks that initiate cell cycle arrest and apoptosis (Aquilina et al., 1992; Branch et al., 
1995; Ochs and Kaina, 2000). MGMT is a DNA repair protein that removes these alkyl 
groups from guanine at the O6 position, preventing mispairing (Tubbs et al., 2007). MGMT 
deficiency is known to cause hypersensitivity to chemotherapeutic methylating agents 
such as temozolomide (Glassner et al., 1999). 
PreB 697 shCBP and shNEG cells were treated with temozolomide or CV over 96 hours 
and relative cell viability was assessed using alamar blue (Section 2.6.2). CREBBP 
knockdown in PreB 697 cells led to a statistically significant increase in sensitivity to 
temozolomide compared to control (GI50 values, mean ±SD; shCBP 135µM ±9.15 versus 
shNEG 174µM ±2.31; p=0.002) (Figure 3.14). These data suggest that CREBBP knockdown 
cells may have deficiency in direct DNA damage repair by MGMT. 
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Figure 3.14. Effect of stable CREBBP knockdown in PreB 697 cells on sensitivity to 
temozolomide. ShCBP and shNEG cells were assessed for sensitivity to temozolomide by 
alamar blue drug sensitivity assay over 96 hours. Histogram shows mean survival ±SD 
(n=3). 
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3.8.4 CREBBP Knockdown and MGMT Expression 
Given that PreB 697 cells with CREBBP knockdown showed an increased sensitivity to 
temozolomide compared to control (Section 3.8.3), MGMT protein expression was 
assessed by western blotting (Section 2.5). MGMT is predicted to be 25kDa on a western 
blot, but the antibody used showed bands at 37kDa and 20kDa as well as a band at 25kDa 
(Figure 3.15). This suggests that other isoforms or modified versions of MGMT could be 
present in the cell line, or that the antibody is prone to non-specific binding. Complications 
aside, western blotting for MGMT in CREBBP knockdown PreB 697 cells showed no 
evidence of reduced MGMT expression. 
 
 
 
 
 
 
Figure 3.15. MGMT expression in PreB 697 cells with stable CREBBP Knockdown. Whole 
cell lysates from PreB 697 shCBP and shNEG cells were collected on three separate 
occasions (A-C) and western blotting for MGMT expression was carried out. Alpha tubulin 
was included as loading control. 
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3.8.5 CREBBP Knockdown and Ionising Radiation Sensitivity 
BER is responsible for the repair of damage induced by ionising radiation (Curtin, 2012). 
Further to this, Zimmer et al. (2012), showed that CREBBP heterozygous mice were 
hypersensitive to gamma radiation compared to wild type controls (Zimmer et al., 2012). 
For these reasons, the effect of CREBBP knockdown on response to ionising radiation (IR) 
in PreB 697 cells was assessed. Cells growing in exponential phase were dosed with 0.3-
6.1 Gy radiation, and their viability assessed by alamar blue following 96 hours incubation 
(Section 2.6.2). CREBBP knockdown had no effect on sensitivity to IR in PreB 697 cells 
compared to isogenic controls (GI50 values, mean ±SD; shCBP 1.453Gy ±0.07 versus shNEG 
1.493 ±0.27; p=0.8) (Figure 3.16), again suggesting an intact BER response. 
 
 
 
 
 
 
 
Figure 3.16. Effect of stable CREBBP knockdown in PreB 697 cells on sensitivity to 
ionising radiation. ShCBP and shNEG cells were assessed for sensitivity to ionising 
radiation by alamar blue drug sensitivity assay over 96 hours. Histogram shows mean 
survival ±SD (n=3). 
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3.9 Enhanced RAS Pathway Activation in NRAS Mutant PreB 697 Cells with 
Stable CREBBP Knockdown 
As discussed in Chapter 1, genetic profiling of childhood ALL has shown that CREBBP 
mutations frequently co-occur with RAS pathway mutations (Malinowska-Ozdowy et al., 
2015; Paulsson et al., 2015). Given this co-occurrence, it is possible that CREBBP mutations 
cooperate with oncogenic RAS mutations. As the PreB 697 cell line is known to harbour 
an NRAS mutation (Irving et al., 2014), CREBBP knockdown in this cell line provided a 
model to assess the effect of the co-occurrence of these mutations on RAS pathway 
activation. 
3.9.1 CREBBP Knockdown and p-ERK Expression 
The MAPK, ERK, is phosphorylated during RAS pathway activation. For this reason, 
assessment of phosphorylated ERK (p-ERK) is a useful measure of RAS pathway activation. 
PreB 697 shCBP and shNEG cells were harvested in exponential growth phase and western 
blotting was carried out probing for p-ERK and basal ERK (Section 2.5). In 3 of 4 replicate 
experiments (B, C and D), levels of p-ERK were found to be increased in PreB 697 shCBP 
cells compared to shNEG controls (Figure 3.17). Basal ERK levels were found to be 
consistent between shCBP and shNEG cells, so changes in p-ERK expression cannot be 
explained by altered basal ERK expression. These data suggest that CREBBP knockdown 
enhances RAS pathway activation in PreB 697 cells. 
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Figure 3.17. Stable CREBBP knockdown in PreB 697 cells and p-ERK expression. Whole 
cell lysates from PreB 697 shCBP and shNEG cells were collected on four separate 
occasions (A-D) and western blotting for p-ERK and ERK expression was carried out. Alpha 
tubulin was included as loading control. 
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3.9.2 CREBBP Knockdown and MEK Inhibitor Sensitivity 
Given that CREBBP knockdown in RAS pathway mutant PreB 697 cells led to increased RAS 
pathway activation as assessed by p-ERK expression (Section 3.9.1), it was hypothesised 
that this may lead to altered sensitivity to MEKi. Selumetinib is a potent MEKi and recently, 
pre-clinical evaluation by our group showed significant differential sensitivity in RAS 
pathway-mutated ALL compared with wildtype cells both in vitro and in an orthotopic 
xenograft model engrafted with primary ALL cells (Irving et al., 2014). PreB 697 cells with 
CREBBP knockdown were assessed for sensitivity to selumetinib by alamar blue drug 
sensitivity assay. An initial experiment (n=1) showed no difference in sensitivity to 
selumetinib between shCBP and shNEG cells (Figure 3.18 A). Importantly, this experiment 
showed that PreB 697 cells were resistant to selumetinib (GI50 values >100µM), suggesting 
that any effect of CREBBP knockdown on MEKi sensitivity may be masked by this. To 
overcome this, shCBP and shNEG cells were assessed for sensitivity to U0126, a selective, 
non-competitive inhibitor of MEK1 and MEK2, by alamar blue drug sensitivity assay 
(Duncia et al., 1998) (Section 2.6.2). Cells with CREBBP knockdown, again had no 
differential response to treatment with U0126 than control cells (GI50 values, mean ±SD; 
shCBP 9.8µM ±3.5 versus shNEG 10.4µM ±1.7; p=0.8) (Figure 3.18 B). This suggests that 
CREBBP deficient RAS mutated ALL retain sensitivity to MEKi. 
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Figure 3.18. Effect of stable CREBBP knockdown in RAS mutant PreB 697 cells on 
sensitivity to MEK inhibition. ShCBP and shNEG cells were assessed for sensitivity to the 
MEKis A. Selumetinib and B. U0126 by alamar blue drug sensitivity assay over 96 hours. 
Histogram shows mean survival ±SD (A. n=1, B. n=3). 
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3.10 In Vivo Growth of PreB 697 Cells with Stable CREBBP Knockdown 
Whilst informative, in vitro assays lack many factors which are present in whole organisms 
and so it may be that some important characteristics of CREBBP knockdown were not seen 
in these assays. To understand the effect of CREBBP knockdown on cells growing in a 
whole organism, PreB 697 shCBP and shNEG cells were grown in vivo. NOD SCID γ null 
mice were injected intrafemorally with 10 000 cells, either shCBP (n=5) or shNEG (n=6) 
(Section 2.2.8). Mouse numbers were determined based on previously published 
xenograft data, in which between 5 and 6 mice per group were sufficient to show a 
statistical difference in in vivo sensitivity to the MEKi selumetinib, given orally (Irving et 
al., 2014). Engraftment was monitored by tail vein bleed (Section 2.2.7.1) and mice were 
culled when signs of ill health were seen (weakness, difficulty walking, slow movement 
etc.). Upon culling, spleens and livers were weighed and fixed along with femurs. Section 
of spleen were also put into suspension and assessed for engraftment by flow cytometry 
(Section 2.3.2).  
Tail vein bleeds showed 0% peripheral blood engraftment at week 3 post-injection and 
for mice injected with shCBP (the only surviving mice at this time point) showed between 
3.9 and 27.7% peripheral blood engraftment at week 6. Importantly, GFP expression of 
transduced cells was maintained in vivo (shCBP; 99.6% GFP positive, shNEG; 99.4% GFP 
positive), suggesting that cells retained CREBBP knockdown (or control sequence) (Figure 
3.19). Time to death was significantly longer in shCBP mice, with all shNEG being culled 
based on health criteria, before shCBP mice (Time to death, mean ±SD; shCBP 42 days 
±1.23 versus shNEG 28.17 days ±3.71; p=<0.0001) (Figure 3.20 A). Spleen weight and liver 
weight was also significantly higher in shCBP mice compared to shNEG (Spleen weight, 
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mean ±SD; shCBP 0.23g ±0.05 versus shNEG 0.13g ±0.03; p=<0.004, Liver weight, mean 
±SD; shCBP 4.75g ±0.46 versus shNEG 3.66g ±0.59; p=<0.009)  (Figure 3.20 B & C). There 
was a trend towards greater spleen engraftment in shCBP than shNEG, but this was not 
statistically significant (Spleen engraftment, mean ±SD; shCBP 20.88% ±9.33 versus shNEG 
12.86% ±8.53; p=<0.2) (Figure 3.20 D). These data show that CREBBP knockdown leads to 
a markedly altered in vivo growth profile in PreB 697 cells. 
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Figure 3.19. GFP expression of spleen cells from mice engrafted with PreB 697 shCBP 
and shNEG cells. Spleen cells from mice engrafted with PreB 697 (A. shNEG or B. shCBP) 
were stained with antibodies specific to human leukaemia and mouse blood cells and 
assessed for GFP expression. Living cells were gated based on forward and side scatter 
and human cells were gated based on low expression of mouse CD45 and high expression 
of CD19. 
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Figure 3.20. Effect of stable CREBBP knockdown in PreB 697 cells on in vivo growth. 
Immunodeficient mice were injected intrafemorally with either shCBP or shNEG and 
culled when signs of ill health were seen. A. Time to death (time from injection to culling), 
B. & C. spleen & liver weight and D. spleen engraftment. Bar charts represent mean ±SD 
(shCBP n=5, shNEG n=6). 
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3.10 Discussion 
The aim of this chapter was to further characterise a BCP-ALL cell line with stable CREBBP 
knockdown, in order to gain understanding of how CREBBP haploinsufficiency contributes 
to relapse in childhood ALL. These studies have addressed the effects of CREBBP 
knockdown on gene expression, cell proliferation, drug sensitivity, oncogene/tumour 
suppressor activity, DNA damage repair and RAS pathway activation.  
CREBBP haploinsufficiency is predicted to cause dexamethasone resistance in childhood 
ALL, thus explaining the associated propensity to relapse with this alteration (Mullighan 
et al., 2011). This prediction is based on data from CREBBP/EP300 double knockout MEF 
models engineered to express a range of CREBBP mutations (Mullighan et al., 2011). To 
date, the effect of CREBBP haploinsufficiency on sensitivity to GC and other 
chemotherapeutic agents has not been assessed in an isogenic leukaemia context.  
Data collected in this chapter show that CREBBP knockdown in PreB 697 cells leads to 
impaired expression of the GR targets; GILZ, FKBP5 and NR3C1 and IPA of GEP data in 
these cells predicts altered GR expression. Despite these finding, cells were no more 
resistant to GC than controls, suggesting that CREBBP haploinsufficiency may not 
contribute to relapse by inducing GC resistance. These data are in keeping with recent 
reports that patients with CREBBP mutations at relapse do not have a poor response to 
the GC, prednisone, administered during front-line treatment and that CREBBP mutations 
at relapse are not associated with intensive front line GC-containing protocols 
(Malinowska-Ozdowy et al., 2015; Yu et al., 2015). Importantly, data gathered in this 
chapter show that CREBBP knockdown in PreB 697 cells had no effect on sensitivity to a 
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panel of ALL chemotherapeutics, suggesting that CREBBP haploinsufficiency does not 
contribute to relapse through drug resistance. Another possibility is that important 
elements of biological context are being missed in the use of the PreB 697 cell line. For 
example, the majority of CREBBP mutations are found in the high hyperdiploid (HHD) and 
hypodiploid cytogenetic subgroups, and PreB 697 cells do not match this context (Inthal 
et al., 2012; Holmfeldt et al., 2013; Malinowska-Ozdowy et al., 2015). Further to this, only 
a single shRNA sequence was used to knockdown CREBBP, so the data gathered may be 
specific to this shRNA sequence. It is also possible that the use of in vitro modelling of 
CREBBP haploinsufficiency ignores important microenvironmental factors that are 
present in vivo. For example, adhesion of leukaemia cells to the bone marrow stroma has 
been shown to contribute to chemoresistance, something which is not accounted for 
using in vitro models (Manabe et al., 1992; Kumagai et al., 1996; Mudry et al., 2000). To 
overcome these limitations, studies should be carried out using additional shRNA 
constructs or another form of RNAi in cell lines or primary derived material with relevant 
cytogenetic context, or preferably in vivo models of CREBBP haploinsufficiency in ALL 
should be employed, where a bone marrow microenvironment is present.  
CREBBP plays an important role in cAMP-dependent signalling, acting as a co-transcription 
factor for CREB, a transcription factor with the ability to bind ~4000 different promoter 
start sites, and substrate to PKA (Zhang et al., 2005). Importantly there is known to be 
interplay between cAMP/PKA and GC-induced apoptotic response, with the GR being 
required for cAMP/PKA induced apoptosis in lymphoma cells (Rickles et al., 2010). Data 
collected in this chapter identified CXCR4 and MKNK2 as cAMP-dependent targets in PreB 
697 cells and confirmed that RGS16 and DUSP10, previously identified as cAMP-
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dependent in MEF cells (Mullighan et al., 2011), are cAMP-dependent in PreB 697 cells. 
These data showed that CREBBP knockdown had no effect on the cAMP-induced 
expression of these genes in PreB 697 cells suggesting that remaining levels of CREBBP 
expression are sufficient to maintain cAMP-dependent gene expression.  
CREBBP is known to play a role in many aspects of cell cycle progression and control, 
though whether it promotes apoptosis or cell proliferation appears to be context 
dependent (Kwok et al., 1994; Yuan et al., 1996; Goodman and Smolik, 2000; Turnell et 
al., 2005). For example, a recent study in hepatocellular carcinoma showed that inhibiting 
CREBBP and its paralog EP300s, using the HAT inhibitor C646, led to reduced cell 
proliferation, exemplifying how CREBBP/EP300 activity can be oncogenic (Inagaki et al., 
2016). Further to this a recent report in lung cancer showed that CREBBP was synthetically 
lethal with its paralog EP300, and depletion of either, where its paralog is absent, led to 
apoptosis (Ogiwara et al., 2015). On the contrary, CREBBP appears to act as a tumour 
suppressor in the context of haematopoiesis, with heterozygous loss of CREBBP in mice 
causing multilineage defects in haematopoietic differentiation and an increased incidence 
of haematological malignancies (Kung et al., 2000). This shows that altered cell cycle 
control represents a potential mechanism by which CREBBP mutation could contribute to 
relapse in childhood ALL. Indeed, GO analysis of GEP data predicted that DNA replication 
and cell cycle may be altered by CREBBP knockdown in PreB 697 cells. However, previous 
analysis of PreB 697 cells with stable CREBBP knockdown showed no effect on the growth 
rate of cells and further analysis of cell proliferation based on CV treated cells from drug 
sensitivity experiments confirmed these previous analyses. Given that CREBBP plays a 
clear, but contradictory role in cell proliferation, it is possible that the use of the PreB 697 
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cell line model overlooks important biological context. As described previously, ALL cell 
have numerous interactions with bone marrow stroma and rely on these interactions for 
survival (Sison and Brown, 2011). For example, WNT/β-catenin signalling is involved in 
important in the bone marrow niche, playing a role in modulating the expression of B-cell 
progenitor cell cycle regulators including E2F1, MYBL2 and CDC25B (Khan et al., 2007; 
Malhotra and Kincade, 2009). Therefore, further study of the effects of CREBBP 
haploinsufficiency on cell cycle control in ALL may be better performed using in vivo 
models. 
CREBBP mutation has been shown to impact on p53 and BCL6 acetylation impacting on 
their activation and inactivation respectively (Pasqualucci et al., 2011). P53 is a universally 
expressed tumour suppressor involved in apoptotic signalling and BCL6 is an oncogene 
involved in transcriptional repression, which provides an environment tolerant of DNA 
breaks, and can inhibit p53, leading to suppression of apoptosis (Phan and Dalla-Favera, 
2004; Basso and Dalla-Favera, 2012). As acetylation is vital for p53 function and BCL6 
inactivity, this suggests that dysfunctional acetylation due to CREBBP mutation may lead 
to an imbalance between their activities, potentially causing resistance to apoptosis 
(Bereshchenko et al., 2002; Tang et al., 2008). In this chapter, CREBBP knockdown in PreB 
697 cells showed an inconsistent effect on acetylation of p53, but importantly showed no 
effect on expression of an important downstream target of p53, p21 (el-Deiry et al., 1994). 
This would suggest that CREBBP knockdown in PreB 697 cells does not impact on p53 
response. Further to this, basal expression of BCL6 protein was unaffected in shCBP cells 
compared to shNEG and expression of BCL6 and its targets were assessed based on GEP 
data showed that BCL6 and the majority of its targets were unaffected by CREBBP 
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knockdown. This suggests that CREBBP mutation may not be sufficient to alter p53/BCL6 
activity in childhood ALL. 
CREBBP is known to play a role in a number of DNA damage repair processes, and 
abrogation of DNA damage repair through CREBBP mutation represents a potential 
mechanism for drug resistance and relapse development (Pao et al., 2000; Teo et al., 
2001; Tini et al., 2002; Hassa et al., 2005; Zimmer et al., 2012; Leger et al., 2014). This is 
particularly relevant as hypermutable genotypes at relapse have been identified by whole 
exome sequencing in ALL (Ma et al., 2015). Stable CREBBP knockdown in PreB 697 cells 
had no effect on expression of BER genes, PARP-1 protein expression or PARP-1 activity. 
CREBBP knockdown did however, led to an increased sensitivity to the alkylating agent, 
temozolomide. Despite this increased sensitivity to temozolomide, the expression of the 
direct DNA damage repair protein MGMT, responsible for the repair of damage induced 
by alkylating agents, was found to be normal (Tubbs et al., 2007). Further to this, CREBBP 
knockdown was not sufficient to induce hypersensitivity to gamma radiation as is seen in 
CREBBP heterozygous mice (Zimmer et al., 2012). Taken together, the data collected in 
this chapter do not support a role for CREBBP haploinsufficiency in abrogation of DNA 
damage repair.  
CREBBP mutations frequently co-occur with RAS pathway activating mutations, including 
KRAS, NRAS, PTPN11 and FLT3 (Malinowska-Ozdowy et al., 2015). PreB 697 cells harbour 
an NRAS (G12D) mutation, which leads to RAS pathway activation. Cells with CREBBP 
knockdown were shown to have increased expression of p-ERK, indicative of increased 
RAS pathway activation. This may explain the observation that time to relapse in patients 
with both CREBBP and KRAS mutations was shorter than in patients without or with only 
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one mutation (Malinowska-Ozdowy et al., 2015). KRAS was shown to be directly 
acetylated by CREBBP (manuscript submitted), a secondary modification shown to have a 
negative regulatory effect on RAS activity by altering conformational stability of the Switch 
II domain and thus interaction with guanine nucleotide exchange factors (Yang et al., 
2012). This link identified between mutations CREBBP and enhanced oncogenic signalling 
is supported by a recent study in early thymocyte precursor ALL which found that 
inactivation of the methyltransferase, EZH2, cooperates with mutant RAS to induce 
hyperactive cytokine signalling, principally through STAT3, and was associated with a 
reduced sensitivity to JAK inhibitors.(Danis et al., 2016). Despite an enhanced RAS 
pathway activation in CREBBP attenuated ALL cells, sensitivity to MEKi was retained, 
which may have important clinical implications. Our group has recently reported on the 
preclinical evaluation of the MEKi, selumetinib, and demonstrated significant differential 
sensitivity in RAS pathway-mutated ALL compared to ALL without RAS mutations, both in 
vitro and in an orthotopic xenograft model engrafted with primary ALL cells (Irving et al., 
2014) (Ryan et al., 2016). Clinical trials of selumetinib for relapsed RAS pathway mutated 
ALL cases are underway and the data presented here suggest that patients with co-
occurring CREBBP and RAS mutations might still be good candidates for MEKi therapy.  
To overcome the limitations of using in vitro cell models, PreB 697 cells with stable 
CREBBP knockdown were injected into immunodeficient mice and their engraftment was 
characterised. PreB 697 shCBP and shNEG cells engrafted successfully in the spleens of 
mice and crucially maintained expression of GFP, suggesting that the cells maintained 
expression of their lentiviral constructs. Mice injected with PreB 697 cells with stable 
CREBBP knockdown lived longer, had bigger spleens and livers and showed a trend 
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towards increased spleen engraftment compared to mice injected with shNEG control 
cells. Data presented in this chapter show that CREBBP knockdown does not impact on 
cell cycle control in vitro, but does alter in vivo growth characteristics, suggesting future 
studies should be carried out using in vivo models of CREBBP haploinsufficiency. 
CREBBP is known to be involved in the self-renewal and differentiation of HSCs, though it 
is not currently known whether it exerts its effects through histone remodelling functions, 
recruitment and/or acetylation of highly specific transcription factors or a combination of 
these functions (Rebel et al., 2002). It is possible that CREBBP mutations do not work alone 
in the epigenetic reprogramming of cells and that other epigenetic modifiers may also be 
altered in CREBBP haploinsufficient cells. EZH2, responsible for repressive H3K27 
trimethylation, is frequently mutated in DLBCL and FL and has been associated with poor 
prognosis in a range of cancers (Vire et al., 2006; Morin et al., 2011; Takawa et al., 2011; 
Bodor et al., 2013). Further to this, there is evidence to suggest that EZH2 
methyltransferase activity is antagonistic to CREBBP acetyltransferase activity (Pasini et 
al., 2010). CREBBP haploinsufficiency combined with an EZH2 activating mutation, would 
therefore cause a shift from activating H3K27 acetylation to repressive H3K27 
trimethylation leading to epigenetic reprogramming. Given the altered in vivo growth 
characteristics of PreB 697 cells with stable CREBBP knockdown, it is possible that CREBBP 
haploinsufficiency works by contributing to reprogramming the epigenetic landscape of 
cells to confer a cancer stem cell transcriptional profile. 
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In summary, these data suggest that CREBBP haploinsufficiency in ALL leads to increased 
RAS/RAF/MEK/ERK signalling in cells harbouring RAS mutation, but crucially MEKi 
sensitivity is retained. CREBBP attenuation in PreB 697 cells in vitro does not appear to 
contribute to drug resistance, and similarly does not impact on cell cycle control, 
p53/BCL6 activity or DNA damage repair. However, the in vivo growth characteristics of 
cells with CREBBP knockdown were shown to be markedly different from those in vitro, 
suggesting a potential effect on cell cycle control and a need to carry out future 
experiments in vivo.  
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CREBBP Knockdown in BCP-ALL Cell Lines and High Hyperdiploid 
Primagrafts 
 
4.1 Introduction 
The effect of stable CREBBP knockdown in PreB 697 cells was extensively characterised in 
Chapter 3. One disadvantage of the approached used was that it was based on analysis of 
a single BCP-ALL cell line with a single lentiviral construct used to knock down expression 
of CREBBP. Another disadvantage of this model is the cytogenetic context. CREBBP 
mutations are most frequently found in relapsed HHD and hypodiploid childhood ALL, and 
PreB 697 cells do not represent this context (Inthal et al., 2012; Holmfeldt et al., 2013; 
Malinowska-Ozdowy et al., 2015). The aim of this chapter was to validate the results 
described in Chapter 3, using transient CREBBP knockdown in a range of cell lines and 
primary derived (primagraft) samples. This would further test the hypotheses that CREBBP 
haploinsufficiency does not impact on sensitivity to ALL chemotherapeutics, and that 
CREBBP haploinsufficiency in RAS pathway mutant cells leads to increased oncogenic 
signalling through the RAS/RAF/MEK/ERK pathway. 
 
4.2 Transient CREBBP Knockdown in PreB 697 Cells Using siRNA Pool 
Transfection 
To confirm the results of CREBBP knockdown by shRNA in PreB 697 cells, transient siRNA 
knockdown of CREBBP was carried out. Knockdown by siRNA pool transfection was carried 
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out as described in section 2.7.2. As siRNA transfection is transient, knockdown was 
carried out before each successive downstream experiment.  
4.2.1 Characterising the Effect of Transient CREBBP Knockdown in PreB 697 
Cells 
CREBBP knockdown was confirmed at the mRNA and/or protein level for each individual 
experiment. CREBBP mRNA expression was assessed by QRT-PCR (Section 2.4.7). As 
shown in PreB 697 cells with stable CREBBP knockdown, cells transfected with siRNA pool 
showed around 40% reduction in CREBBP mRNA expression (Figure 4.1). To assess the 
level of CREBBP protein knockdown, western blotting was carried out (Section 2.5). The 
reduction in CREBBP protein expression seen in transiently knocked down cells was 
comparable to that seen in stably knocked down cells and CREBBP deleted patient 
samples (Figure 4.2A) (Section 3.2), and was maintained for at least 96 hours (Figure 4.2B). 
The functional effect of CREBBP knockdown was assessed by western blotting for 
AcH3K18 and AcH3K27, both targets of CREBBP HAT activity (Kasper et al., 2010; Henry et 
al., 2013) (Section 2.5). CREBBP knockdown had a variable effect on AcH3K18 expression, 
but consistently led to reduction of AcH3K27 expression (Figure 4.3).  
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Figure. 4.1 CREBBP mRNA expression in PreB 697 with transient CREBBP knockdown. 
Cells were harvested 24 hours post-transfection and QRT-PCR was carried out for CREBBP 
expression. Expression levels were normalised to TBP by the ΔΔCT method. Histogram 
represents mean ±SD of triplicate experiments. 
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Figure 4.2 CREBBP protein expression in PreB 697 with transient CREBBP knockdown. A. 
PreB 697 cells were transfected with an siRNA pool targeting CREBBP (siCBP), control 
siRNA, or electroporated in absence of siRNA (Mock), and incubated for 24 hours before 
whole cell lysates were extracted and western blotting was carried out for CREBBP. Blot 
shown is representative of CREBBP knockdown following each siRNA transfection. B. 
CREBBP protein expression in whole cell lysates extracted from cells transfected with 
siCBP or control after 48, 72 and 96 hour incubation. Alpha tubulin was included as loading 
control. 
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Figure 4.3 Expression of AcH3K18 and AcH3K27 in PreB 697 with transient CREBBP 
knockdown. PreB 697 cells were transfected with an siRNA pool targeting CREBBP (siCBP), 
control siRNA, or electroporated in absence of siRNA (Mock) on separate occasions, and 
incubated for 48 hours before whole cell lysates were extracted and western blotting was 
carried out for AcH3K18 (A, i-iii) or AcH3K27 (B, i-ii). Alpha tubulin was included as loading 
control. 
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4.2.2 cAMP response in PreB 697 Cells with Transient CREBBP Knockdown 
In Chapter 3, stable CREBBP knockdown in PreB 697 cells showed no impact on cAMP-
induced expression of cAMP-dependent genes (Section 3.3). To validate these results, 
PreB 697 cells transfected with an siRNA pool targeting CREBBP (siCBP) or control siRNA 
(control) were assessed for cAMP-dependent gene expression. Cells were treated with 
IBMX and forskolin to induce a maximal intracellular cAMP response, or CV and QRT-PCR 
was carried out using probes for the cAMP-dependent targets identified in Chapter 3 
(Sections 2.4.7 and 3.3). CXCR4 and RGS16 were significantly induced by cAMP in both 
siCBP and control cells, with around 11 fold increase in CXCR4 and 3 fold increase in RGS16 
being observed (p values <0.03 for CXCR4 and <0.06 for RGS16). Whilst a trend towards 
increased MKNK2 and DUSP10 expression was seen following cAMP stimulation for siCBP 
and control cells, this was not statistically significant (p values >0.1 for both genes). 
CREBBP knockdown had no impact on the level of cAMP-stimulated expression for any 
gene (p values >0.4) or on unstimulated gene expression compared to control cells (p 
values > 0.6) (Figure 4.4).  
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Figure 4.4. Effect of transient CREBBP knockdown in PreB 697 cells on cAMP-dependent 
gene expression. PreB 697 siCBP and control cells were treated with either control vehicle 
(CV) or IBMX and forskolin (I&F) before determining expression of cAMP-dependent genes 
by QRT-PCR relative to endogenous TBP expression by the ΔΔCT method. Histograms show 
mean ±SD (n=3). 
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4.2.3 Induction of GR Transcriptional Targets in PreB 697 Cells with Transient 
CREBBP Knockdown  
In Chapter 3, stable CREBBP knockdown in PreB 697 cells was shown to cause impaired 
GC-induced expression of GR targets (Section 3.2). To validate these results, PreB 697 
siCBP and control cells were treated with dexamethasone for 24 hours to induce GR target 
expression, or CV and QRT-PCR was carried out to assess the expression of GR targets; 
GILZ, FKBP5, NR3C1 and ITGA9 (Section 2.4.7).  
Unlike PreB 697 cells with stable CREBBP knockdown, GILZ and FKBP5 were only 
significantly induced by GC exposure in siCBP cells (GILZ ~40 fold increase p=0.04, FKBP5 
~6 fold increase p=0.02) with control cells showing a clear trend towards GC-induced GR 
targets expression that failed to reach significance (GILZ ~17 fold increase p=0.09, FKBP5 
~4 fold increase p=0.06). NR3C1 was found to be significantly induced in both siCBP and 
control cells, as shown in PreB 697 cells with stable CREBBP knockdown (~2 fold increase, 
p values <0.002). Despite a trend towards increased expression, ITGA9 was not 
significantly induced by GC exposure in either siCBP or control cells (p values >0.08). 
Transient CREBBP knockdown led to a statistically significant reduction of basal GILZ and 
NR3C1 expression (p=0.02 and p=0.01 respectively) but had no such effect on FKBP5 and 
ITGA9 (p=0.5 and p=0.3 respectively). CREBBP knockdown did not significantly impair the 
expression of genes which were shown to be significantly induced by GC in both siCBP and 
control transfected cells (GILZ p=0.6, FKBP5 p=0.6). GC induced NR3C1 expression was 
shown to be higher in siCBP cells compared to control (p=0.01), differing significantly from 
PreB 697 cells with stable CREBBP knockdown in which GC induced NR3C1 expression was 
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significantly impaired (Section 3.2). Taken together these data suggest that transient 
CREBBP knockdown in PreB 697 cells does not impair transcription of GR targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Effect of transient CREBBP knockdown in PreB 697 cells on GR target gene 
expression. PreB 697 siCBP and control cells were treated with either control vehicle (CV) 
or dexamethasone (Dex) for 24 hours before determining expression of GR target genes 
by QRT-PCR relative to endogenous TBP expression by the ΔΔCT method. Histograms show 
mean ±SD (n=3). 
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4.2.4 Dexamethasone Sensitivity of PreB 697 Cells with Transient CREBBP 
Knockdown 
Previously obtained data (MRes project) showed that stable knockdown of CREBBP in 
PreB 697 cells had no effect on sensitivity to dexamethasone (Section 3.2). To further 
validate this observation, siCBP and control cells were assessed for sensitivity to 
dexamethasone using alamar blue drug sensitivity assays (Section 2.6.2). Cells with 
transient CREBBP knockdown were no more resistant to dexamethasone than controls, 
but showed a small, statistically significant increase in sensitivity to dexamethasone (GI50 
values, mean ±SD; siCBP 17nM ±1.6, control 34.7nM±2.7; p=0.0006) (Figure 4.6).  Given 
the actual difference in GI50 values, this difference is likely too small to be biologically 
relevant.  
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Figure 4.6 Dexamethasone sensitivity of PreB 697 cells with transient CREBBP 
knockdown. PreB 697 siCBP and control cells were treated with a range of 
dexamethasone concentrations or CV, 24 hours post-transfection and incubated for 96 
hours. Alamar blue was used to determine cell survival as a % of CV treated cells. Values 
plotted represent the mean % survival ±SD (n=3). 
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4.2.5 Cell Proliferation in PreB 697 Cells with Transient CREBBP Knockdown 
In Chapter 3, PreB 697 cells with stable CREBBP knockdown were shown to proliferate at 
the same rate as controls (Sections 3.2 and 3.5). To validate these data, PreB 697 cells 
with transient CREBBP knockdown were assessed for survival 96 hours post-transfection 
as described previously (Section 3.5). Fluorescent output readings from cells treated with 
CV only from dexamethasone sensitivity experiments were compared (Section 4.2.4). The 
average fluorescence output for PreB 697 siCBP cells compared to control was not 
significantly different (Mean fluorescent output ±SD; siCBP 1.22x105 ±1.4x104, control 
1.21x105 ±1.05x104; p=0.8), suggesting that CREBBP knockdown did not influence cell 
proliferation over 96 hours (Figure 4.7).  
 
 
 
 
 
 
 
 
Figure 4.7. Transient CREBBP knockdown in PreB 697 cells and survival at 96 hours. The 
raw fluorescence output values from control treated cells used in dexamethasone 
sensitivity experiments were combined and compared. Graph shows average relative 
fluorescence ±SD (n=3). 
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4.2.6 Temozolomide Sensitivity of PreB 697 Cells with Transient CREBBP 
Knockdown 
Stable knockdown of CREBBP in PreB 697 cells led to a significant increase in sensitivity to 
temozolomide, suggesting CREBBP mutation may impair direct DNA damage repair by 
MGMT (Section 3.8.3). Further study of these cells showed that MGMT was unaffected by 
stable CREBBP knockdown (Section 3.8.4). To explore these findings further, PreB 697 cells 
with transient CREBBP knockdown were assessed for sensitivity to temozolomide (Section 
2.6.2). This showed that PreB 697 siCBP cells were not differentially sensitive to 
temozolomide compared to controls (GI50 values, mean ±SD; siCBP 225µM ±19.5, control 
229µM ±14.8; p=0.8) (Figure 4.8). This would suggest that, contrary to results shown in 
stably knocked down cells, transient CREBBP knockdown does not lead to increased 
sensitivity to temozolomide. This may also explain the lack of MGMT deficiency seen in 
PreB 697 cells with stable CREBBP knockdown. 
 
 
 
 
 
 
 
 
                                                Chapter 4 CREBBP Knockdown in BCP-ALL Cell Lines and Primagrafts 
 
 
 
156 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Effect of transient CREBBP knockdown in PreB 697 cells on sensitivity to 
temozolomide. Cells were treated with a range of temozolomide concentrations or CV, 
24 hours post-transfection and incubated for 96 hours. Alamar blue was used to 
determine cell survival as a % of CV treated cells. Values plotted represent the mean % 
survival ±SD (n=3). 
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4.3 Transient CREBBP Knockdown in Hypodiploid MHH-CALL-2 Cells  
Given that all observations on the effect of CREBBP haploinsufficiency had been made in 
the PreB 697 cell line, comparison with another cell line was sought. The MHH-CALL-2 cell 
line is a CREBBP wild type, BCP-ALL cell line and is near-haploid by cytogenetics (Aburawi 
et al., 2011) (COSMIC database). This is of particular relevance as CREBBP mutations are 
enriched in this cytogenetic subgroup (Holmfeldt et al., 2013). 
4.3.1 Characterising the Effect of Transient CREBBP Knockdown in MHH-CALL-
2 Cells 
MHH-CALL-2 cells were transfected with an siRNA pool targeting CREBBP (Section 2.7.2). 
Again, given the transient nature of this procedure, knockdown was carried out before 
each individual experiment. CREBBP knockdown was confirmed at the mRNA and/or 
protein level. CREBBP knockdown by siRNA pool transfection in MHH-CALL-2 cells led to 
~50% CREBBP mRNA reduction compared to control (p=0.001), similar to that achieved in 
PreB 697 cells with stable and transient knockdown (Sections 3.2 and 4.2.1) (Figure 4.9 A). 
CREBBP protein knockdown in MHH-CALL-2 cells was consistent with that shown in PreB 
697 cells with stable and transient CREBBP knockdown, as well as patient derived material 
with mono-allelic CREBBP deletions (Sections 3.2 and 4.2.1) (Figure 4.9 B). 
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Figure 4.9. CREBBP mRNA and protein expression in MHH-CALL-2 cells with transient 
CREBBP knockdown. A. MHH-CALL-2 cells transfected with an siRNA pool targeting 
CREBBP (siCBP) and control cells were harvested 24 hours post-transfection and QRT-PCR 
was carried out for CREBBP expression. Expression levels were normalised to TBP by the 
ΔΔCT method. Histogram represents mean ±SD of triplicate experiments. B. Whole cell 
lysates from MHH-CALL-2 siCBP or control cells were extracted 24 hours post-transfection 
and western blotting was carried out for CREBBP. Blot shown is representative of CREBBP 
protein expression following each siRNA transfection. Alpha tubulin was included as 
loading control. 
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The functional effect of CREBBP knockdown was assessed by western blotting for 
AcH3K18 and AcH3K27 (Section 2.5). Transient CREBBP knockdown in MHH-CALL-2 cells 
gave a consistent reduction of AcH3K18 and AcH3K27 levels, showing a clear functional 
impact of the knockdown (Figure 4.10). Cell growth was again analysed based on cell 
survival in CV treated cells from dexamethasone sensitivity experiments (Section 4.3.4). A 
trend towards reduced cell survival in MHH-CALL-2 siCBP cells compared to control was 
observed which was close to statistical significance (Mean fluorescent output ±SD; siCBP 
2.7x104 ±8.94x103, control 2.2x104 ±6.09x103; p=0.06) (Figure 4.11), suggesting that 
CREBBP knockdown may influence cell proliferation in MHH-CALL-2 cells.  
 
 
 
 
 
 
 
 
 
Figure 4.10. Expression of AcH3K18 and AcH3K27 in MHH-CALL-2 cells with transient 
CREBBP knockdown. MHH-CALL-2 cells were transfected with an siRNA pool targeting 
CREBBP (siCBP) or control on separate occasions and incubated for 48 hours before whole 
cell lysates were extracted and western blotting was carried out for AcH3K18 (A, i-iii) or 
AcH3K27 (B, i-iii). Alpha tubulin was included as loading control. 
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Figure 4.11. Transient CREBBP knockdown in MHH-CALL-2 cells and survival at 96 hours. 
The raw fluorescence output values from CV treated cells from MHH-CALL-2 siCBP 
dexamethasone sensitivity experiments were combined and compared. Histogram shows 
average relative fluorescence ±SD (n=3). 
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4.3.2 cAMP response in MHH-CALL-2 Cells with Transient CREBBP Knockdown 
Both stable and transient knockdown of CREBBP in PreB 697 cells had no effect on cAMP-
induced gene expression (Sections 3.3 and 4.2.3). To validate these data, induction of 
cAMP-dependent genes in response to cAMP stimulation was assessed in MHH-CALL-2 
cells with transient CREBBP knockdown. Cells were treated with IBMX and forskolin to 
induce a maximal intracellular cAMP response or CV and QRT-PCR was carried out using 
probes specific to cAMP-dependent genes identified in PreB 697 cells in Chapter 3 
(Sections 2.4.7 and 3.3). CXCR4, and DUSP10 were significantly upregulated in both siCBP 
and control cells following cAMP stimulation (CXCR4 ~4 fold upregulated; p values <0.01, 
DUSP10 ~2 fold upregulated; p values <0.01). RGS16 was shown to be significantly 
upregulated by cAMP in siCBP cells only, despite a trend towards cAMP induction being 
shown in control cells (siCBP; ~6 fold upregulation p=0.02, control; ~6 fold upregulation 
p=0.08). MKNK2 was not significantly upregulated by cAMP in siCBP or control cells (p 
values >0.05) and basal expression of all genes was unaffected by CREBBP knockdown (p 
values >0.08). As shown in PreB 697 cells with both stable and transient CREBBP 
knockdown, transient CREBBP knockdown in MHH-CALL-2 cells had no effect on the level 
of cAMP-induced expression achieved for any cAMP-dependent gene assessed (p values 
>0.2) (Figure 4.12). 
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Figure 4.12. Effect of transient CREBBP knockdown in MHH-CALL-2 cells on cAMP-
dependent gene expression. MHH-CALL-2 siCBP and control cells were treated with either 
control vehicle (CV) or IBMX and forskolin (I&F), before determining expression of cAMP-
dependent genes by QRT-PCR relative to endogenous TBP expression by the ΔΔCT method. 
Histograms show mean ±SD (n=3). 
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4.3.3 Induction of GR Transcriptional Targets in MHH-CALL-2 Cells with 
Transient CREBBP Knockdown 
Knockdown of CREBBP in PreB 697 cells gave conflicting  results on the induction of GR 
transcriptional targets, with stably knocked down cells showing impaired GC-induced 
expression of GR targets (Section 3.2), and transiently knocked down cells showing no 
such impairment (Section 4.2.3). To further study this effect, MHH-CALL-2 cells with 
transient CREBBP knockdown were assessed for GC-induced GR target expression (Section 
2.4.7). Both GILZ and FKBP5 showed significant induction in response to GC, in siCBP and 
control cells, unlike in PreB 697 siCBP cells (GILZ; ~50 fold increase, p values <0.02, FKBP5; 
~10 fold increase, p values <0.02) (Section 4.2.3). NR3C1 was only significantly induced by 
GC in MHH-CALL-2 control cells, but a trend towards induction was seen in siCBP cells 
(Control ~3 fold increase, p=0.04, siCBP ~2 fold increase, p=0.1). Unlike in PreB 697 cells, 
ITGA9 was significantly induced by GC in both control and siCBP MHH-CALL-2 cells (~6 fold 
increase, p values <0.02). CREBBP knockdown had no significant effect on the basal 
expression of any gene assessed (p values >0.3). As in PreB 697 cells with transient CREBBP 
knockdown, the level of dexamethasone induced GILZ or FKBP5 expression achieved was 
unaffected by CREBBP knockdown in MHH-CALL-2 cells (GILZ; p=0.9, FKBP5; p=0.7, NR3C1; 
p=0.9, ITGA9; p=1.0) (Figure 4.13). 
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Figure 4.13. Effect of transient CREBBP knockdown in MHH-CALL-2 cells on GR target 
gene expression. MHH-CALL-2 siCBP and control cells were treated with either control 
vehicle (CV) or dexamethasone (Dex) for 24 hours before determining expression of GR 
target genes by QRT-PCR, relative to endogenous TBP expression, by the ΔΔCT method. 
Histograms show mean ±SD (n=3). 
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4.3.4 Dexamethasone Sensitivity of MHH-CALL-2 Cells with Transient CREBBP 
Knockdown 
Both stable and transient knockdown of CREBBP in PreB 697 cells did not lead to 
dexamethasone resistance (Sections 3.2 and 4.2.4). To further address this hypothesis, 
MHH-CALL-2 cells with transient CREBBP knockdown were assessed for sensitivity to 
dexamethasone (Section 2.6.2). CREBBP knockdown in these cells did not lead to 
dexamethasone resistance (GI50 values, mean ±SD; siCBP 2.8nM ±0.59, control 3.8nM ±SD 
0.7; p=0.1), and no increase in dexamethasone sensitivity, as was seen in PreB 697 cells 
with transient CREBBP knockdown, was observed (Figure 4.14).  
 
 
 
 
 
 
 
 
Figure 4.14. Dexamethasone sensitivity of MHH-CALL-2 cells with transient CREBBP 
knockdown. Cells were treated with a range of dexamethasone concentrations or CV, 24 
hours post-transfection and incubated for 96 hours. Alamar blue was used to determine 
cell survival as a % of CV treated cells. Values plotted represent the mean % survival ±SD 
(n=3). 
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4.4 CREBBP Knockdown in Primagraft Cells 
Cells lines are useful biological models of disease, they provide an unlimited supply of 
material, divide in culture (unlike primary leukaemia samples) and give a pure population 
of cells allowing reproducible results to be obtained (Kaur and Dufour, 2012). Cell lines 
are not perfect models however, they are genetically modified so their phenotype, native 
functions and response to stimuli may differ from that of primary samples in ways that 
are difficult to determine (Kaur and Dufour, 2012). In order to strengthen key findings in 
cell lines, it is important to carry out experiments using primary cells. To this end, a 
method for transient CREBBP knockdown was optimised and carried out in primagraft 
cells, primary patient cells implanted into mice to amplify their numbers. Three HHD 
primagraft samples were used for these experiments; L779, L829 relapse (L829R) and 
L914, all of which harboured RAS pathway mutations (Section 2.2.7). 
HHD primagrafts were formed by intrafemoral injection into immunodeficient mice as 
described in section 2.2.7. Briefly, NSG mice were anaesthetised and 1x106 patient cells 
were injected intrafemorally. Leukaemic engraftment was monitored in the peripheral 
blood using flow cytometry (Section 2.3.2). Mice were culled when peripheral blood 
leukaemia engraftment reached >30% and only spleens with leukaemia engraftment of 
>80% were used. Figure 4.15 shows a representative example of peripheral blood 
engraftment by flow cytometry, describing a peripheral blood engraftment of 88.6% for 
L914 cells 11 weeks after intrafemoral injection. Figure 4.16 shows the spleen 
engraftment of the same sample at the same time point (96.4% spleen engraftment). 
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Figure 4.15. Monitoring peripheral blood leukaemia engraftment by flow cytometry. 
Peripheral blood taken from mice engrafted with leukaemia was stained with a panel of 
antibodies specific to human leukaemia and mouse blood cells. Living cells were gated 
based on forward and side scatter and human cells were gated based on low expression 
of mouse CD45. 
 
 
                                                Chapter 4 CREBBP Knockdown in BCP-ALL Cell Lines and Primagrafts 
 
 
 
168 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. Assessment of leukaemia engraftment in mouse spleen by flow cytometry. 
Spleen cells were resuspended in growth media and stained with a panel of antibodies 
specific to human leukaemia and mouse blood cells. Living cells were gated based on 
forward and side scatter and human cells were gated based on low expression of mouse 
CD45. 
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4.4.1 Optimisation of an Electroporation Method for siRNA Delivery in 
Primagraft Cells 
The transfection of primary cells with siRNA is known to be challenging. Electroporation 
is a highly effective method of siRNA delivery in suspension cell lines and has been shown 
to be effective in primary cells, though conditions differ between cell types and 
optimisation is required (Jordan et al., 2008). To determine the effective concentration of 
CREBBP siRNA pool required to transduce primagraft cells, a dose titration was carried 
out. Cells were subjected to the same electroporation parameters as PreB 697 cells with 
between 250 and 750nM of siCBP pool, control siRNA or in the absence of siRNA (Section 
2.7.2). Twenty four and forty eight hours post-transfection, western blotting was carried 
out to determine CREBBP protein expression (Section 2.5). A reduction in CREBBP protein 
expression was seen for all siRNA concentrations used at both 24 and 48 hours, with a 
greater degree of protein knockdown seen at 24 hours (Figure 4.17). For this reason, 
electroporation parameters used on cell lines and an siRNA concentration of 250nM was 
selected as optimal for knockdown of primagraft cells (Section 2.7.2). Twenty four hours 
was chosen as the optimal time point at which to assess protein knockdown in siRNA 
transfected primagraft cells. 
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Figure 4.17. Optimisation of siRNA delivery by electroporation in primagraft cells. 
Primagraft cells were transfected with an siRNA pool targeting CREBBP, control siRNA or 
electroporated in the absence of siRNA (Mock) and incubated for 24 and 48 hours before 
whole cell lysates were extracted and western blotting was carried out for CREBBP. Alpha 
tubulin was included as loading control. 
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4.4.2 Characterising the Effect of Transient CREBBP Knockdown in Primagraft 
Samples 
CREBBP mRNA and/or protein expression was assessed following each siRNA transfection 
to ensure CREBBP levels had been successfully reduced. To determine CREBBP mRNA 
expression, QRT-PCR was carried out probing for CREBBP (Section 2.4.7). Around 50% 
reduction of CREBBP mRNA expression was achieved in siCBP transfected primagraft cells, 
which is consistent with that shown in cell lines (Sections 3.2, 4.2.1 and 4.3.1) (Figure 4.18 
A). Western blotting was used to determine CREBBP protein expression (Section 2.5). 
CREBBP knockdown by siRNA pool transfection in all primagraft samples led to a 
significant reduction in CREBBP protein expression that was in line with that seen in cell 
line models and in patient derived material with mono-allelic CREBBP deletion (Sections 
3.2, 4.2.1 and 4.3.1) (Figure 4.18 B).  
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Figure 4.18 CREBBP mRNA and protein expression in primagraft cells with transient 
CREBBP knockdown. A. Cells transfected with an siRNA pool targeting CREBBP (siCBP) or 
control were harvested 24 hours post-transfection and QRT-PCR was carried out for 
CREBBP expression. Expression levels were normalised to TBP by the ΔΔCT method. 
Histogram represents mean ±SD of triplicate experiments. B. Whole cell lysates from 
primagraft siCBP or control cells were extracted and western blotting was carried out for 
CREBBP. Blots shown are representative, α-tubulin was included as loading control. 
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To assess the functional impact of CREBBP knockdown, AcH3K18 expression was 
determined in each transfected primagraft sample by western blotting (Section 2.5). 
Knockdown of CREBBP led to reduced AcH3K18 expression in 2 of 3 primagraft samples 
(Figure 4.19). Cell survival was analysed, as described in section 3.5, based on fluorescence 
output readings from control treated cells in dexamethasone sensitivity alamar blue 
experiments (Section 4.4.5). As primagraft cells do not divide in culture, this assay was 
only able to assess the effect of CREBBP knockdown on the ability of cell to survive in 
culture. CREBBP knockdown in all primagraft cells had no effect on cell survival at 96 hours 
(Mean fluorescent output ±SD; siCBP 8.78x104 ±3.73x104, Control 7.43x104 ±2.71x104; 
p=0.3) (Figure 4.20). 
 
 
 
 
 
 
 
 
Figure 4.19. Expression of AcH3K18 in primagraft cells with transient CREBBP 
knockdown. Primagraft cells were transfected with an siRNA pool targeting CREBBP or 
control siRNA and incubated for 24 hours before whole cell lysates were extracted and 
western blotting was carried out for AcH3K18. Alpha tubulin was included as loading 
control. 
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Figure 4.20. Transient CREBBP knockdown in HHD primagraft cells and survival at 96 
hours. The raw fluorescence output values from CV treated cells from primagraft 
dexamethasone sensitivity experiments were combined and compared. Histogram shows 
average relative fluorescence ±SD (n=5). 
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4.4.3 cAMP response in HHD Primagraft Cells with Transient CREBBP 
Knockdown 
CREBBP knockdown in cell lines was shown to have no effect on the expression of cAMP-
dependent target genes (Sections 3.3, 4.2.2 and 4.3.2). HHD primagrafts were used to 
study this effect in a relevant cytogenetic context. 
Transfected primagraft samples were treated with IBMX and forskolin to induce a 
maximal intracellular cAMP response, or CV and expression of the cAMP-dependent genes 
identified in Chapter 3 (Section 3.3) was assessed by QRT-PCR (Section 2.4.7). Primagraft 
sample L914 represents the most statistically powerful data as this sample was obtained 
from three separate mice, allowing triplicate experiments to be carried out. For L779 and 
L829R, only material from one mouse was available for each. In L914, all genes assessed 
were shown to be significantly upregulated by cAMP in both siCBP and control cells 
(CXCR4 ~9 fold upregulated; p values <0.01, MKNK2 ~5 fold upregulated; p values <0.006, 
DUSP10 ~3 fold upregulated; p values <0.001, RGS16 ~15 fold upregulated; p values 
<0.004). This differs from data collected in cells lines, where some of the assessed genes 
were not found to be significantly upregulated by cAMP (Sections 3.3, 4.2.3 and 4.3.3). In 
L914 primagraft cells, CREBBP knockdown had no effect on the basal expression of any 
cAMP-dependent gene assessed (p values >0.7). These data were recapitulated in both 
L779 and L829R primagraft cells, with all genes assessed shown to be significantly 
upregulated by cAMP stimulation, with comparable fold change (L779 fold upregulation; 
CXCR4 ~6 fold, p values <0.0004, MKNK2 ~5 fold, p values <0.0001, DUSP10 ~3.5 fold, p 
values <0.002, RGS16 ~3 fold, p values <0.0001, L829R fold upregulation; CXCR4 ~6 fold, 
p values <0.0001, MKNK2 ~5 fold, p values <0.0001, DUSP10 ~3 fold, p values <0.001) with 
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the exception of RGS16 in L829R cells which showed a much higher level of upregulation 
than in other primagraft cells (~43 fold upregulation, p values <0.0001). In L779, basal 
DUSP10 expression was significantly reduced by CREBBP knockdown (p=0.01), with no 
effect being seen on basal expression of the other genes assessed (p values >0.08). In 
L829R cells basal expression of CXCR4, MKNK2 and DUSP10 was significantly impaired by 
CREBBP knockdown (p values <0.02) with no effect being seen on basal RGS16 expression 
(p=0.6). Importantly, CREBBP knockdown did not lead to impaired cAMP-induced 
expression of the majority of genes assessed in primagraft samples (p values >0.06). 
However, a slight, statistically significant, reduction in RGS16 expression was seen in L779 
and L829 control transfected cells (p=0.002 and p=0.008 respectively), though this could 
be explained by the lack of biological replicates for these samples (Figure 4.21).  
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Figure 4.21. Effect of transient CREBBP knockdown in primagraft cells on cAMP-
dependent gene expression. SiCBP and control transfected primagraft cells A. L914, B. 
L779 and C. L829R, were treated with either control vehicle (CV) or IBMX and forskolin 
(I&F) before determining expression of cAMP-dependent genes by QRT-PCR relative to 
endogenous TBP expression by the ΔΔCT method. Histograms show mean ±SD. Values 
plotted represent triplicate experiments for L914 and triplicate wells for L779 and L829R. 
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4.4.4 Induction of GR Transcriptional Targets in HHD Primagraft Cells with 
Transient CREBBP Knockdown 
Cell line models with CREBBP knockdown showed a variable effect on the expression of 
GR targets in response to GC treatment, with the majority showing unaffected GR target 
expression (Sections 3.2, 4.2.3 and 4.3.3). To investigate this further, primagraft samples 
were assessed for GR target gene expression following stimulation with GC. 
Transfected primagraft cells were treated with dexamethasone to induce GR target 
expression, or CV and expression of GILZ and FKBP5 was assessed by QRT-PCR (Section 
2.4.7). Both GILZ and FKBP5 were significantly upregulated by dexamethasone exposure 
in L914 siCBP and control cells (GILZ ~8 fold, p values <0.02, FKBP5 ~40 fold for siCBP and 
~30 fold for control, p=<0.0001 for both) and basal expression was unaffected (p=0.2 and 
p=0.7 respectively). GILZ and FKBP5 were significantly induced by dexamethasone in both 
L779 and L829R siCBP and control cells (L779 fold upregulation; GILZ ~19 fold, p values 
<0.0004, FKBP5 ~23 fold, p values <0.0002, L829R fold upregulation; GILZ ~5 fold, p values 
<0.0002, FKBP5 ~37 fold, p values <0.0001) and CREBBP knockdown had no effect on basal 
GILZ (L779; p=0.06 and L829R; p=0.2) or FKBP5 expression in L892R cells (p=0.1), but led 
to a slight reduction in basal FKBP5 expression in L779 cells (p=0.01).  
The average fold induction of GILZ and FKBP5 in response to dexamethasone varied across 
the three primagraft samples tested (GILZ 5-19 fold, FKBP5 23-40 fold) suggesting that the 
different patients have different transcriptional responses to dexamethasone. CREBBP 
knockdown had no effect on the GC-induced expression of GILZ in any primagraft sample 
(p values >0.05), but a slight, statistically significant increase in FKBP5 expression was seen 
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in L914 (p=0.002), but not L779 or L829R cells (p values >0.5) (Figure 4.22). This 
recapitulates results from PreB 697 and MHH-CALL-2 cells with transient CREBBP 
knockdown, suggesting that CREBBP knockdown does not impair GR transcriptional 
response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                Chapter 4 CREBBP Knockdown in BCP-ALL Cell Lines and Primagrafts 
 
 
 
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22. Effect of transient CREBBP knockdown in primagraft cells on GR target gene 
expression. SiCBP and control primagraft cells A. L914, B. L779 and C. L829R were treated 
with either CV or dexamethasone (Dex) for 24 hours before determining expression of GR 
target genes by QRT-PCR relative to endogenous TBP expression by the ΔΔCT method. 
Histograms show mean ±SD. Values plotted represent triplicate experiments for L914 and 
triplicate wells for L779 and L829R. 
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4.4.5 Dexamethasone Sensitivity of Primagraft Cells with CREBBP Knockdown 
Contrary to predictions, CREBBP knockdown in cell lines did not lead to dexamethasone 
resistance (Sections 3.2, 4.2.4 and 4.3.4). To further address this in a more biologically 
relevant context, primagraft samples with transient CREBBP knockdown were assessed 
for sensitivity to dexamethasone. 
Transduced primagrafts were treated with a range of concentrations of dexamethasone 
or CV, and survival was assessed by alamar blue assay (Section 2.6.2). CREBBP knockdown 
had no effect on the dexamethasone sensitivity of any primagraft sample compared to 
control (GI50 values, mean ±SD; L914 siCBP 6.1nM ±2.2 versus control 5.6nM ±0.41; L779 
siCBP 65.2nM ±38.3 versus control 90.8nM ±18.2; L829 >10µM for both) (Figure 4.23). 
These data are consistent with those in cells lines, and show that CREBBP knockdown has 
no effect on dexamethasone sensitivity in ALL cells. 
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4.23. Dexamethasone sensitivity of primagraft cells with transient CREBBP knockdown. 
Cells were treated with a range of dexamethasone concentrations or CV, 24 hours post-
transfection and incubated for 96 hours. Alamar blue was used to determine cell survival 
as a % of CV treated cells. Values plotted represent the mean % survival ±SD of triplicate 
experiments for L914 and triplicate wells for L779 and L829R.  
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4.4.6 Enhanced RAS Pathway Activation in RAS Mutant Primagraft Cells with 
Transient CREBBP Knockdown 
In Chapter 3, it was shown that stable knockdown of CREBBP in the RAS pathway mutant 
cell line, PreB 697, led to enhanced RAS pathway activation, as assessed by p-ERK 
expression (Section 3.9). This is of particular importance as CREBBP mutations frequently 
co-exist with RAS pathway mutations (Malinowska-Ozdowy et al., 2015). To further 
address this observation in a more biologically relevant context, transient CREBBP 
knockdown was carried out in primagraft samples with different RAS pathway mutations 
(L779; NRAS, L829R; KRAS and L914; CBL/FLT3 deletion) then each was assessed for RAS 
pathway activation, determined by ERK phosphorylation. 
Twenty four hours post-transfection whole cell lysates were harvested from RAS pathway 
mutant primagraft samples, and western blotting was carried out for p-ERK and ERK with 
α-tubulin serving as loading control (Section 2.5). CREBBP knockdown in L914 and L829R 
cells led to increased expression of p-ERK compared to control, but had no effect on p-
ERK expression in NRAS mutant L779 cells (Figure 4.24). ERK expression was consistent 
between L914 siCBP and control cells and slightly decreased in L829R siCBP compared to 
control cells, so reduced p-ERK expression in these cells cannot be explained by reduced 
basal ERK levels. These data, along with those observed in PreB 697 cells with CREBBP 
knockdown, suggest that CREBBP knockdown leads to increased RAS pathway activation 
in RAS pathway mutant cells. 
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Figure 4.24. Transient CREBBP knockdown in RAS mutant primagraft cells and p-ERK 
expression. A. Primagraft cells were transfected with an siRNA pool targeting CREBBP or 
control siRNA and incubated for 24 hours before whole cell lysates were extracted and 
western blotting was carried out for ERK and p-ERK. Alpha tubulin was included as loading 
control. B. Histogram of the relative expression of p-ERK in PreB 697 (shCBP and shNEG) 
and CREBBP knockdown primagraft samples normalised to ERK after densitometric 
analyses. 
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4.5 Discussion 
The aim of this Chapter was to validate data gathered from the study of PreB 697 cells 
with stable CREBBP knockdown described in Chapter 3, using cell lines and primary 
derived samples with relevant cytogenetic context (i.e. High hyperdiploid or hypodiploid), 
as well as addressing the importance of the in vivo growth environment. 
The use of siRNA pool transfection to knockdown CREBBP in PreB 697 and MHH-CALL-2 
cells confirmed a high level of comparability with the shRNA method used in Chapter 3. 
Reductions of CREBBP at the mRNA and protein level were similar to those shown in cells 
with stable CREBBP knockdown, and in patient samples with CREBBP deletions. CREBBP 
knockdown had no effect on cell proliferation in PreB 697 cells, but MHH-CALL-2 cells with 
CREBBP knockdown showed slightly more cell growth at 96 hours, approaching statistical 
significance (p=0.06). This suggests that CREBBP mutations may influence cell cycle 
control in ALL. 
Whilst both stable and transient CREBBP knockdown in PreB 697 cells showed no 
significant effect on cAMP-induced expression of cAMP-dependent target genes, the fold 
induction of CXCR4 and MKNK2 differed between the two knockdown models (CXCR4 
shRNA ~14 fold induction vs siRNA ~11 fold induction, MKNK2 shRNA ~6 fold induction vs 
siRNA ~3 fold induction), and in transiently transfected cells DUSP10 and RGS16 were not 
found to be significantly induced by cAMP. Basal expression of all cAMP-dependent genes 
assessed was unaffected by transient knockdown of CREBBP, whereas basal MKNK2 and 
RGS16 expression was altered in cells with stable CREBBP knockdown. In MHH-CALL-2 
cells, CREBBP knockdown similarly had no effect on cAMP-induced gene expression, 
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though the fold induction of targets differed in this cell line compared to PreB 697 cells 
(E.g. PreB 697 CXCR4 ~14 fold induction vs MHH-CALL-2 ~4 fold induction). These data 
suggest that CREBBP knockdown in BCP-ALL cell lines is not sufficient to significantly alter 
cAMP-dependent gene expression. 
Transient knockdown of CREBBP in PreB 697 cells did not lead to impaired GC-induced 
expression of the GR targets, GILZ, FKBP5 and NR3C1 as it did in stably knocked down cells, 
but showed greater induction in response to the same dexamethasone concentration 
(GILZ shRNA ~20 fold induction vs siRNA ~40 fold induction, FKBP5 shRNA ~3 fold 
inductions vs siRNA ~6 fold induction, NR3C1 shRNA ~1.5 fold induction vs siRNA ~2.4 fold 
induction). As in PreB 697 cells with stable CREBBP knockdown, basal GILZ expression was 
shown to be slightly reduced in PreB 697 cells with CREBBP knockdown. A slight, 
statistically significant increase in basal NR3C1 expression was seen in PreB 697 siCBP cells 
but no effect on basal FKBP5 or ITGA9 expression was seen. Similar results were shown in 
MHH-CALL-2 cells with transient CREBBP knockdown, again with different fold changes in 
induced expression achieved (GILZ PreB 697 ~40 fold induction vs MHH-CALL-2 ~ 50 fold 
induction, FKBP5 PreB 697 ~6 fold induction vs MHH-CALL-2 ~10 fold). Importantly, 
neither cell line showed any significant reduction in sensitivity to dexamethasone when 
CREBBP was transiently knocked down compared to control, with a small, statistically 
significant increase in dexamethasone sensitivity seen in PreB 697 cells (siCBP 17nM vs 
control 34.7nM). However, given the size of this increase, it is unlikely to be biologically 
relevant. These data validate those collected in PreB 697 cells with stable CREBBP 
knockdown, further suggesting that CREBBP haploinsufficiency does not lead to GC 
resistance in ALL.  
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One possible explanation for the discrepancies in GR target expression between PreB 697 
cells with stable knockdown and PreB 697 and MHH-CALL-2 cells with transient CREBBP 
knockdown is the use of different RNAi methods. It could be argued that transient 
knockdown may not be maintained for a sufficient period of time to see an effect on GR 
target expression or GC sensitivity. However, transient CREBBP knockdown was shown to 
be maintained at the protein level for at least 96 hours and the level of knockdown 
achieved at the mRNA and protein levels and effect on markers of CREBBP activity such 
as acetylation of H3K18, were found to be consistent between stable and transient 
knockdown models. This suggests that transient knockdown of CREBBP in cell lines is a 
relevant model of CREBBP haploinsufficiency in ALL. 
To overcome the limitations associated with the use of cell line models, a method of siRNA 
knockdown in primagraft samples was optimised and used to knockdown CREBBP in 3 
individual HHD primagraft samples. One of these samples, L914, was amplified in 3 
separate mice, giving access to 3 biological repeats. CREBBP mRNA and protein reduction 
were consistent with that achieved in cell lines and patients with CREBBP deletions. All 
cAMP-dependent targets assayed in primagrafts samples were significantly induced by 
cAMP stimulation, and showed a high degree of similarity in terms of fold induction 
achieved (E.g. MKNK2 ~5 fold induction in L914, L779 and L829R) except for RGS16, in 
which fold induction varied between primagraft samples (L914 ~15 fold, L779 ~3 fold, 
L829R ~43 fold). CREBBP knockdown only had a significant effect on the cAMP-induced 
expression of RGS16 in L914 cells, where it led to an increase in expression compared to 
control cells. The effect of CREBBP knockdown on basal expression of cAMP-dependent 
genes differed between primagraft samples, with L914 showing similar results to PreB 697 
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and MHH-CALL-2, with no altered basal expression for any genes tested, whereas L779 
showed altered basal DUSP10 expression and L829R showed altered basal CXCR4, MKNK2 
and DUSP10 expression. These data support those from cell line studies, suggesting that 
CREBBP knockdown does not affect cAMP-dependent gene transcription in ALL, with 
remnant CREBBP expression sufficient to compensate. 
Fold induction of the GR target, GILZ, in response to GC in primagraft cells was much lower 
in all primagraft samples compared to cell lines (E.g. MHH-CALL-2 ~50 fold induction vs 
L914 ~8 fold induction) with the fold induction of FKBP5 being higher in primagraft 
samples than cell lines (E.g. MHH-CALL-2 ~10 fold induction vs L914 ~40 fold induction). 
Basal expression of GILZ and FKBP5 was unaffected by CREBBP knockdown in all 
primagrafts except L779, which showed a small reduction in basal FKBP5 expression. 
Importantly, CREBBP knockdown had no effect on sensitivity to dexamethasone in any of 
the primagraft samples tested, recapitulating the observations from cell line studies. 
Taken together these data validate those collected in BCP-ALL cell lines, with a high level 
of biological and cytogenetic relevance. They suggest that CREBBP knockdown in BCP-ALL 
cell lines is a relevant model of CREBBP haploinsufficiency in ALL and provide a robust data 
set for the understanding of the mechanisms of this mutation in relapsed disease. Overall, 
these data do not support a role for CREBBP haploinsufficiency in resistance to GC. 
Whilst a trend towards reduced acetylation of H3K18 and/or H3K27 was seen for all cells 
with CREBBP knockdown, thus indicating a functional effect of CREBBP knockdown, the 
level of reduction, and residue which was reduced, differed greatly between cell lines and 
primagraft samples. CREBBP and its paralog EP300 are known to have different 
specificities for histone lysine acetylation, specificities which change based on amount of 
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H3 or acetyl-CoA availability (Henry et al., 2013). The varying effect of CREBBP knockdown 
between cell lines and between primagraft cells could be explained by the observation 
that specificities for H3 acetylation vary in a complex way and that there is overlap of H3 
acetylation sites between EP300 and CREBBP, so EP300 or residual CREBBP expression 
could compensate when CREBBP is knocked down (Henry et al., 2013).  
As discussed in Chapter 1, RAS pathway mutations are common in relapsed childhood ALL, 
led to enhanced signalling down the RAS/RAF/MEK/ERK pathway and are associated with 
high risk features and poor prognosis (Case et al., 2008; Irving et al., 2014; Irving et al., 
2016). Further to this, as discussed in Chapter 3, CREBBP mutations frequently co-occur 
with RAS pathway activating mutations, including KRAS, NRAS, PTPN11 and FLT3 
(Malinowska-Ozdowy et al., 2015). Two of three RAS pathway mutant primagraft samples 
(L829R; KRAS G13D and L914; CBL/FLT3 large del/Δ836) showed increased p-ERK 
expression when CREBBP was transiently knocked down. This shows that CREBBP 
knockdown is able to enhance oncogenic RAS signalling in cells with RAS pathway 
mutations. Taken together with data from Chapter 3, these data further support the 
hypothesis that CREBBP haploinsufficiency enhances signalling of the RAS/RAF/MEK/ERK 
pathway in RAS pathway mutated ALL cells.  
 
In summary, the results presented in this chapter validate those collected in Chapter 3, 
with observations made in primary derived cell models with relevant cytogenetic context. 
Data collected in this chapter do not support a role for CREBBP haploinsufficiency in 
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resistance to GC but further support the hypothesis that CREBBP haploinsufficiency in ALL 
cells harbouring RAS pathway mutation leads to increased RAS/RAF/MEK/ERK signalling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 (Results 3) – Stable CREBBP 
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CREBBP Knockdown in Diffuse Large B-Cell Lymphoma 
5.1 Introduction 
CREBBP mutation is a frequent event in DLBCL, with 39% of cases identified as CREBBP 
mutant (Pasqualucci et al., 2011). As in relapsed ALL, mutations commonly affect one 
allele of CREBBP, with the intact allele conferring expression of wild type CREBBP, 
indicating that haploinsufficiency is important (Pasqualucci et al., 2011). Given that these 
mutations are more frequently seen at diagnosis, it is clear that CREBBP haploinsufficiency 
contributes to DLBCL pathogenesis in a different way to ALL, where mutations are more 
commonly associated with relapse (Pasqualucci et al., 2011). CREBBP mutations lead to 
defects in p53 activation and BCL6 inactivation, which have important implications in 
lymphomagenesis and drug sensitivity (Pasqualucci et al., 2011). Understanding the 
mechanisms of CREBBP mutation in DLBCL is important as it may pave the way for novel 
therapy that is clearly needed, and also facilitate the understanding of CREBBP mutation 
in other tumour types, such as relapsed childhood ALL and FL. In order to study CREBBP 
haploinsufficiency in DLBCL, cell lines with stable CREBBP knockdown and isogenic control 
were created and characterised.  
 
5.2 Creation of a DLBCL Cell Line with Stable CREBBP Knockdown 
Lentiviral transduction of shRNA was used to create a DLBCL cell line with stable CREBBP 
knockdown (Section 2.7.1). SU-DHL-4 was selected as a suitable cell line as it had been 
previously shown to express wild type CREBBP (Epstein and Kaplan, 1979; Pasqualucci et 
al., 2011). Following puromycin selection, cells with stable CREBBP knockdown 
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(SUDshCBP) and control cells (SUDshNEG) were assessed for CREBBP expression by QRT-
PCR and western blotting (Sections 2.4.7 and 2.5). Around 30% reduction in CREBBP mRNA 
expression was achieved, which is slightly lower than that seen in CREBBP knockdown 
models of ALL (40-50% reduction in PreB 697, MHH-CALL-2 and primagraft cells) (Sections 
3.2, 4.2.1, 4.3.1 and 4.4.2) (Figure 5.1A). Despite this, a clear reduction in CREBBP protein 
expression was seen in SU-DHL-4 cells with CREBBP knockdown (SUDshCBP) compared to 
control (SUDshNEG), comparable to that achieved in ALL cells and ALL patient samples 
with CREBBP deletions (Sections 3.2, 4.2.1, 4.3.1 and 4.4.2) (Figure 5.1 B).  
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Figure 5.1. CREBBP mRNA and protein expression in SU-DHL-4 cells with stable CREBBP 
knockdown. Cells were transduced with shRNA targeting CREBBP (SUDshCBP) or a non-
silencing control (SUDshNEG). A. Following puromycin selection cells were harvested in 
exponential growth phase on three separate occasions and QRT-PCR was carried out for 
CREBBP expression. Expression levels were normalised to TBP by the ΔΔCT method. 
Histogram represents mean ±SD of triplicate experiments. B. Whole cell lysates from 
transduced cells in exponential growth phase were extracted on three separate occasions 
(i-iii) and western blotting was carried out for CREBBP. Alpha tubulin was included as 
loading control. 
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To assess the functional effect of the knockdown, western blotting was carried out for 
AcH3K18 and AcH3K27 (Section 2.5). The effect of CREBBP knockdown in SU-DHL-4 cells 
was variable, with a lack of consistency seen between replicates for either residue (Figure 
5.2 A, i-iv & B, i-iii). AcH3K18 levels were unaffected by CREBBP knockdown, whereas 
AcH3K27 levels were reduced by CREBBP knockdown in one of the three replicates and 
slightly increased in another. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Expression of AcH3K18 and AcH3K27 in SU-DHL-4 cells with stable CREBBP 
knockdown. Whole cell lysates were extracted from SUDshCBP and SUDshNEG cells and 
western blotting was carried out for AcH3K18 (A, i-iv) or AcH3K27 (B, i-iii). Alpha tubulin 
was included as loading control. Brackets represent individual biological repeats. 
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The effect of CREBBP knockdown in SU-DHL-4 on cells growth was assessed by seeding 
cells at 3 different densities and counting every 24 hours for 120 hours by trypan blue 
staining, using a haemocytometer (Section 2.6.1). This showed that CREBBP knockdown 
had no effect on cell proliferation, with no significant difference in average doubling time 
seen between SUDshCBP and SUDshNEG cells at any of the seeding densities (Average 
doubling time ±SD; SUDshCBP 38.2 ±10.8 vs SUDshNEG 38.4 hours ±11.6; p=1.0) (Figure 
5.3). The effect of CREBBP knockdown on cell proliferation in these cells was further 
assessed by comparing the fluorescence output readings from control treated groups 
from drug sensitivity experiments conducted using SUDshCBP and SUDshNEG cells 
(Section 5.4). These are in keeping with those collected in ALL cell models of CREBBP 
knockdown and confirmed no effect on cell proliferation (Mean fluorescent output ±SD; 
SUDshCBP 7.69x104 ±1.17x104, SUDshNEG 7.64x104 ±1.22x104; p=0.8) (Figure 5.4). 
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Figure 5.3.  Stable CREBBP knockdown in SU-DHL-4 cells and cell proliferation. SUDshCBP 
and SUDshNEG cells were seeded at 1x105 cells/ml, 2x105 cells/ml and 4x105 cells/ml and 
counted every 24 hours for 120 hours by trypan blue staining and a haemocytometer. 
Values plotted represent mean cell count (cells/ml) at each given time point ±SD (n=3). 
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Figure 5.4. Stable CREBBP knockdown in SU-DHL-4 cells and survival at 96 hours. The 
raw fluorescence output values from CV treated cells from drug sensitivity experiments 
were combined and compared. Graph shows average relative fluorescence ±SD (n=17).  
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5.3 cAMP response in SU-DHL-4 Cells with Stable CREBBP Knockdown 
As described in Chapter 3 (Section 3.3), CREBBP is involved in cAMP-dependent signalling, 
a ubiquitous process which modulates transcription of a large number of genes. In 
Chapters 3 and 4, it was shown that CREBBP knockdown had no significant effect on 
cAMP-induced gene expression in ALL cell lines and primagraft cells. To study this effect 
of DLBCL, SU-DHL-4 cells with a stable CREBBP knockdown were assessed for cAMP-
induced gene expression. 
Firstly, to determine relevant cAMP-dependent targets in SU-DHL-4 cells, gene expression 
profiling was carried out using the Affymetrix U133 Plus 2.0 platform. As described 
previously for ALL cells (Section 3.3), SUDshNEG cells were treated with IBMX and 
forskolin or CV for 90 minutes, RNA was then extracted and sent to Source Bioscience for 
gene expression analysis (Section 2.4.8). To select the most significant cAMP-dependent 
genes in SU-DHL-4, genes which were upregulated in the IBMX and forskolin treated group 
were ordered by greatest increase in expression. The two genes at the top of this list, 
RGS1 and DUSP5 were selected as representative cAMP-dependent genes in SU-DHL-4 
cells (Table 5.1). Genes identified as cAMP-dependent in ALL cells (Section 3.3) were also 
included as they appeared on this list (CXCR4), and QRT-PCR probes were available. 
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Feature Gene Log2FC 
216834_at RGS1 3.72 
209457_at DUSP5 2.92 
204912_at IL10RA 2.52 
228846_at MXD1 2.38 
231124_x_at LY9 2.32 
235444_at FOXP1 2.24 
225191_at CIRBP 2.20 
211962_s_at ZFP36L1 2.16 
209201_x_at CXCR4 2.15 
1564970_at SETDB2 2.13 
230142_s_at CIRBP 2.08 
211919_s_at CXCR4 2.07 
221986_s_at KLHL24 2.07 
236293_at RHOH 2.03 
211965_at ZFP36L1 2.02 
201739_at SGK1 1.97 
228426_at CLEC2D 1.90 
221985_at KLHL24 1.89 
217028_at CXCR4 1.89 
242814_at SERPINB9 1.85 
201041_s_at DUSP1 1.83 
1568751_at RGS13 1.80 
201925_s_at CD55 1.76 
213593_s_at TRA2A 1.75 
233463_at RASSF6 1.74 
208763_s_at TSC22D3 1.73 
202388_at RGS2 1.71 
1555858_at THUMPD3-AS1 1.70 
227223_at RBM39 1.70 
215012_at ZNF451 1.69 
1555827_at CCNL1 1.69 
217591_at SKIL 1.66 
201926_s_at CD55 1.63 
213575_at TRA2A 1.63 
225867_at VASN 1.62 
222542_x_at ADCK3 1.62 
202861_at PER1 1.60 
204951_at RHOH 1.58 
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1555950_a_at CD55 1.57 
208536_s_at BCL2L11 1.56 
210322_x_at UTY 1.55 
226541_at FBXO30 1.55 
220035_at NUP210 1.54 
209102_s_at HBP1 1.53 
226404_at RBM39 1.50 
214802_at EXOC7 1.48 
228030_at RBM6 1.48 
1560172_at INTS10 1.46 
1552542_s_at TAGAP 1.42 
202340_x_at NR4A1 1.42 
 
Table 5.1. Genes upregulated by cAMP in SU-DHL-4 cells. List shows the top 50 most 
upregulated genes in SUDshNEG cells treated with IBMX and forskolin compared to cells 
treated with CV. RGS1 and DUSP5 were selected as representative cAMP-dependent 
genes in SU-DHL-4. Genes identified as cAMP-dependent in ALL cells were also 
upregulated upon cAMP stimulation in these cells (List of genes with Log2FC ≥1 available 
in appendix) (n=1).  
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SUDshCBP and SUDshNEG cells were treated with IBMX and forskolin for 90 minutes to 
induce a maximal intracellular cAMP response, or CV and QRT-PCR was carried out using 
probes specific to cAMP-dependent targets identified above (Section 2.4.7). Only the 
genes identified by GEP, RGS1 and DUSP5, were found to be significantly upregulated by 
cAMP-stimulation in both SUDshCBP and SUDshNEG cells (Fold upregulation; RGS1 ~36 
fold; p values <0.003, DUSP5 ~7 fold for SUDshCBP and ~9 fold for SUDshNEG; p values 
<0.003) (Figure 5.5). CXCR4 was only significantly induced by cAMP stimulation in 
SUDshNEG cells (~4 fold induction, p=0.001) and other genes assessed did not show 
significantly increased expression in either cell line (p values >0.3) (Figure 5.5). The cAMP-
induced expression of DUSP5 was significantly impaired in cells with CREBBP knockdown 
compared to control (DUSP5 ~7 fold for SUDshCBP and ~9 fold for SUDshNEG; p=0.047) 
(Figure 5.5). RGS1 expression also appeared reduced in SUDshCBP cells compared to 
SUDshNEG, but this was not statistically significant (p=0.1). CREBBP knockdown had no 
effect on basal expression of any of the genes assessed (p values >0.2). These data suggest 
that, as in BCP-ALL models, CREBBP knockdown does not have a significant effect on 
cAMP-dependent signalling in SU-DHL-4 cells.  
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Figure 5.5. Effect of transient CREBBP knockdown in SU-DHL-4 cells on cAMP-dependent 
gene expression. SUDshCBP and SUDshNEG cells were treated with either control vehicle 
(CV) or IBMX and forskolin (I&F) before determining expression of cAMP-dependent genes 
by QRT-PCR relative to endogenous TBP expression by the ΔΔCT method. Histograms show 
mean ±SD (n=3). 
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5.4 Chemosensitivity of SU-DHL-4 Cells with Stable CREBBP Knockdown 
To elucidate the effect of CREBBP knockdown on drug response in DLBCL, SU-DHL-4 cells 
with stable CREBBP knockdown were tested for sensitivity to a range of 
chemotherapeutics used in the treatment of lymphoma.  
As discussed in previous chapters, CREBBP haploinsufficiency has been implicated in 
resistance to GC therapy (Mullighan et al., 2011). SUDshCBP and SUDshNEG cells were 
therefore assessed for sensitivity to the GC, dexamethasone by alamar blue drug 
sensitivity assay (Section 2.6.2). Unfortunately, both SUDshCBP and SUDshNEG cells were 
found to be resistant to dexamethasone, making these cells a poor model for assessment 
of response to GC (GI50 values >100µM) (Figure 5.6). CREBBP plays a role in global 
acetylation, small changes in which have been shown to give significant biological 
consequences, through altering a wide range of cellular functions (Legube and Trouche, 
2003). Treatment with HDACi could be used as a novel therapeutic strategy, in an attempt 
to rebalance levels of acetylation in CREBBP-mutated cells. To test this hypothesis, 
SUDshCBP and SUDshNEG cells were assessed for sensitivity to vorinostat using an alamar 
blue drug sensitivity assay (Section 2.6.2). This showed that CREBBP knockdown in SU-
DHL-4 cells had no effect on sensitivity to HDACi (GI50 values, mean ±SD; SUDshCBP 1.9µM 
±0.21 versus SUDshNEG 1.9µM ±0.43; p=1.0) (Figure 5.6). 
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Figure 5.6. Dexamethasone and vorinostat sensitivity of SU-DHL-4 cells with stable 
CREBBP knockdown. SUDshCBP and SUDshNEG cells were assessed for sensitivity to A. 
dexamethasone and B. vorinostat by alamar blue drug sensitivity assay over 96 hours. 
Histograms show mean survival ±SD (n=3). 
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Given that CREBBP knockdown had no effect on sensitivity to GC or HDACi treatment, 
SUDshCBP and SUDshNEG cells were assessed for sensitivity to a panel of 
chemotherapeutics used to treat lymphoid malignancies (Section 2.6.2). CREBBP 
knockdown had no effect on sensitivity to daunorubicin or 6-thioguanine (GI50 values, 
mean ±SD; daunorubicin SUDshCBP 42.5nM ±7.6 versus SUDshNEG 76.9nM ±23.1; 
p=0.07, 6-thioguanine SUDshCBP 12.8µM ±5.7 versus SUDshNEG 13.1µM ±8.1; p=1.0), but 
gave a statistically significant reduction in sensitivity to vincristine (GI50 values, mean ±SD; 
SUDshCBP 2.6nM ±0.12 versus SUDshNEG 3.1nM ±0.11; p=0.009) (Figure 5.7). Given the 
size of the difference in GI50 values however (2.6nM vs 3.1nM) this difference is unlikely 
to be biologically relevant. Taken together these data support those found in ALL cell lines 
and primagrafts, suggesting that CREBBP haploinsufficiency does not lead to 
chemoresistance in DLBCL. 
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Figure 5.7. Effect of stable CREBBP knockdown in SU-DHL-4 cells on sensitivity to 
chemotherapeutics used to treat lymphoid malignancies. SUDshCBP and SUDshNEG cells 
were assessed for sensitivity to A. daunorubicin, B. 6-thioguanine and C. vincristine by 
alamar blue drug sensitivity assay over 96 hours. Histograms show mean survival ±SD 
(n=3). 
 
 
 
 
 
 
 
Chapter 5 Stable CREBBP Knockdown in Diffuse Large B-cell Lymphoma 
 
 
 
209 
 
5.5 DNA Damage Repair in SU-DHL-4 Cells with Stable CREBBP Knockdown 
As discussed in Chapter 1, CREBBP plays a role in multiple DNA repair pathways. Of 
particular note is the discovery that mice heterozygous for CREBBP, are hypersensitivity 
to gamma radiation (Zimmer et al., 2012). Experiments carried out in PreB 697 cells in 
suggest that CREBBP deficiency does not significantly influence DNA damage response in 
ALL (Section 3.8). To understand the effect of CREBBP haploinsufficiency on DNA damage 
response in the context of DLBCL however, these experiments were carried out in SU-DHL-
4 cells with stable CREBBP knockdown. 
 
5.5.1 CREBBP Knockdown and PARP Expression 
As discussed in Chapter 3, CREBBP is known to acetylate PARP allowing its interaction with 
p50 and synergistic co-activation of NF-κB by p300 (Hassa et al., 2005). Knockdown of 
CREBBP in PreB 697 cells had no effect on PARP-1 protein expression however (Section 
3.8.2). To study the effect of CREBBP knockdown on PARP-1 expression in SU-DHL-4 cells, 
western blotting was carried out (Section 2.5). This showed that, like in the PreB 697 
model, CREBBP knockdown had no effect on PARP-1 protein expression (Figure 5.8). In 
the third replicate experiment there was some evidence of increased cleaved PARP-1 
expression, however this was not consistent. 
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Figure 5.8. PARP-1 expression in SU-DHL-4 cells with stable CREBBP knockdown. Whole 
cell lysates from SUDshCBP and SUDshNEG were collected on three separate occasions 
(A-C) and western blotting for PARP-1 expression was carried out. A band for cleaved PARP 
was also detected by the antibody and can be seen at around 100kDa. Alpha tubulin was 
included as loading control.  
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5.5.2 CREBBP Knockdown and Temozolomide Sensitivity 
As discussed previously, temozolomide is an alkylating agent which can add methyl 
adducts to N7 guanine, O6 guanine and N3 adenine (Horspool et al., 1990; Cheng et al., 
2005). This makes it a useful tool for studying DNA damage repair. CREBBP knockdown in 
PreB 697 ALL cells gave inconsistent results, with shRNA transduced cells showing an 
increased sensitivity to temozolomide and siRNA transfected cells showing no differential 
sensitivity (Sections 3.8.3 and 4.2.6). To test this in the context of DLBCL, SUDshCBP and 
SUDshNEG cells were treated with temozolomide and cell viability was assessed after 96 
hours by alamar blue assay (Section 2.6.2). Both cell lines were found to be completely 
resistant to temozolomide with a GI50 concentration not being reached at up to 257µM 
temozolomide treatment (Figure 5.9). Given that these cells were resistant to 
temozolomide, it is clear that they are not an informative model for the study of CREBBP 
knockdown on response to damage induced by alkylating agents in DLBCL. 
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Figure 5.9. Effect of transient CREBBP knockdown in SU-DHL-4 cells on sensitivity to 
temozolomide. SUDshCBP and SUDshNEG cells were assessed for sensitivity to 
temozolomide by alamar blue drug sensitivity assay over 96 hours. Histogram shows mean 
survival ±SD (n=1). 
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5.5.3 CREBBP Knockdown and MGMT Expression 
Given that SU-DHL-4 cells were found to be resistant to temozolomide, other means were 
sought to study the effect of CREBBP knockdown on direct DNA damage response. In 
Chapter 3 PreB ALL cells with CREBBP knockdown were shown to have no effect on the 
expression of direct DNA damage repair protein MGMT (Section 3.8.4). To assess this in 
DLBCL, western blotting for MGMT was carried out using whole cell lysates from 
SUDshCBP and SUDshNEG cells (Section 2.5). MGMT is predicted to separate at 25kDa on 
a western blot but the antibody used showed bands at 37kDa and 20kDa as well as a band 
at 25kDa. This suggests that other isoforms or modified versions of MGMT could be 
present in the cell line, or that the antibody is prone to non-specific binding. Attempts 
were made to establish western blotting with an alternative anti-MGMT antibody (Santa 
Cruz N-16) but were not successful. Regardless of antibody complications, there is no 
consistent evidence in the band pattern to suggest that MGMT protein expression is 
altered in CREBBP knockdown cells compared to controls (Figure 5.10).  
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Figure 5.10. MGMT expression in SU-DHL-4 cells with stable CREBBP Knockdown. Whole 
cell lysates from SUDshCBP and SUDshNEG were collected on three separate occasions 
(A-C) and western blotting for MGMT expression was carried out. Alpha tubulin was 
included as loading control. 
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5.5.4 CREBBP Knockdown and Ionising Radiation Sensitivity 
To study the effect of CREBBP knockdown on response to ionising radiation in DLBCL, 
SUDshCBP and SUDshNEG cells were assessed for sensitivity to ionising radiation. Cells 
were exposed to 0.3-8.8 Gy radiation and their viability was assessed by alamar blue assay 
following 96 hours incubation (Section 2.6.2). SU-DHL-4 cells were found to be highly 
resistant to ionising radiation, with a GI50 concentration not being reached (>8Gy) (Figure 
5.8). This makes them a poor model for studying the effects of CREBBP knockdown in 
lymphoma on sensitivity to ionising radiation, and indeed no differential sensitivity was 
seen between SUDshCBP and SUDshNEG cells. 
 
 
 
 
 
 
 
 
Figure 5.11. Effect of stable CREBBP knockdown in SU-DHL-4 cells on sensitivity to 
ionising radiation. SUDshCBP and SUDshNEG cells were assessed for sensitivity to ionising 
radiation by alamar blue drug sensitivity assay over 96 hours. Histogram shows mean 
survival ±SD (n=1). 
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5.6 Assessment of MHC Class II Surface Expression on SU-DHL-4 and PreB 697 
Cells with Stable CREBBP Knockdown 
Studies in FL have identified that CREBBP mutations are associated with a signature of 
decreased antigen presentation, with reduction in the abundance of MHC class II on 
tumour B cells, hypothesised to contribute to immune evasion by the tumour (Green et 
al., 2015). To assess this in DLBCL, SU-DHL-4 cells with CREBBP knockdown were assessed 
for cell surface expression of the MHC class II protein, HLA-DR, by flow cytometry. Though 
antigen presentation by ALL cells is known to be weak, PreB 697 cells with stable CREBBP 
knockdown were also assessed for HLA-DR surface expression to assess this hypothesis in 
the context of ALL (Todisco et al., 2002). 
Cells were stained with an antibody targeting HLA-DR and assessed by flow cytometry 
(Section 2.3.3). A trend towards reduced HLA-DR expression was seen in SU-DHL-4 cells 
with CREBBP knockdown, with ~1.2 fold reduction compared to control, much less than 
the ~8 fold reduction seen in FL cells with CREBBP mutation (Figure 5.12) (Green et al., 
2015). As expected, cell surface expression of HLA-DR was lower in SU-DHL-4 cells 
compared to PreB 697 cells, with around ~5 fold lower expression observed (Figure 5.12). 
Interestingly, PreB 697 cells with stable CREBBP knockdown had ~1.3 fold greater 
expression of HLA-DR compared to control (Figure 5.12). These data suggest that CREBBP 
haploinsufficiency may play a role in suppression of antigen presentation as in FL, though 
may have the opposite effect in BCP-ALL cells. 
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Figure 5.12. Effect of stable CREBBP knockdown in SU-DHL-4 and PreB 697 cells on HLA-
DR expression. A. SU-DHL-4 and B. PreB 697 cells in exponential growth phase were 
assessed for cell surface expression of the MHC class II protein HLA-DR by flow cytometry 
using a HLA-DR APC antibody and isotype control. 
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5.7 Discussion 
The aim of this chapter was to investigate the molecular pathology of CREBBP mutations 
in DLBCL through the creation and characterisation of an isogenic cell line with stable 
CREBBP knockdown and to compare data with those gathered in ALL cells. This chapter 
has addressed the effects of CREBBP knockdown in DLBCL on cell proliferation, cAMP-
dependent gene expression, drug sensitivity, DNA damage repair and antigen 
presentation. 
Stable knockdown of CREBBP in SU-DHL-4 produced a model of CREBBP haploinsufficiency 
in DLBCL with CREBBP protein expression that closely matched that seen in DLBCL cell 
lines with CREBBP mutation and patients with mono-allelic CREBBP deletions (Pasqualucci 
et al., 2011). Whilst reduction in CREBBP mRNA expression was slightly lower in SU-DHL-
4 cells with CREBBP knockdown than was shown in BCP-ALL cell lines, protein knockdown 
was comparable. In keeping with data collected in BCP-ALL cell lines and primagraft 
samples, CREBBP knockdown in SU-DHL-4 cells showed no effect on cell proliferation, 
further suggesting that CREBBP haploinsuffiency does not contribute to relapse/tumour 
progression by disrupting cell cycle control. CREBBP knockdown in SU-DHL-4 cells had an 
inconsistent effect on acetylation of H3K18 and H3K27, which differs from studies in BCP-
ALL cells and primagrafts in which acetylation of at least one of these residues was 
reduced by CREBBP knockdown. This is however, in keeping with previous evidence which 
shows that different CREBBP mutations lead to varying levels of AcH3K18 impairment 
(Pasqualucci et al., 2011). 
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The cAMP-dependency of genes differed in SU-DHL-4 cells compared to BCP-ALL cells, 
with RGS1 and DUSP5 identified as most cAMP-dependent by GEP (3.7 and 2.9 Log2 fold 
change compared to untreated, respectively) and none of the genes identified as cAMP-
dependent in BCP-ALL showing significant upregulation in response to cAMP stimulation. 
Importantly however, CREBBP knockdown only led to impaired cAMP-induced expression 
of DUSP5 that just reached statistical significance (p=0.047) and had no significant effect 
on RGS1, suggesting that, like in ALL CREBBP haploinsufficiency does not significantly 
impair cAMP-dependent gene expression and that residual CREBBP expression is able to 
compensate. 
Previous studies have shown that HDACi can lead to apoptosis in GC-resistant cells, that 
CREBBP/EP300 mutation in DLBCL may lead to increased sensitivity to HDACi and that 
histone acetylation deficits in RSTS cell lines can be reversed using HDACi  (Tsapis et al., 
2007; Mullighan et al., 2011; Andersen et al., 2012; Lopez-Atalaya et al., 2012). Despite 
this and as shown in BCP-ALL models of CREBBP knockdown, SU-DHL-4 cells with CREBBP 
knockdown were not shown to be differentially sensitivity to vorinostat compared to 
control. This suggests that, in both BCP-ALL and DLBCL, rebalancing HDAC levels alone is 
not sufficient to cause cell death in CREBBP haploinsufficient cells.  
In FL, CREBBP haploinsufficiency has been linked to immune evasion. CREBBP mutation 
was shown to cause an 8.1 fold reduction in expression of the MHC class II protein HLA-
DR on the surface of CREBBP mutant tumour B cells compared to those with wild type 
CREBBP expression (Green et al., 2015). Similar to FL, expression of HLA-DR was lower in 
SU-DHL-4 cells with stable CREBBP knockdown compared to control cells, though the fold 
difference was much more modest (~1.2 fold SU-DHL-4). This suggests that, as in FL, 
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CREBBP haploinsufficiency in DLBCL may contribute to tumour progression and drug 
resistance through immune evasion, though to a lesser extent. As expected, given that 
PreB cells are poor antigen presenting cells (Todisco et al., 2002), PreB 697 cells had lower 
expression of HLA-DR but surprisingly, cells with stable CREBBP knockdown showed ~1.3 
fold increase in HLA-DR expression compared to control cells. This suggest that CREBBP 
haploinsufficiency may not contribute to immune evasion in ALL but may actually serve 
to increase antigen presentation.  
Unfortunately, SU-DHL-4 cells proved to be a poor model for the study of many molecular 
mechanisms in which CREBBP is involved. For example, SU-DHL-4 cells were shown to be 
dexamethasone resistant, precluding any studies into the effects of CREBBP knockdown 
on GC induced GR target expression and GC sensitivity. Further to this cells were found to 
be p53 mutant and resistant to ionising radiation and temozolomide, so studying the 
effects of CREBBP knockdown on p53 acetylation and DNA damage response in DLBCL was 
not possible using this cell line. SU-DHL-4 cells do not harbour a RAS pathway mutation 
and though important, RAS pathway mutations are rare in DLBCL so studies into the effect 
of CREBBP haploinsufficiency on enhancement of oncogenic RAS pathway activation were 
not carried out using this cell line (Lohr et al., 2012).  
Given the drawbacks of using the SU-DHL-4 cell line and that many B-NHL cell lines with 
CREBBP wild type status are GC resistant and/or p53 mutant, the use of in vivo models 
may be more effective for future studies (Chang et al., 1995; Amini et al., 2002; Warris et 
al., 2015). Patient lymphoma cells are amenable to engraftment in immunodeficient mice, 
as was shown using patient ALL samples in Chapter 4 (Donnou et al., 2012). Again, the 
tumour microenvironment is a vital and complicated part of tumour growth and 
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development, which is not present in vitro. The use of in vivo models for future studies is 
further supported by data collected in Chapter 4, which suggest that CREBBP knockdown 
alters cell line growth in vivo. A study looking at NF1 mutations cooperating with SUZ12 
mutations in cancer showed consistency between shRNA knockdown in cell lines, patient 
samples and in vivo models of NF1 and SUZ12 deficiency (De Raedt et al., 2014). This 
shows that use of shRNA and in vitro models can successfully model patient disease. On 
the other hand inconsistency between in vitro and in vivo data often occurs. For example, 
resveratrol was shown to cause cell death in the mouse myeloid leukaemia cell line 
32Dp210, but only a very weak anti-leukaemic effect was seen when administered to mice 
injected with leukaemia cells (Gao et al., 2002). Further to this, inconsistencies between 
in vitro, ex vivo and in vivo models have been shown in a study of stress hormones on the 
cell cytotoxicity of natural killer cells, with in vitro models overestimating the suppressive 
effects of stress hormones and ex vivo models potentially exaggerating suppression by GC 
(Gotlieb et al., 2015). 
 
In summary, data collected in SU-DHL-4 cells with stable CREBBP knockdown show many 
similarities with those collected in ALL cell lines and primagraft samples. Expression of 
MHC class II surface protein HLA-DR was reduced in SU-DHL-4 cells with CREBBP 
knockdown suggesting that CREBBP haploinsufficiency in DLBCL, like FL, may lead to 
immune evasion by reduced antigen presentation to some extent. The opposite effect 
was seen in PreB 697 cells with stable CREBBP knockdown suggesting that this immune 
evasion phenotype may not exist in ALL. Whilst DLBCL cells clearly have different 
specificities for acetylation of H3 lysines and cAMP-dependent targets, CREBBP 
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knockdown only had a minor effect on cAMP-dependent target expression. Similarly, 
CREBBP knockdown does not appear to induce chemoresistance in DLBCL or impact on 
DNA damage response. Unfortunately, the use of a cell line based approach did not allow 
for assessment of GC response or p53/BCL6 activity and so future studies in vivo are 
required to address the effect of CREBBP haploinsufficiency in DLBCL on these processes. 
Further to this, a similar approach should be carried out in FL to address to address the 
role of CREBBP haploinsufficiency in this form of B-NHL. 
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6.1 Overall Summary and Future Directions 
Childhood relapsed ALL, DLBCL and FL represent a group of malignancies which have a 
poor prognosis and for which there is a clear need for development of novel therapies. All 
three of these malignancies show frequent heterozygous inactivating mutations in the 
epigenetic modifier CREBBP (Mullighan et al., 2011, Pasqualucci et al., 2011). The 
molecular mechanisms behind the pathogenesis of CREBBP haploinsufficiency in these 
diseases remains poorly understood, with few functional studies carried out to date. A 
previous study in T-ALL and MEF cell lines suggested that CREBBP haploinsufficiency alters 
GC response and with GC comprising a pivotal treatment for lymphoid malignancies, could 
explain the frequency of CREBBP mutation in these diseases (Mullighan et al., 2011). 
Understanding the role of CREBBP haploinsufficiency in lymphoid malignancies is of key 
importance and could allow the development of novel therapies which are so crucially 
needed. 
The aim of the study described in this thesis was to investigate the molecular pathology 
of CREBBP haploinsufficiency in  relapsed ALL and B-NHL, addressing the hypothesis that 
CREBBP haploinsufficiency leads to drug resistance and that targeting it may allow 
resensitisation to therapy in childhood relapsed ALL, DLBCL and FL. 
As the majority of CREBBP mutations found in ALL and DLBCL lead to mono-allelic HAT 
inactivation, recapitulation of this was sought in model systems (Mullighan et al., 2011, 
Pasqualucci et al., 2011). Initially, an isogenic BCP-ALL cell line with stable CREBBP 
knockdown (established as part of MRes project) was characterised. This PreB 697 cell line 
was shown to have around 40% reduction of CREBBP mRNA expression and a protein 
reduction similar to that observed in primary ALL samples with monoallelic CREBBP 
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deletions. Transient CREBBP knockdown was also carried out in PreB 697 cells, 
hypodiploid MHH-CALL-2 cells and a method of transient knockdown of CREBBP in 
primagraft cells was optimised and carried out in 3 individual primagraft samples to 
validate data collected in PreB 697 cells with stable CREBBP knockdown. This allowed the 
study of CREBBP haploinsufficiency in relevant cytogenetic contexts and in patient derived 
ALL. Reduction in mRNA and protein expression was found to be similar across all of these 
models and protein reduction was in line with that seen in patient derived material. Using 
the same shRNA construct, stable CREBBP knockdown was carried out in the DLBCL cell 
line SU-DHL-4, in order to study the effects of CREBBP haploinsufficiency in the context of 
DLBCL. CREBBP mRNA and protein reduction were in line with those seen in ALL CREBBP 
knockdown models and also DLBCL cell lines with CREBBP mutation (Pasqualucci et al., 
2011). Two key CREBBP target residues include H3K18 and H3K27 and these were used to 
assess the functional effect of CREBBP knockdown in cell lines and primagraft samples. In 
the majority of cases acetylation at one of these residues was reduced when CREBBP was 
knocked down. This was not true in all cases, for example L779 primagraft cells and SU-
DHL-4 cells showed no consistent effect of CREBBP knockdown on acetylation of these 
residues. This could be explained by compensation from EP300, or different specificities 
for acetylation of these residues between cell types (Henry et al., 2013).  
New, more specific techniques for modelling heterozygous mutations now exist, such as 
the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system. 
CRISPR/Cas9 is a genome editing technique in which cells are transfected with the Cas9 
endonuclease along with specifically designed RNA guides which direct the induction of 
double strand DNA breaks through hybridisation. This system can be used to specifically 
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induce mono-allelic sequence changes (Paquet et al., 2016). Using this system in ALL and 
DLBCL cell lines and primagraft samples would allow modelling of patient specific mono-
allelic CREBBP mutations, better representing patient disease and allowing more precise 
study and comparison of specific individual CREBBP mutations. 
CREBBP plays an important role in cAMP-dependent signalling, a ubiquitous signalling 
pathway which regulates genes involved in metabolism, signalling, proliferation, 
differentiation and survival, through CREB activation (Mayr and Montminy, 2001). This 
pathway is critically involved in lymphocyte development and is known to interplay with 
the GC-induced apoptotic response in lymphoma cells (Rickles et al., 2010). De-regulation 
of cAMP signalling is found in a number of cancers, including AML, with CREB playing a 
role in myelopoiesis and CREB knockdown shown to reduce proliferation of myeloid cells 
(Sakamoto and Frank, 2009). Lymphocytes at different stages of differentiation are highly 
susceptible to cAMP/PDE-induced apoptosis, a susceptibility which has also been shown 
in murine lymphoma models and T-ALL cell lines (Daniel et al., 1973, Coffino et al., 1975, 
Ogawa et al., 2002, Smith et al., 2005). Crucially, this signalling pathway can be enhanced 
by using cAMP agonists, or by inhibiting PDEs, an approach which has proved successful 
in overcoming CREBBP functional deficiency in a mouse mode of RSTS (Bourtchouladze et 
al., 2003). The cAMP-induced expression of cAMP transcriptional targets was unaffected 
by CREBBP knockdown in the majority of ALL models and similarly, most targets were 
unaffected in SU-DHL-4 cells. These data suggest that CREBBP haploinsufficiency does not 
interfere with cAMP-dependent gene expression in ALL and DLBCL and preclude the use 
of PDEi to enhance cAMP signalling in CREBBP haploinsufficient disease. 
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CREBBP plays a body-wide role in transcription and cell cycle control, interacting with the 
TATA-box binding protein (TBP) and transcription factor II B (TFIIB), both of which are 
involved in the formation of the RNA polymerase pre-initiation complex, as well as the 
APC/C which is involved in cell cycle progression (Yuan et al., 1996, Kwok et al., 1994, 
Turnell et al., 2005). Further to this, CREBBP has been shown to play a role in cell fate 
decisions, influencing the timing and level of pre-mRNA processing in genes involved in 
HSC regulation (Lemieux et al., 2011). Although stable CREBBP knockdown in PreB 697, or 
transient knockdown in any cell line or primagraft sample, had no significant impact on 
cell proliferation in vitro, the in vivo growth of stably transduced PreB 697 cells was 
markedly different. Cells with stable CREBBP knockdown maintained this knockdown 
when engrafted into mice, as assessed by GFP expression of spleen cells. Mice engrafted 
with these CREBBP knockdown cells lived longer and had larger spleens and livers than 
mice engrafted with control cells. The actions of CREBBP are known to be highly context 
dependent, so it is possible that growth in vivo offers a better insight into the behaviour 
of cells with CREBBP haploinsufficiency (Giordano and Avantaggiati, 1999, Goodman and 
Smolik, 2000). Given the role of CREBBP in HSC regulation, it is possible that CREBBP 
knockdown alters in vivo cell growth through the production of a sub-set of cells with a 
stem-cell-like profile. In AML, stem cell gene expression signatures have been linked to 
inferior outcomes (Eppert et al., 2011). Cell cycle studies should be carried out to 
determine any differences between CREBBP knockdown and control cells grown in vivo 
and future experiments should utilise in vivo models of CREBBP haploinsufficiency, so as 
not to miss any important microenvironment-mediated effects. 
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Glucocorticoids are a mainstay treatment for lymphoid malignancies, so resistance to 
these therapeutic agents could contribute to refractory disease or establishment of 
relapse. In childhood ALL, GC sensitivity is a significant prognostic indicator, with patients 
who respond well shown to have a better outcome than poor responders (Riehm et al., 
1987, Reiter et al., 1994, Schrappe et al., 2000). Further to this, the in vitro sensitivity of 
cells from patients with relapsed ALL is reduced up to 300 fold compared to cells taken at 
diagnosis (Klumper et al., 1995, Kaspers et al., 2005). Stable CREBBP knockdown in PreB 
697 cells showed impaired induction of GILZ, FKBP5 and NR3C1 following GC stimulation 
and microarray data predicted impaired GR transcription. This was not recapitulated in 
transiently knocked down cell lines and primagraft samples, all of which showed normal 
GC-induced GR target expression for the majority of genes assayed. This could be 
explained by differences between stable and transient knockdown of CREBBP, though 
protein and mRNA knockdown were consistent between these RNAi methods. Crucially 
CREBBP knockdown did not lead to GC resistance in any cell line or primagraft sample 
assayed, suggesting that CREBBP haploinsufficiency in ALL does not contribute to relapse 
through GC resistance. Taken together, these data suggest that CREBBP haploinsufficiency 
in ALL does not impair GC response and that residual wild type CREBBP expression is 
clearly sufficient to compensate for this haploinsufficient loss of expression. This 
hypothesis was not addressed in SU-DHL-4 cells as they were found to be inherently GC 
resistant.  
Though CREBBP knockdown did not lead to GC resistance in any ALL cell model assessed, 
it was hypothesised that it may play a role in drug resistance, explaining the frequency of 
CREBBP mutations at relapse. Heterozygous loss of the methyltransferase SETD2 in 
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leukaemia has been shown to cause resistance to the ALL chemotherapeutics, 6-
thioguanine and cytarabine (Mar et al., 2015). PreB 697 cells with stable CREBBP 
knockdown were assessed for sensitivity to a panel of common ALL chemotherapeutics 
and it was found that CREBBP knockdown had no effect on sensitivity to these agents. 
Similarly stable CREBBP knockdown in SU-DHL-4 cells had no effect on sensitivity to 
daunorubicin or 6-thioguanine. These cells did however, show a slight significant increase 
in sensitivity to the tubulin binding drug vincristine, though given that this difference was 
in the nm range (GI50 values, mean ±SD; SUDshCBP 2.6nM ±0.12 versus SUDshNEG 3.1nM 
±0.11; p=0.009), it is unlikely to be biologically relevant. Taken together with 
dexamethasone sensitivity data, these data suggests that CREBBP haploinsufficiency does 
not induce a drug resistance phenotype in vitro in ALL and DLBCL. 
Previous studies have shown that HDACi can lead to apoptosis in GC-resistant cells, that 
CREBBP/EP300 mutation in DLBCL may lead to increased sensitivity to HDACi and that 
histone acetylation deficits in RSTS cell lines can be reversed using HDACi  (Mullighan et 
al., 2011, Tsapis et al., 2007, Andersen et al., 2012, Lopez-Atalaya et al., 2012). 
Haematological malignancies seem to be particularly sensitive to HDACi and this type of 
therapy is generally well tolerated in patients, with two HDACi drugs being approved for 
the treatment of cutaneous T-cell lymphoma (Stimson et al., 2009, Thurn et al., 2011, 
Mann et al., 2007). Dexamethasone sensitivity data precluded the hypothesis that the use 
of HDACi could resensitise to GC treatment by rebalancing acetylation levels in CREBBP 
haploinsufficient cells and indeed, PreB 697 and SU-DHL-4 cells with stable CREBBP 
knockdown were no more sensitive to HDACi alone or in combination with GC treatment. 
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CREBBP mutations frequently co-occur with RAS pathway mutations, including KRAS, 
NRAS, PTPN11 and FLT3 (Malinowska-Ozdowy et al., 2015). Further to this, CREBBP can 
directly acetylate KRAS (manuscript submitted), a secondary modification shown to have 
a negative regulatory effect on RAS activity by altering conformational stability of the 
Switch II domain and thus interaction with guanine nucleotide exchange factors (Yang et 
al., 2012). This prompted investigation into the effects of CREBBP mutation on RAS 
signalling. Both cell lines and primagraft cells with different RAS pathway mutations, 
showed consistently increased levels of p-ERK, suggesting that CREBBP inactivation 
enhances the oncogenic action of RAS pathway activation. Epigenetic modifiers have 
previously been shown to enhance the oncogenic action of RAS pathway mutations, with 
homozygous inactivation of the polycomb repressive complex 2 (PRC2) methyltransferase 
EZH2 shown to cooperate with NRAS (Q16K) mutation in a model of early T-cell precursor 
(ETP) ALL (Danis et al., 2016). Inactivation of the methyltransferase, EZH2 was shown to 
cooperate with mutant RAS to induce hyperactive cytokine signalling, principally through 
STAT3 and was associated with a reduced sensitivity to JAK inhibitors (Danis et al., 2016). 
Another member of the PRC2, SUZ12, has also been shown to cooperate with RAS 
mutation in a number of solid tumours (De Raedt et al., 2014). Aside from direct 
interaction with KRAS, another possible candidate to mediate interaction between 
CREBBP and the RAS pathway is WNT3, which was found to be significantly upregulated 
in CREBBP knockdown cells and which has been shown to activate MAPK signalling in 
other cell types through a non-canonical pathway (Anne et al., 2013). Notably, increased 
RAS pathway activation was associated with retention of MEKi sensitivity, which may have 
important clinical implications. Our group has recently reported on the preclinical 
evaluation of the MEKi, selumetinib, and demonstrated significant differential sensitivity 
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in RAS pathway-mutated ALL compared to ALL without RAS mutations, both in vitro and 
in an orthotopic xenograft model engrafted with primary ALL cells (Irving et al., 2014). We 
recently showed the same response in iAMP21-ALL patients with RAS pathway mutations 
(Ryan et al., 2016). These robust data have prompted clinical trials of selumetinib for 
multiple relapsed RAS pathway mutated ALL. As our data show that CREBBP deficient, RAS 
mutated cells retain sensitivity to MEKi, patients with co-occurring CREBBP and RAS 
mutations are clearly candidates for MEKi therapy. Future studies should concentrate on 
determining the nature of the interaction between CREBBP and the RAS pathway, 
particularly KRAS, at relapse in ALL, addressing the potential for targeting CREBBP 
alongside RAS pathway components as a novel therapeutic approach in CREBBP-mutated 
cancer. 
TP53, the gene which encodes p53, is the most commonly mutated gene in cancer 
(Kandoth et al., 2013). Expression of p53 is also altered by epigenetic regulation, with 
methylation of the p53 promotor region seen in ~50% of epithelial ovarian cancer 
specimens (Chmelarova et al., 2013). BCL6 is a transcriptional repressor which provides 
an environment tolerant of DNA breaks important in the development of germinal centre 
B-cells and is able to supress apoptosis by directly inhibiting p53 (Basso and Dalla-Favera, 
2012, Phan and Dalla-Favera, 2004). Acetylation by CREBBP is vital for the activity of p53, 
influencing its stability, DNA binding and recruitment of co-activators (Brooks and Gu, 
2003, Tang et al., 2008). CREBBP mediated acetylation is also important in the inactivation 
of BCL6 by disrupting interaction with HDACs and reducing the ability to repress 
transcription of anti-apoptotic genes, including p53 (Bereshchenko et al., 2002). CREBBP 
mutation has been shown to cause reduced acetylation of p53 and BCL6 in vitro and has 
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also been associated with impaired BCL6 activity (Green et al., 2013, Pasqualucci et al., 
2011). The consequence of losing this regulation in lymphoid malignancies would be an 
environment with increased tolerance for DNA damage with reduced control of cell cycle 
arrest and apoptosis. Stable CREBBP knockdown in PreB 697 cells had a variable effect on 
the acetylation of p53, but crucially showed no effect on its basal expression or the 
expression of downstream p21, suggesting an intact p53 response. Similarly, CREBBP 
knockdown did not alter basal BCL6 expression. This was not addressed in SU-DHL-4 cells 
as they were found to be inherently p53 mutant. Taken together these data suggest that 
CREBBP haploinsufficiency does not lead to imbalance of p53/BCL6 activity in ALL. Further 
experimentation is required to understand the role of CREBBP haploinsufficiency in 
regulation of this tumour suppressor/oncogene pair in B-NHL and solid tumours. 
CREBBP has functions within a number of DNA damage response pathways, so abrogation 
of DNA damage repair represents a potential mechanism of relapse 
establishment/development in CREBBP haploinsufficient malignancies. Indeed, 
hypermutable genotypes at relapse in ALL have been identified by whole exome 
sequencing (Ma et al., 2015). A study of CREBBP heterozygous mice showed 
hypersensitivity to gamma radiation, with reduced expression of BER components and 
reduced PARP activity (Zimmer et al., 2012). This was not recapitulated in PreB 697 cells 
with stable CREBBP knockdown, suggesting intact BER in these cells. CREBBP plays a role 
in regulation of the direct DNA damage repair protein MGMT (Bhakat and Mitra, 2000, 
Teo et al., 2001). MGMT deficiency is known to cause hypersensitivity to 
chemotherapeutic methylating agents such as temozolomide (Glassner et al., 1999). 
Interestingly, PreB 697 cells with stable CREBBP knockdown were hypersensitive to 
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temozolomide, though this was not explained by impairment in MGMT protein 
expression. Data were not consistent in PreB 697 cells with transient CREBBP knockdown 
however, where cells were equally sensitive to temozolomide as controls. This difference 
may be due to the transient nature of siRNA knockdown, however this is unlikely as 
temozolomide and its derivative 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide 
(MTIC), have a half-life of around 2 hours and CREBBP protein knockdown was shown to 
be sustained for at least 96 hours (Kim et al., 1997). SU-DHL-4 cells were found to be 
resistant to temozolomide and ionising radiation so could not be used for assessment of 
these DNA damage repair pathways. These observations suggest that CREBBP 
haploinsufficiency in ALL does not alter BER or direct DNA damage repair, though further 
studies are required to understand if these pathways are abrogated in B-NHL with CREBBP 
mutation. 
CREBBP mutations in FL have been associated with reduced antigen presentation, which 
may allow CREBBP mutated cells to evade the immune system (Green et al., 2015). 
Immune evasion represents a method by which cancer cells can thrive, preventing 
recognition and destruction by the immune system. As seen in FL cells with CREBBP 
mutation, DLBCL cells with stable CREBBP knockdown showed reduced expression of the 
MHC class II protein HLA-DR, though the level of reduction was much less profound (~1.2 
fold in SU-DHL-4 compared to ~8 fold in FL derived B-cells) (Green et al., 2015). Antigen 
presentation by ALL cells has been shown to be weak and indeed PreB 697 cells were 
shown to express lower levels of HLA-DR than SU-DHL-4 cells (Todisco et al., 2002). 
Interestingly, CREBBP knockdown in PreB 697 cells led to an increase in expression of HLA-
DR. These data suggest that CREBBP haploinsufficiency may contribute to reduced antigen 
Chapter 6 Overall Summary and Future Directions 
 
 
234 
 
presentation in DLBCL, much like FL, but not in ALL, where it appears to enhance antigen 
presentation. Future studies should investigate this further, looking at a range of MHC 
class II components and using primary derived samples. 
Mutations in epigenetic regulators represents a mechanism by which cancer cells can 
drastically alter gene expression and cellular functions. Global alterations in the epigenetic 
landscape are a hallmark of cancer and can result in inhibition or activation of various 
signalling pathways which lead to cancer (Sharma et al., 2010).  A wide range of epigenetic 
regulators have been identified as frequently mutated in cancer, but the exact functional 
impact of these mutations is poorly understood because of their complex and often 
context-dependent roles. For example, a number of epigenetic regulators are frequently 
mutated in AML, including DNMT3A and TET2, both of which are associated with adverse 
outcome (Abdel-Wahab and Levine, 2013, Chou et al., 2011). CREBBP mutations have 
been identified as a frequent event in a large number of solid tumours including; 
transitional cell carcinoma of the bladder, medulloblastoma, small cell lung cancer, 
adenoid cystic carcinoma, oesophageal squamous cell cancer, glioblastoma, squamous 
cell carcinoma and breast cancer (Gui et al., 2011, Robinson et al., 2012, Huether et al., 
2014, Peifer et al., 2012, Gao et al., 2014a, Han et al., 2014, Ho et al., 2013, Song et al., 
2014, Gao et al., 2014b, Mukasa et al., 2014, Watt et al., 2016, Jansen et al., 2016). Given 
that CREBBP appears to be acting as an enhancer of oncogenic signalling in relapsed ALL, 
this suggests that it may carry out a similar role in solid tumours. Further to this, mutations 
in other epigenetic regulators found in cancer may play a similar role. Screening for genes 
which are synthetically lethal when knocked out in CREBBP mutant cells could unearth 
therapeutic targets for these CREBBP mutant tumours. This also could allow the 
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development of a novel therapeutic targeting method in which both oncogene and 
respective epigenetic enhancer are targeted in order to achieve better treatment efficacy.   
 
6.2 Overview 
This study has shown some of the first mechanistic insights into CREBBP haploinsufficiency 
in childhood relapsed ALL and DLBCL, using cell lines and primary derived cells. The data 
collected in this study do not support a role for CREBBP mutation in resistance to 
chemotherapy, but have identified its role in enhancing oncogenic RAS signalling in ALL. 
This function may be relevant in a wide range of cancers, with targeting of CREBBP 
mutation in combination with cancer-specific oncogenes representing a potential novel 
therapeutic approach. 
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Appendix 1 – Gene expression microarray data 
Differential Gene Expression in PreB 697 Cells Treated with IBMX and Forskolin 
 
ID symbol log2FC AveExpr P.Value 
217028_at CXCR4 3.964 10.779 7.896E-08 
218205_s_at MKNK2 2.544 10.695 2.126E-09 
202431_s_at MYC -5.790 10.323 5.765E-08 
209486_at UTP3 -1.783 9.042 1.590E-09 
215111_s_at TSC22D1 2.151 9.002 1.068E-08 
209201_x_at CXCR4 4.618 8.848 1.938E-09 
203752_s_at JUND 2.139 8.837 5.571E-08 
202284_s_at CDKN1A 1.260 8.406 4.629E-08 
211919_s_at CXCR4 4.697 8.163 6.295E-09 
201751_at JOSD1 1.927 8.152 4.067E-08 
208622_s_at EZR 2.343 8.117 6.804E-08 
201368_at ZFP36L2 3.152 7.895 5.680E-09 
212430_at RBM38 2.511 7.439 1.058E-07 
223199_at MKNK2 2.736 7.426 4.413E-08 
227846_at GPR176 1.734 7.424 3.331E-08 
209324_s_at RGS16 4.134 7.118 2.218E-08 
201473_at JUNB 3.488 7.076 2.146E-10 
239427_at SLAMF1 -1.610 6.983 4.900E-08 
201531_at ZFP36 2.975 6.723 3.457E-08 
243174_at NA -3.080 6.613 3.467E-08 
202499_s_at SLC2A3 4.614 6.176 2.055E-08 
226924_at LINC00909 -2.144 6.029 4.134E-08 
205289_at BMP2 4.636 5.992 3.463E-09 
227410_at FAM43A 4.165 5.698 5.124E-09 
202815_s_at HEXIM1 2.343 5.561 9.961E-08 
41577_at PPP1R16B 2.960 5.436 1.450E-08 
203910_at ARHGAP29 5.476 5.421 3.930E-08 
207630_s_at CREM 4.677 5.327 3.560E-09 
1553099_at TIGD1 -2.468 4.891 8.901E-08 
201236_s_at BTG2 4.681 4.624 2.678E-08 
208763_s_at TSC22D3 5.218 4.599 1.821E-10 
202340_x_at NR4A1 3.749 4.432 4.547E-08 
216236_s_at NA 3.165 4.374 5.753E-10 
204491_at PDE4D 4.680 4.244 4.040E-09 
214508_x_at CREM 5.503 4.231 3.122E-10 
217875_s_at PMEPA1 3.738 4.147 5.145E-08 
209967_s_at CREM 4.776 4.094 7.059E-09 
205463_s_at PDGFA 4.373 4.082 2.710E-11 
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221563_at DUSP10 1.475 4.040 3.286E-08 
216268_s_at JAG1 2.661 4.007 2.022E-08 
214873_at LRP5L 1.481 3.837 5.431E-08 
222088_s_at NA 4.718 3.761 2.727E-08 
209189_at FOS 5.394 3.756 3.202E-08 
202497_x_at SLC2A3 4.615 3.713 1.253E-10 
209305_s_at GADD45B 3.376 3.507 7.289E-08 
209099_x_at JAG1 3.574 3.365 1.887E-09 
230233_at NA 3.181 3.292 3.351E-11 
229072_at RAB30 3.367 3.229 5.222E-08 
223217_s_at NFKBIZ 2.235 2.962 6.877E-10 
223887_at GPR132 2.057 2.896 2.594E-08 
201883_s_at B4GALT1 2.685 7.103 1.150E-07 
224797_at ARRDC3 2.521 6.437 1.153E-07 
202498_s_at SLC2A3 3.375 3.926 1.174E-07 
238039_at LOC728769 -1.699 5.326 1.175E-07 
200605_s_at PRKAR1A 1.399 9.717 1.325E-07 
226767_s_at FAHD1 -1.354 5.693 1.342E-07 
223218_s_at NFKBIZ 3.467 3.300 1.421E-07 
219522_at FJX1 -2.820 7.427 1.451E-07 
227558_at CBX4 3.113 9.107 1.488E-07 
202388_at RGS2 5.405 7.243 1.559E-07 
209304_x_at GADD45B 3.397 6.011 1.609E-07 
201369_s_at ZFP36L2 2.560 5.154 1.711E-07 
204602_at DKK1 -4.014 5.168 1.743E-07 
225606_at BCL2L11 2.604 8.398 1.778E-07 
204908_s_at BCL3 2.296 3.881 1.882E-07 
200921_s_at BTG1 3.034 9.400 1.920E-07 
222449_at PMEPA1 3.868 3.807 2.076E-07 
225224_at C20orf112 1.712 5.261 2.151E-07 
203708_at PDE4B 4.283 3.421 2.821E-07 
200920_s_at BTG1 3.242 8.676 2.894E-07 
228498_at B4GALT1 3.078 5.993 2.894E-07 
201739_at SGK1 3.055 4.453 3.009E-07 
201170_s_at BHLHE40 3.875 3.624 3.406E-07 
205562_at RPP38 -1.941 5.736 3.897E-07 
212558_at SPRY1 4.361 4.694 4.289E-07 
229817_at ZNF608 -1.517 7.625 4.536E-07 
212750_at PPP1R16B 2.799 4.832 4.590E-07 
202241_at TRIB1 -1.314 5.707 4.727E-07 
209325_s_at RGS16 3.736 6.443 4.769E-07 
210260_s_at TNFAIP8 -1.277 9.464 5.377E-07 
201631_s_at IER3 2.179 4.741 5.475E-07 
201416_at SOX4 1.429 10.364 5.482E-07 
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229943_at TRIM13 -1.821 7.898 5.625E-07 
205290_s_at BMP2 5.636 4.800 5.935E-07 
209034_at PNRC1 1.198 7.768 6.034E-07 
206724_at CBX4 3.083 3.368 6.083E-07 
208078_s_at NA 5.494 5.076 6.304E-07 
204015_s_at DUSP4 3.499 8.014 6.638E-07 
225954_s_at MIDN 1.142 7.122 6.666E-07 
225227_at SKIL 4.563 4.847 7.224E-07 
228098_s_at MYLIP 2.211 5.610 7.318E-07 
223130_s_at MYLIP 1.616 5.735 7.386E-07 
204014_at DUSP4 3.485 8.347 7.907E-07 
212642_s_at HIVEP2 1.137 7.805 8.700E-07 
222450_at PMEPA1 3.437 3.754 8.841E-07 
1555372_at BCL2L11 2.295 3.502 8.856E-07 
202644_s_at TNFAIP3 3.556 8.071 9.461E-07 
204523_at ZNF140 -1.282 7.949 9.788E-07 
209567_at RRS1 -1.204 9.806 1.020E-06 
 
Genes were sorted by highest average expression then sorted by most significant P value. 
Top 100 most significant are displayed above. See section 3.3. 
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Differential Gene Expression in SU-DHL-4 Cells Treated with IBMX and Forskolin 
 
ID symbol log2FC 
216834_at RGS1 3.725 
209457_at DUSP5 2.922 
204912_at IL10RA 2.525 
228846_at MXD1 2.379 
231124_x_at LY9 2.318 
235444_at FOXP1 2.241 
225191_at CIRBP 2.205 
211962_s_at ZFP36L1 2.155 
209201_x_at CXCR4 2.147 
1564970_at SETDB2 2.127 
230142_s_at CIRBP 2.083 
211919_s_at CXCR4 2.070 
221986_s_at KLHL24 2.068 
236293_at RHOH 2.028 
211965_at ZFP36L1 2.019 
201739_at SGK1 1.969 
228426_at CLEC2D 1.898 
221985_at KLHL24 1.894 
217028_at CXCR4 1.893 
242814_at SERPINB9 1.849 
201041_s_at DUSP1 1.830 
1568751_at RGS13 1.802 
201925_s_at CD55 1.760 
213593_s_at TRA2A 1.745 
233463_at RASSF6 1.741 
208763_s_at TSC22D3 1.728 
202388_at RGS2 1.714 
1555858_at THUMPD3-AS1 1.703 
227223_at RBM39 1.696 
215012_at ZNF451 1.693 
1555827_at CCNL1 1.692 
217591_at SKIL 1.656 
201926_s_at CD55 1.633 
213575_at TRA2A 1.632 
225867_at VASN 1.623 
222542_x_at ADCK3 1.621 
202861_at PER1 1.605 
204951_at RHOH 1.585 
1555950_a_at CD55 1.565 
208536_s_at BCL2L11 1.556 
210322_x_at UTY 1.548 
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226541_at FBXO30 1.548 
220035_at NUP210 1.539 
209102_s_at HBP1 1.526 
226404_at RBM39 1.496 
214802_at EXOC7 1.480 
228030_at RBM6 1.477 
1560172_at INTS10 1.465 
1552542_s_at TAGAP 1.424 
202340_x_at NR4A1 1.420 
229574_at TRA2A 1.410 
209750_at NR1D2 1.399 
227231_at KIAA1211 1.399 
235287_at CDK6 1.396 
235167_at LOC100190986 1.386 
225957_at CREBRF 1.378 
210001_s_at SOCS1 1.377 
226318_at TBRG1 1.373 
213359_at HNRNPD 1.369 
225606_at BCL2L11 1.357 
209034_at PNRC1 1.342 
207001_x_at TSC22D3 1.341 
1553785_at RASGEF1B 1.337 
205115_s_at RBM19 1.313 
230060_at CDCA7 1.313 
223494_at MGEA5 1.310 
224797_at ARRDC3 1.308 
1556088_at RPAIN 1.308 
222863_at ZBTB10 1.301 
214508_x_at CREM 1.284 
232431_at NR3C1 1.274 
206530_at RAB30 1.265 
233819_s_at LTN1 1.263 
232421_at SCARB1 1.241 
1553703_at ZNF791 1.232 
228723_at NPTN-IT1 1.228 
229072_at RAB30 1.225 
226158_at KLHL24 1.218 
1565681_s_at DIP2C 1.216 
207980_s_at CITED2 1.208 
206126_at CXCR5 1.182 
221768_at SFPQ 1.158 
207339_s_at LTB 1.158 
204286_s_at PMAIP1 1.151 
1553096_s_at BCL2L11 1.151 
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216734_s_at CXCR5 1.147 
219312_s_at ZBTB10 1.135 
81737_at LOC100505915 1.123 
209606_at CYTIP 1.123 
228793_at JMJD1C 1.123 
1558143_a_at BCL2L11 1.122 
236402_at BRAF 1.120 
209357_at CITED2 1.119 
215933_s_at HHEX 1.113 
228390_at RAB30 1.107 
230083_at USP53 1.107 
211584_s_at NPAT 1.088 
237625_s_at IGKC 1.083 
1555878_at RPS24 1.079 
200920_s_at BTG1 1.066 
210077_s_at SRSF5 1.064 
235638_at RASSF6 1.061 
1553704_x_at ZNF791 1.061 
217173_s_at LDLR 1.060 
1556318_s_at CAND1 1.060 
212400_at FAM102A 1.058 
204269_at PIM2 1.045 
229723_at TAGAP 1.043 
238787_at DENND1B 1.039 
213450_s_at ICOSLG 1.038 
219889_at FRAT1 1.036 
201295_s_at WSB1 1.034 
222343_at BCL2L11 1.032 
237504_at INTS10 1.030 
219841_at AICDA 1.029 
217921_at MAN1A2 1.022 
1556183_at ANKRD36BP2 1.021 
236613_at RBM25 1.018 
224499_s_at AICDA 1.018 
1557081_at RBM25 1.013 
232330_at COA1 1.003 
202842_s_at DNAJB9 1.003 
 
Genes were sorted by greatest Log2 fold change (Log2FC). Shown above are all genes with 
a Log2FC of ≥1 in IBMX and forskolin treated cells compared to controls. See section 5.3. 
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Appendix 2 – Presentations 
‘Targeted therapy for CREBBP-mutated lymphoid disease’ Oral Presentation, Childhood 
Leukaemia Research UK Annual Meeting, September 2015, The Royal Marsden Education 
and Conference Centre, London 
 
 
CREBBP Knockdown does not Impact on 
Glucocorticoid Induced Apoptosis in 
Childhood Acute Lymphoblastic Leukaemia
Zach Dixon 
2nd Year PhD
24.09.15
1
 
 
CREBBP Mutations in Childhood ALL
2
• Relapsed Childhood ALL: 18.3%
• High Hyperdiploid: 63%
• Hypodiploid: 32%
• Inactivating mutations – leading to haploinsufficiency
• Impaired transcription of glucocorticoid (GC) responsive genes
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CREBBP
3
• Multiple functions carried out by numerous 
discrete functional domains
• Cotranscription factor for CREB
• cAMP Dependent Signalling
• Cyclic adenosine monophosphate (cAMP) response element binding 
protein (CREB), binding protein (CREBBP)
 
 
CREBBP
4
• Acetylation of histone tails
• H3K18
• H3K27
• Acetylation mediated activation and inactivation of non-histone 
proteins
• p53
• BCL6
• Association with DNA damage repair
• BER (Radiation, alkylating agents)
• Direct
• Inherited haploinsufficiency = Rubinstein-Taybi Syndrome
 
 
Aims
• To assess CREBBP as a novel target for 
therapy in relapsed childhood ALL
– Study the effect of CREBBP knockdown on 
glucocorticoid sensitivity
5
 
Appendices 
 
 
245 
 
6
CREBBP Knockdown PreB ALL Cell Line
• PreB 697 cells are CREBBP wild type
• Lentiviral transduction of shRNA used
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CREBBP Knockdown Does Not Influence Induction of 
cAMP-dependent Genes
8
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CREBBP Knockdown in PreB 697 shCBP Cells is 
Functionally Relevant
7
• Average doubling times
• 32.4 hours shCBP
• 30.7 hours shNEG
• p=0.7
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CREBBP Knockdown Leads to Impaired Induction of 
Glucocorticoid Receptor (GR) Targets
9
F K B P 5
s
h
C
B
P
 C
V
 2
4
h
r
s
h
C
B
P
 D
e
x
 2
4
h
r
s
h
N
E
G
 C
V
 2
4
h
r
s
h
N
E
G
 D
e
x
 2
4
h
r
0
5 0
1 0 0
1 5 0
2 0 0
*  p = 0 .0 2 7 5
• As seen in Dexamethasone resistant sublines
 
 
Ingenuity Pathway Analysis Predicts Altered Glucocorticoid 
Receptor Transcription in PreB 697 shCBP Cells
10
Symbol Name log2FC
SCG2 secretogranin II 2.811834464
THSD7B thrombospondin, type I, domain containing 7B 2.639797207
OAT ornithine aminotransferase 2.589780949
DNAJC15 DnaJ (Hsp40) homolog, subfamily C, member 15 -2.498590624
PTGER4 prostaglandin E receptor 4 (subtype EP4) -2.482098654
FAM198B family with sequence similarity 198, member B -2.264160273
SLC22A16 solute carrier family 22 (organic cation/carnitine transporter), member 16 -1.703688787
CASP1 caspase 1, apoptosis-related cysteine peptidase -1.614572454
SLC16A14 solute carrier family 16, member 14 -1.6082457
ARL10 ADP-ribosylation factor-like 10 -1.563078133
PDIA5 protein disulfide isomerase family A, member 5 -1.500770057
RRAS2 related RAS viral (r-ras) oncogene homolog 2 -1.377499619
SAMHD1 SAM domain and HD domain 1 1.369527899
SMARCAD1 SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1 -1.330626813
CASP2 caspase 2, apoptosis-related cysteine peptidase -1.283517323
FAM169A family with sequence similarity 169, member A 1.226601308
ADCY3 adenylate cyclase 3 -1.187742915
PTPRF protein tyrosine phosphatase, receptor type, F -1.174186892
NA NA -1.173135969
FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) 1.168795854
PHACTR2 phosphatase and actin regulator 2 1.161687475
CASP1 caspase 1, apoptosis-related cysteine peptidase -1.156531947
TPST1 tyrosylprotein sulfotransferase 1 -1.145784216
PMS2P1 postmeiotic segregation increased 2 pseudogene 1 -1.131322987
PHF20 PHD finger protein 20 -1.126434047
WNT3 wingless-type MMTV integration site family, member 3 1.114859575
LGR6 leucine-rich repeat containing G protein-coupled receptor 6 1.053475268
KIAA1462 KIAA1462 -1.01380384
 
 
CREBBP Knockdown Has No Effect on Sensitivity to 
Dexamethasone
11
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Confirmation of Results in siRNA Transfected 
Cells – PreB 697
12
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CREBBP Knockdown in MHH-CALL-2 Had no Effect on cAMP-dependent Gene 
Transcription, GR target expression or Dexamethasone Sensitivity 
13
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CREBBP Knockdown in High Hyperdiploid Primagraft Cells (L779) Had no Effect 
on cAMP-dependent Gene Transcription, GR Target Expression or 
Dexamethasone Sensitivity
14
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Conclusion
15
• CREBBP Knockdown in ALL cell lines and high hyperdiploid primagraft 
cells
• No significant effect on induction of cAMP dependent genes
• Variable effect on glucocorticoid receptor target induction
• No reduction in GC sensitivity
• CREBBP mutation at relapse in childhood ALL may be exerting its 
effect through other mechanisms
• DNA damage repair?
• p53/BCL6 balance?
• Interaction with RAS pathway mutations?
 
 
Future Work
16
• Carry out CREBBP knockdown on more high 
hyperdiploid primagraft samples
• CREBBP Knockdown in Lymphoma Cell lines
• Synthetic lethality screen in CREBBP knockdown clones
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1429 Crebbp Knockdown Does Not Impact on Glucocorticoid Induced Apoptosis in 
Childhood Acute Lymphoblastic Leukemia 
Acute Lymphoblastic Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis 
and Prognosis 
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Zach Dixon, BSc Hons, MRes1*, Julie A.E. Irving, PhD1 and Lindsay Nicholson, PhD2* 
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2Haematological Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom 
 
Childhood acute lymphoblastic leukemia (ALL) is the most common childhood cancer and, 
despite a cure rate approaching 90%, relapse is a significant cause of death in young 
people. Recently it has been shown that inactivating mutations in the histone 
acetyltransferase, CREB binding protein (CREBBP or CBP) are frequently seen at relapse in 
childhood ALL, with enrichment in high hyperdiploid and hypodiploid cases. Mutations 
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are usually heterozygous, suggesting haploinsufficiency, and are often acquired at 
relapse, implying a role in drug resistance. Since glucocorticoid (GC) response genes are 
known targets of CREBBP and, given the pivotal role of GCs in ALL therapy, it has been 
postulated that CREBBP mutations confer GC chemoresistance. 
CREBBP is a multifunctional protein, playing a role in cAMP dependent signalling, 
acetylation mediated activation of p53 and inactivation of BCL6 and a range of DNA 
damage repair pathways including base excision repair (BER) and direct DNA damage 
repair. To assess the role of CREBBP haploinsufficiency in ALL, RNAi techniques were used 
to create isogenic CREBBP knockdown models of ALL. CREBBP knockdown was carried out 
using small hairpin RNA (shRNA) transduction (termed shCBP cells) or small interfering 
RNA (siRNA) transfection (termed siCBP cells) in the PreB 697 B-cell precursor cell line 
(t(1;19)) and the hypodiploid MHH-CALL-2 cell line, as well as high hyperdiploid primagraft 
ALL cells. Knockdown of at least 50% of control was confirmed at both mRNA and protein 
level. The functional impact of CREBBP knockdown in cells was determined by analysis of 
known CREBBP target residues; acetyl H3K18 and H3K27, and transcription of cAMP 
dependent genes (CXCR4, MKNK2, DUSP5, DUSP10 and RGS16). To assess the impact of 
CREBBP knockdown on response to GCs, cells were treated with dexamethasone and 
expression of the classic glucocorticoid receptor (GR) targets; GILZ and FKBP51, was 
assessed by quantitative reverse transcriptase PCR (QRT-PCR). Alamar blue cell viability 
assays were used to determine the sensitivity of each CREBBP knockdown model to 
dexamethasone compared to isogenic controls. 
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 Three out of four cell models displayed a reduction in H3K18 or H3K27 acetylation 
compared to isogenic control, indicating a relevant functional impact of CREBBP 
knockdown. Cell lines showed a trend towards reduced induction of some of the selected 
cAMP dependent targets but statistical significance was not achieved (p values >0.2). 
Gene expression profiling and Ingenuity Pathway Analysis of PreB 697 shCBP cells 
compared to isogenic control predicted that upstream transcription of NR3C1, the gene 
encoding the GR, would be affected in CREBBP knockdown cells. However, while induction 
of GILZ and FKBP51 in PreB 697 shCBP cells in response to GC was significantly impaired  
in knockdown compared to control cells (GILZ p=0.009, FKBP51 p=0.03), they were no 
more resistant to dexamethasone (p=0.9). This was mirrored in siCBP cell lines and 
primagraft cells, where a significant impairment in basal expression of GILZ and/or FKBP51 
was seen in some lines (GILZ reduction; p=0.03 PreB 697 shCBP, p=0.02 PreB 697 siCBP, 
FKBP51 reduction; p=0.01 primagraft siCBP cells) but no significant impairment in the 
transcriptional induction of these genes in response to GC compared to isogenic control 
was observed (p values >0.5). Importantly, no decreased sensitivity to dexamethasone 
was seen in any model after CREBBP knockdown (p values >0.1). 
 
CREBBP knockdown in ALL cells had no significant effect on the induction of cAMP 
dependent genes, had a variable effect on GR target expression, but consistently showed 
no impact on GC sensitivity, regardless of cytogenetic context. These data show that the 
acquisition of CREBBP mutations at relapse in childhood ALL is not mediated through GC 
resistance and suggest that other CREBBP associated mechanisms, such as DNA damage 
repair, may influence drug response. Understanding the role of CREBBP in carcinogenesis 
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and drug resistance is crucial as it is implicated as a tumour suppressor in a growing 
number of cancers, making it a potential multi-tumour target for novel therapies. 
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